



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

30 July 2018  
EMA/CHMP/442216/2018  
Inspections, Human Medicines Pharmacovigilance and Committees Division

## Committee for medicinal products for human use (CHMP) Minutes of the meeting on 28-31 May 2018

Chair: Tomas Salmonson – Vice-Chair: Harald Enzmann

### Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

### Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



## Table of contents

<b>1.</b>	<b>Introduction</b>	<b>8</b>
1.1.	Welcome and declarations of interest of members, alternates and experts.....	8
1.2.	Adoption of agenda .....	8
1.3.	Adoption of the minutes .....	8
<b>2.</b>	<b>Oral Explanations</b>	<b>9</b>
2.1.	Pre-authorisation procedure oral explanations.....	9
2.1.1.	caplacizumab - Orphan - EMEA/H/C/004426 .....	9
2.1.2.	tezacaftor / ivacaftor - Orphan - EMEA/H/C/004682.....	9
2.1.3.	vonicoq alfa - Orphan - EMEA/H/C/004454 .....	9
2.2.	Re-examination procedure oral explanations .....	10
2.3.	Post-authorisation procedure oral explanations .....	10
2.3.1.	Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0063/G .....	10
2.4.	Referral procedure oral explanations .....	10
<b>3.</b>	<b>Initial applications</b>	<b>10</b>
3.1.	Initial applications; Opinions.....	10
3.1.1.	Aimovig - erenumab - EMEA/H/C/004447 .....	10
3.1.2.	Exondys - eteplirsen - Orphan - EMEA/H/C/004355 .....	11
3.1.3.	Halimatoz - adalimumab - EMEA/H/C/004866 .....	11
3.1.4.	Hefiya - adalimumab - EMEA/H/C/004865 .....	12
3.1.5.	Hyrimoz - adalimumab - EMEA/H/C/004320.....	12
3.1.6.	Myalepta - metreleptin - Orphan - EMEA/H/C/004218 .....	13
3.1.7.	Nityr - nitisinone - EMEA/H/C/004582 .....	13
3.1.8.	RXULTI - brexpiprazole - EMEA/H/C/003841 .....	14
3.1.9.	Tegsedi - inotersen - Orphan - EMEA/H/C/004782 .....	14
3.1.10.	Trazimera - trastuzumab - EMEA/H/C/004463.....	15
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) .....	15
3.2.1.	viable T-cells - Orphan - ATMP - EMEA/H/C/002397 .....	15
3.2.2.	glycopyrronium / formoterol fumarate dihydrate - EMEA/H/C/004245 .....	16
3.2.3.	encorafenib - EMEA/H/C/004580 .....	16
3.2.4.	caplacizumab - Orphan - EMEA/H/C/004426 .....	16
3.2.5.	deferiprone - EMEA/H/C/004710.....	17
3.2.6.	dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171 .....	17
3.2.7.	gefitinib - EMEA/H/C/004826 .....	17
3.2.8.	tildrakizumab - EMEA/H/C/004514.....	18
3.2.9.	durvalumab - EMEA/H/C/004771 .....	18

3.2.10.	tisagenlecleucel - Orphan - ATMP - EMEA/H/C/004090 .....	18
3.2.11.	lenalidomide - EMEA/H/C/004857 .....	19
3.2.12.	voretigene neparovec - Orphan - ATMP - EMEA/H/C/004451 .....	19
3.2.13.	binimetinib - EMEA/H/C/004579 .....	19
3.2.14.	melatonin - PUMA - EMEA/H/C/004425.....	20
3.2.15.	mexiletine hydrochloride - Orphan - EMEA/H/C/004584 .....	20
3.2.16.	paclitaxel - EMEA/H/C/004441 .....	20
3.2.17.	pegfilgrastim - EMEA/H/C/003961 .....	20
3.2.18.	tezacaftor / ivacaftor - Orphan - EMEA/H/C/004682.....	21
3.2.19.	meropenem / vaborbactam - EMEA/H/C/004669 .....	21
3.2.20.	vonicon alfa - Orphan - EMEA/H/C/004454 .....	21
3.2.21.	daunorubicin / cytarabine - Orphan - EMEA/H/C/004282 .....	22
3.2.22.	eravacycline - EMEA/H/C/004237 .....	22
<b>3.3.</b>	<b>Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) .....</b>	<b>23</b>
3.3.1.	fremanezumab - EMEA/H/C/004833.....	23
3.3.2.	cannabidiol - Orphan - EMEA/H/C/004675 .....	23
3.3.3.	asparaginase - Orphan - EMEA/H/C/004736.....	23
3.3.4.	lorlatinib - EMEA/H/C/004646 .....	23
3.3.5.	lusutrombopag - EMEA/H/C/004720.....	24
3.3.6.	treosulfan - Orphan - EMEA/H/C/004751 .....	24
3.3.7.	canakinumab - EMEA/H/C/004754 .....	24
<b>3.4.</b>	<b>Update on on-going initial applications for Centralised procedure.....</b>	<b>24</b>
3.4.1.	brigatinib - EMEA/H/C/004248 .....	24
3.4.2.	vestronidase alfa - Orphan - EMEA/H/C/004438 .....	25
3.4.1.	volanesorsen - Orphan - EMEA/H/C/004538.....	25
3.4.2.	- galcanezumab - EMEA/H/C/004648 .....	25
<b>3.5.</b>	<b>Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 .....</b>	<b>26</b>
3.5.1.	Dexxience - betrixaban - EMEA/H/C/004309 .....	26
<b>3.6.</b>	<b>Initial applications in the decision-making phase.....</b>	<b>26</b>
<b>3.7.</b>	<b>Withdrawals of initial marketing authorisation application .....</b>	<b>26</b>

<b>4.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008</b>	<b>26</b>
-----------	---	-----------

<b>4.1.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion .....</b>	<b>26</b>
4.1.1.	Xeljanz - tofacitinib - EMEA/H/C/004214/X/0005/G.....	26
<b>4.2.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues .....</b>	<b>27</b>
4.2.1.	Inhixa - enoxaparin sodium - EMEA/H/C/004264/X/0018 .....	27

<b>4.3.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question .....</b>	<b>27</b>
4.3.1.	ELOCTA - efmoroctocog alfa - EMEA/H/C/003964/X/0021 .....	27
<b>4.4.</b>	<b>Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>28</b>
<b>4.5.</b>	<b>Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>28</b>

## **5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008**

<b>5.1.</b>	<b>Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....</b>	<b>28</b>
5.1.1.	Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0055.....	28
5.1.2.	Briviact - brivaracetam - EMEA/H/C/003898/II/0010/G .....	28
5.1.3.	Inovelon - rufinamide - Orphan - EMEA/H/C/000660/II/0045 .....	29
5.1.4.	Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0063/G .....	29
5.1.5.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0052 .....	30
5.1.6.	Lenvima - lenvatinib - Orphan - EMEA/H/C/003727/II/0011/G .....	30
5.1.7.	Mozobil - plerixafor - Orphan - EMEA/H/C/001030/II/0034 .....	31
5.1.8.	Sprycel - dasatinib - EMEA/H/C/000709/II/0059 .....	31
5.1.9.	Tecentriq - atezolizumab - EMEA/H/C/004143/II/0007/G.....	32
5.1.10.	Tecentriq - atezolizumab - ANX 003 and EMEA/H/C/004143/II/0010.....	32
5.1.11.	Translarna - ataluren - Orphan - EMEA/H/C/002720/II/0037.....	33
5.1.12.	Xarelto - rivaroxaban - EMEA/H/C/000944/II/0058.....	33
5.1.13.	Xtandi - enzalutamide - EMEA/H/C/002639/II/0039/G .....	34
5.1.14.	WS1274 Mekinist - trametinib - EMEA/H/C/002643/WS1274/0023 Tafinlar - dabrafenib - EMEA/H/C/002604/WS1274/0031 .....	35
5.1.15.	WS1278 OPDIVO - nivolumab - EMEA/H/C/003985/WS1278/0042 Yervoy - ipilimumab - EMEA/H/C/002213/WS1278/0053 .....	35
5.1.16.	WS1344 Edistride - dapagliflozin - EMEA/H/C/004161/WS1344/0025 Forxiga - dapagliflozin - EMEA/H/C/002322/WS1344/0044 .....	36
5.1.17.	WS1369 Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781/WS1369/0001 Trelegy Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363/WS1369/0001 .....	36
<b>5.2.</b>	<b>Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>37</b>
5.2.1.	Opdivo - nivolumab - EMEA/H/C/003985/II/0041 .....	37
<b>5.3.</b>	<b>Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>37</b>
5.3.1.	Sutent - sunitinib - EMEA/H/C/000687/II/0065 .....	37

<b>6.</b>	<b>Ancillary medicinal substances in medical devices</b>	<b>38</b>
6.1.	Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions .....	38
6.2.	Update of Ancillary medicinal substances in medical devices .....	38
<b>7.</b>	<b>Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)</b>	<b>38</b>
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	38
<b>8.</b>	<b>Pre-submission issues</b>	<b>38</b>
8.1.	Pre-submission issue .....	38
8.1.1.	Sodium salt of gamma-hydroxybutyric acid - H0004962 .....	38
8.1.2.	Angiotensin II - H0004930.....	38
8.2.	Priority Medicines (PRIME) .....	39
8.2.1.	List of applications received .....	39
8.2.2.	Recommendation for PRIME eligibility.....	39
<b>9.</b>	<b>Post-authorisation issues</b>	<b>39</b>
9.1.	Post-authorisation issues .....	39
9.1.1.	Ceplene - histamine dihydrochloride - EMEA/H/C/000796/II/0034, Orphan .....	39
9.1.2.	Daptomycin Hospira - daptomycin - EMEA/H/C/004310/II/0006/G.....	40
<b>10.</b>	<b>Referral procedures</b>	<b>40</b>
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004 .....	40
10.1.1.	Esmya - ulipristal acetate - EMEA/H/A-20/1460.....	40
10.1.2.	Zinbryta - daclizumab – EMEA/H/A-20/1456 .....	41
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 .	41
10.2.1.	Norethisterone and Ethinylestradiol – EMEA/H/A-5(3)/1470.....	41
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 .....	42
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC .....	42
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	42
10.5.1.	Scandonest and associated names – mepivacaine - EMEA/H/A-30/1455 .....	42
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC .....	43
10.6.1.	Bacterial lysates-containing based medicinal products for respiratory conditions - EMEA/H/A-31/1465 .....	43
10.6.2.	Metamizole containing medicinal products – metamizole sodium - EMEA/H/A-31/1469 ....	43
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	44
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC .....	44

10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 .....	44
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	44
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 .....	44
<b>11.</b>	<b>Pharmacovigilance issue</b>	<b>44</b>
11.1.	Early Notification System .....	44
<b>12.</b>	<b>Inspections</b>	<b>44</b>
12.1.	GMP inspections .....	44
12.2.	GCP inspections .....	44
12.3.	Pharmacovigilance inspections.....	45
12.4.	GLP inspections .....	45
<b>13.</b>	<b>Innovation Task Force</b>	<b>45</b>
13.1.	Minutes of Innovation Task Force.....	45
13.2.	Innovation Task Force briefing meetings.....	45
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 .....	45
13.4.	Nanomedicines activities .....	45
<b>14.</b>	<b>Organisational, regulatory and methodological matters</b>	<b>45</b>
14.1.	Mandate and organisation of the CHMP .....	45
14.1.1.	PRAC and CHMP involvement in type II variations.....	45
14.1.2.	Anti-PD-1/PD-L1 – Trend for initial worse efficacy performance .....	46
14.2.	Coordination with EMA Scientific Committees.....	46
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC) .....	46
14.2.2.	Committee for Advanced Therapies (CAT).....	46
14.2.3.	Paediatric Committee (PDCO).....	46
14.2.4.	Committee for Orphan Medicinal Products (COMP) .....	47
14.2.5.	Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).....	47
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups .....	47
14.3.1.	Scientific Advice Working Party (SAWP) .....	47
14.3.2.	Name Review Group (NRG).....	48
14.3.3.	Biologics Working Party (BWP) .....	48
14.3.4.	Coordination with EMA Working Parties/Working Groups/Drafting Groups on ICH E9 (R1) addendum on estimands.....	48
14.3.5.	Modelling and Simulation Working Party (MSWP) .....	48
14.3.6.	Blood Products Working Party (BPWP) .....	49

14.3.7.	Pharmacogenomics Working Party (PGWP) .....	49
14.3.8.	Pharmacokinetics Working Party (PKWP) .....	49
<b>14.4.</b>	<b>Cooperation within the EU regulatory network .....</b>	<b>50</b>
<b>14.5.</b>	<b>Cooperation with International Regulators.....</b>	<b>50</b>
<b>14.6.</b>	<b>Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee .....</b>	<b>50</b>
<b>14.7.</b>	<b>CHMP work plan .....</b>	<b>51</b>
<b>14.8.</b>	<b>Planning and reporting .....</b>	<b>51</b>
<b>14.9.</b>	<b>Others .....</b>	<b>51</b>
<b>15.</b>	<b>Any other business</b>	<b>51</b>
<b>15.1.</b>	<b>AOB topic.....</b>	<b>51</b>
15.1.1.	Preparedness of the system and capacity increase .....	51
15.1.2.	Article 58: Update from the March 2017 'Malta' CHMP meeting with African regulators .....	51
15.1.3.	Update on Ebola and Nipah Virus .....	51
<b>16.</b>	<b>List of participants</b>	<b>52</b>
<b>17.</b>	<b>Explanatory notes</b>	<b>56</b>

## **1. Introduction**

### **1.1. Welcome and declarations of interest of members, alternates and experts**

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified as included in the list of participants and restrictions. See (current) May 2018 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 28-31 May 2018.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

### **1.2. Adoption of agenda**

CHMP agenda for 28-31 May 2018

The CHMP adopted the agenda.

### **1.3. Adoption of the minutes**

CHMP minutes for 23-26 April 2018

The CHMP adopted the CHMP minutes for 23-26 April 2018. The Minutes of the May 2018 CHMP ORGAM meeting held on 22 May 2018, together with all decisions taken at that meeting, were adopted.



## 2. Oral Explanations

### 2.1. Pre-authorisation procedure oral explanations

#### 2.1.1. caplacizumab - Orphan - EMEA/H/C/004426

---

Ablynx NV; indicated for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

Scope: Oral explanation

**Action:** Oral explanation to be held on 30 May 2018 at time 15:00

List of Outstanding Issues adopted on 25.01.2018. List of Questions adopted on 22.06.2017.

The CHMP agreed that no oral explanation was needed at this time.

See 3.2

#### 2.1.2. tezacaftor / ivacaftor - Orphan - EMEA/H/C/004682

---

Vertex Pharmaceuticals (Europe) Ltd.; treatment of cystic fibrosis

Scope: Oral explanation

**Action:** Oral explanation to be held on 29 May 2018 at time 11:00

List of Outstanding Issues adopted on 22.03.2018. List of Questions adopted on 14.12.2017.

The CHMP agreed that no oral explanation was needed at this time.

See 3.2

#### 2.1.3. vonicog alfa - Orphan - EMEA/H/C/004454

---

Baxalta Innovations GmbH; Treatment of von Willebrand Disease (VWD)

Scope: List of outstanding issue

**Action:** For adoption

List of Outstanding Issues adopted on 22.03.2018. List of Questions adopted on 12.10.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

It was agreed to schedule an oral explanation with the applicant. An oral explanation was held via TC on Tuesday 29 May 2018, at 15:00.

See 3.2

## 2.2. Re-examination procedure oral explanations

No items

## 2.3. Post-authorisation procedure oral explanations

### 2.3.1. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0063/G

---

Vertex Pharmaceuticals (Europe) Ltd

Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Dolores Montero Corominas

Scope: Oral explanation

**Action:** Oral explanation to be held on 29 May 2018 at time 11:00

Request for Supplementary Information adopted on 22.03.2018, 14.12.2017.

The CHMP agreed that no oral explanation was needed at this time.

See 5.1

## 2.4. Referral procedure oral explanations

No items

# 3. Initial applications

## 3.1. Initial applications; Opinions

### 3.1.1. Aimovig - erenumab - EMEA/H/C/004447

---

Novartis Europharm Limited; indicated for prophylaxis of migraine in adults

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 26.04.2018, 22.02.2018. List of Questions adopted on 12.10.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that erenumab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

### 3.1.2. Exondys - eteplirsen - Orphan - EMEA/H/C/004355

---

AVI Biopharma International Ltd; treatment of Duchenne muscular dystrophy

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.12.2017. List of Questions adopted on 21.04.2017.

The CHMP was concerned that the main study, which involved just 12 patients, did not compare Exondys with placebo beyond 24 weeks, during which there was no meaningful difference between Exondys and placebo in the 6-minute walking distance. The methods for comparing results of the main studies with historical data were not satisfactory for showing that the medicine was effective. The Committee considered further data were needed to show that the very low amounts of shortened dystrophin produced as a result of Exondys treatment bring lasting benefits relevant to the patient.

Therefore, the CHMP was of the opinion that the balance of benefits and risks of Exondys in the treatment of DMD could not be established. Hence, the CHMP recommended that the marketing authorisation be refused.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the marketing authorisation application. The CHMP adopted the assessment report.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation. The refusal question and answers document was circulated for information.

### 3.1.3. Halimatoz - adalimumab - EMEA/H/C/004866

---

Sandoz GmbH; treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, uveitis, paediatric uveitis

Scope: Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Hyrimoz

List of Outstanding Issues adopted on 26.04.2018, 22.02.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.  
The legal status was agreed as medicinal product subject to restricted medical prescription.  
The summary of opinion was circulated for information.  
The CHMP noted the letter of recommendation dated 5 June 2018.

#### 3.1.4. Hefiya - adalimumab - EMEA/H/C/004865

---

Sandoz GmbH; Juvenile idiopathic arthritis, Axial spondyloarthritis, Psoriatic arthritis, Psoriasis, Paediatric plaque psoriasis, Hidradenitis suppurativa (HS), Uveitis, Paediatric uveitis

Scope: Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Hyrimoz

List of Outstanding Issues adopted on 26.04.2018, 22.02.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP noted the letter of recommendation dated 5 June 2018.

#### 3.1.5. Hyrimoz - adalimumab - EMEA/H/C/004320

---

Sandoz GmbH; treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa (HS), Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis

Scope: Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 26.04.2018, 22.02.2018. List of Questions adopted on 14.09.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP noted the letter of recommendation dated 5 June 2018.

### 3.1.6. [Myalepta - metreleptin - Orphan - EMEA/H/C/004218](#)

---

Aegerion Pharmaceuticals B.V.; treatment of leptin deficiency (lipodystrophy)

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.02.2018, 14.12.2017. List of Questions adopted on 18.05.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 30 May 2018.

The summary of opinion was circulated for information.

### 3.1.7. [Nityr - nitisinone - EMEA/H/C/004582](#)

---

Cycle Pharmaceuticals Ltd; treatment of hereditary tyrosinemia type 1

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Orfadin

List of Outstanding Issues adopted on 26.04.2018, 22.02.2018. List of Questions adopted on 22.06.2017.

The CHMP noted the letter by the applicant dated 22 May 2018 notifying EMA about the withdrawal of the 2mg and 5mg strength.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing

authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the PKWP report.

### 3.1.8. [RXULTI - brexpiprazole - EMEA/H/C/003841](#)

---

Otsuka Pharmaceutical Europe Ltd; treatment of schizophrenia

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.03.2018. List of Questions adopted on 20.07.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that brexpiprazole is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 31 May 2018.

The summary of opinion was circulated for information.

### 3.1.9. [Tegsedil - inotersen - Orphan - EMEA/H/C/004782](#)

---

IONIS USA Ltd; treatment of transthyretin amyloidosis (hATTR)

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.04.2018. List of Questions adopted on 20.02.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

Furthermore, the CHMP considered that inotersen is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

### 3.1.10. Trazimera - trastuzumab - EMEA/H/C/004463

---

Pfizer Europe MA EEIG; treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 26.04.2018. List of Questions adopted on 09.11.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

## 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

### 3.2.1. viable T-cells - Orphan - ATMP - EMEA/H/C/002397

---

Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 08.09.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues. The CHMP was updated on discussions at the CAT during their May 2018 meeting.

The Committee adopted a list of outstanding issues with amendments together with a specific timetable.

### 3.2.2. glycopyrronium / formoterol fumarate dihydrate - EMEA/H/C/004245

---

indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 09.11.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.3. encorafenib - EMEA/H/C/004580

---

in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.4. caplacizumab - Orphan - EMEA/H/C/004426

---

Ablynx NV; indicated for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 25.01.2018. List of Questions adopted on 22.06.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.



### 3.2.5. deferiprone - EMEA/H/C/004710

---

treatment of iron overload in thalassemia major

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 09.11.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.6. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171

---

indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4

Scope: List of outstanding issues, SAG report

**Action:** For adoption

List of Outstanding Issues adopted on 23.03.2017. List of Questions adopted on 21.07.2016.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP noted the report from the SAG Vaccines meeting held on 30 April 2018.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the 2<sup>nd</sup> list of outstanding issues with a specific timetable.

### 3.2.7. gefitinib - EMEA/H/C/004826

---

treatment of non-small cell lung cancer

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.8. tildrakizumab - EMEA/H/C/004514

---

treatment of adults with moderate-to-severe plaque psoriasis

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 20.07.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.9. durvalumab - EMEA/H/C/004771

---

treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 25.01.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.10. tisagenlecleucel - Orphan - ATMP - EMEA/H/C/004090

---

Accelerated assessment

Novartis Europharm Limited; treatment of B cell acute lymphoblastic leukaemia (ALL) and diffuse large B cell lymphoma (DLBCL)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 16.03.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues. The CHMP was updated on discussions at the CAT during their May 2018 meeting.

The Committee adopted a list of outstanding issues with a specific timetable as adopted by the CAT.

The CHMP agreed to consult a SAG and endorsed the list of questions to this group as adopted by the CAT.

### 3.2.11. lenalidomide - EMEA/H/C/004857

---

treatment of multiple myeloma

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.12. voretigene neparvovec - Orphan - ATMP - EMEA/H/C/004451

---

Spark Therapeutics Ireland Ltd; treatment of patients with vision loss due to Leber congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 08.12.2017.

The CHMP was updated on the discussions at the CAT.

The Committee was reminded of the status of this application and its remaining outstanding issues. The CHMP was updated on discussions at the CAT during their May 2018 meeting.

The Committee adopted the CAT list of outstanding issues with amendments together with a specific timetable.

The CHMP endorsed a list of questions to an ad-hoc expert group with amendments to be adopted by written procedure by the CAT.

### 3.2.13. binimetinib - EMEA/H/C/004579

---

in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.14. melatonin - PUMA - EMEA/H/C/004425

---

treatment of insomnia in children with Autism Spectrum Disorders and neurogenetic diseases

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.09.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.15. mexiletine hydrochloride - Orphan - EMEA/H/C/004584

---

LUPIN (EUROPE) LIMITED; Treatment of myotonic disorders

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult a SAG and adopted a list of questions to this group.

### 3.2.16. paclitaxel - EMEA/H/C/004441

---

treatment of metastatic breast cancer

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the QWP and the PKWP.

### 3.2.17. pegfilgrastim - EMEA/H/C/003961

---

treatment of neutropenia

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.09.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.18. tezacaftor / ivacaftor - Orphan - EMEA/H/C/004682

---

Vertex Pharmaceuticals (Europe) Ltd.; treatment of cystic fibrosis

Scope: Oral explanation, List of outstanding issues

**Action:** Oral explanation to be held on 29 May 2018 at time 11:00

List of Outstanding Issues adopted on 22.03.2018. List of Questions adopted on 14.12.2017.

The CHMP agreed that no oral explanation was needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

### 3.2.19. meropenem / vaborbactam - EMEA/H/C/004669

---

treatment of urinary tract infection (cUTI), including pyelonephritis, intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), bacteraemia, infections due to bacterial organisms

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 09.11.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.20. vonicog alfa - Orphan - EMEA/H/C/004454

---

Baxalta Innovations GmbH; Treatment of von Willebrand Disease (VWD)

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 22.03.2018. List of Questions adopted on 12.10.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

It was agreed to schedule an oral explanation with the applicant. An oral explanation was held via TC on Tuesday 29 May 2018, at 15:00.

See 2.1

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

### 3.2.21. daunorubicin / cytarabine - Orphan - EMEA/H/C/004282

Jazz Pharmaceuticals Ireland Limited; treatment of adults with high-risk acute myeloid leukaemia (AML)

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 24.04.2018. List of Questions adopted on 20.02.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

The CHMP agreed to revert back from accelerated assessment to a standard timetable.

The CHMP adopted the similarity assessment report.

### 3.2.22. eravacycline - EMEA/H/C/004237

treatment of complicated intra-abdominal infections (cIAI) in adults

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

#### 3.3.1. fremanezumab - EMEA/H/C/004833

---

prevention of episodic and chronic migraine

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.2. cannabidiol - Orphan - EMEA/H/C/004675

---

GW Research Ltd; Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions .

The CHMP adopted the similarity assessment report.

#### 3.3.3. asparaginase - Orphan - EMEA/H/C/004736

---

ERYTECH Pharma S.A.; treatment of acute lymphoblastic leukaemia

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.4. lorlatinib - EMEA/H/C/004646

---

treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.5. [lusutrombopag - EMEA/H/C/004720](#)

---

treatment of thrombocytopenia

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.6. [treosulfan - Orphan - EMEA/H/C/004751](#)

---

medac Gesellschaft für klinische Spezialpräparate mbH; conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP adopted the similarity assessment report.

### 3.3.7. [canakinumab - EMEA/H/C/004754](#)

---

prevention of major cardiovascular events

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

## 3.4. **Update on on-going initial applications for Centralised procedure**

### 3.4.1. [brigatinib - EMEA/H/C/004248](#)

---

treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Scope: Request for an additional extension of clock stop to respond to the List of



Outstanding Issues adopted in January 2018.

Action: For adoption

List of Outstanding Issues adopted on 25.01.2018, 12.10.2017. List of Questions adopted on 22.06.2017.

The CHMP agreed to the request by the applicant for an additional extension of clock stop to respond to the List of Outstanding Issues adopted in January 2018.

#### 3.4.2. vestronidase alfa - Orphan - EMEA/H/C/004438

---

Ultragenyx Germany GmbH; indicated for the treatment of Mucopolysaccharidosis VII (MPS VII; Sly syndrome) for patients of all ages

Scope: Draft list of experts for adoption for the ad hoc expert group meeting

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2018, 22.02.2018, List of Questions adopted on 14.09.2017.

The CHMP adopted the list of experts for the ad hoc expert group meeting.

#### 3.4.1. volanesorsen - Orphan - EMEA/H/C/004538

---

Akcea Therapeutics UK Ltd.; indicated as an adjunct to diet for the treatment of patients with familial chylomicronemia syndrome (FCS).

Scope: Draft list of experts for adoption for the ad hoc expert group meeting

**Action:** For adoption

List of Outstanding Issues adopted on 26.04.2018, List of Questions adopted on 14.12.2017

The CHMP adopted the list of experts for the ad hoc expert group meeting.

#### 3.4.2. - galcanezumab - EMEA/H/C/004648

---

prophylaxis of migraine

Scope: Final SWP response on CHMP questions

**Action:** For adoption

The CHMP adopted the final SWP response to CHMP.

### 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

#### 3.5.1. Dextience - betrixaban - EMEA/H/C/004309

---

Portola Pharma UK Limited; treatment of prophylaxis of venous thromboembolism (VTE)

Scope: Updated timetable (SAG meeting)

**Action:** For information

Opinion adopted on 22.03.2018.

The CHMP noted the updated timetable.

### 3.6. Initial applications in the decision-making phase

No items

### 3.7. Withdrawals of initial marketing authorisation application

No items

## 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

### 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

#### 4.1.1. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0005/G

---

Pfizer Limited

Rapporteur: Robert James Hemmings, PRAC Rapporteur: Sabine Straus

Scope: "Extension application to introduce a new strength (10 mg film coated tablets). In addition, the MAH proposed a type II variation (C.I.6.a) to extend the indication to include 'the induction and maintenance of treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.'"

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP agreed by consensus on an additional 1 year of market protection for a new indication.

## 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

### 4.2.1. Inhixa - enoxaparin sodium - EMEA/H/C/004264/X/0018

---

Techdow Europe AB

Rapporteur: Andrea Laslop, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add two new strengths of 12,000 IU (120 mg)/0.8 mL and 15,000 IU (150 mg)/1 mL for enoxaparin sodium solution for injection in pre-filled syringe, for subcutaneous, extracorporeal and intravenous administration."

**Action:** For adoption

List of Questions adopted on 14.12.2017.

The Committee discussed the issues identified in this application and noted that only minor quality issues were left.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

## 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

### 4.3.1. ELOCTA - efmoroctocog alfa - EMEA/H/C/003964/X/0021

---

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Jan Mueller-Berghaus

Scope: "Extension application to introduce new strength of 4000 IU, 5000 IU and 6000 IU primarily enabling phophylactic dosing in adult patients."

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

#### 4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

### 5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

#### 5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

##### 5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0055

---

Takeda Pharma A/S

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Jan Mueller-Berghaus, PRAC  
Rapporteur: Sabine Straus

Scope: "Extension of the existing Hodgkin lymphoma (HL) indication to include the frontline treatment of adult patients with CD30+ advanced HL in combination with chemotherapy, based on data from ECHELON-1 (C25003), a phase 3 multi-centre, randomised, open-label study comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin, doxorubicin, vinblastine and dacarbazine versus the mPFS obtained with doxorubicin, bleomycin, vinblastine and dacarbazine. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10. The MAH also submitted an updated RMP version 13."

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

##### 5.1.2. Briviact - brivaracetam - EMEA/H/C/003898/II/0010/G

---

UCB Pharma S.A.

Rapporteur: Filip Josephson, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of Indication to include adjunctive therapy in the treatment of partial-

onset seizures with or without secondary generalisation in patients with epilepsy 4 years of age and older for Briviact. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.5 of the SmPC are updated.

In addition, the Marketing authorisation holder (MAH) has provided a 5ml oral dosing syringe and adaptor for the 10mg/ml oral solution, for use in the paediatric population. The Annex A, Package Leaflet and Labelling are updated in accordance."

**Action:** For adoption

Request for Supplementary Information adopted on 22.03.2018, 12.10.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

### 5.1.3. Inovelon - rufinamide - Orphan - EMEA/H/C/000660/II/0045

Eisai Ltd

Rapporteur: Alexandre Moreau, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Ghania Chamouni

Scope: "Extension of indication to include the treatment of seizures associated with Lennox Gastaut syndrome in patients 1 year of age and older as adjunctive therapy. As a consequence sections 4.1, 4.2, 4.5, 5.1 and 5.2 are updated. The Package Leaflet and the RMP (version 10.0) are updated accordingly. In addition the Marketing Authorisation Holder (MAH) took the opportunity to make small corrections with the Product Information and to update the name and contact details of the local representative in Belgium and Luxembourg. Furthermore, the Product Information is brought in line with the latest QRD template version 10."

**Action:** For adoption

Request for Supplementary Information adopted on 14.12.2017.

The Committee discussed the issues identified in this application, mainly relating to the pharmacokinetics and the accurate dosing regimen for the targeted population using the proposed syringes at low volumes.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.4. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/II/0063/G

Vertex Pharmaceuticals (Europe) Ltd.

Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Dolores Montero Corominas

Scope: "1) C.I.6.a (type II) - Extension of Indication to include the combination regimen of the ivacaftor 150 mg evening dose and tezacaftor/ivacaftor;  
2) B.IIe.5.a.2 (type IB) - to add a blister card pack presentation containing 28-tablets for the 150 mg film-coated tablets (EU/1/12/782/005);  
3) B.IIe.5.a.2 (type IB) - to add a blister pack presentation containing 28-tablets for the 150 mg film-coated tablets (EU/1/12/782/006).  
As a consequence, section 4.1, 4.2, 4.4, 4.5, 4.8, 6.5 and 8 of the SmPC are updated.  
Annex A, the Package Leaflet and Labelling are updated in accordance.  
An updated RMP (version 6.0) is included."

**Action:** For adoption

Request for Supplementary Information adopted on 22.03.2018, 14.12.2017.

The CHMP agreed that no oral explanation was needed at this time.

The Committee discussed the issues identified in this application. The Committee adopted a 3<sup>rd</sup> request for supplementary information with a specific timetable.

#### 5.1.5. [Keytruda - pembrolizumab - EMEA/H/C/003820/II/0052](#)

---

Merck Sharp & Dohme B.V.

Rapporteur: Daniela Melchiorri

Scope: "Restriction of the currently authorised indication in cisplatin-ineligible urothelial carcinoma patients to exclude patients whose tumors express PD-L1 CPS<10, as well as to exclude only the patients who have 1 or more risk factors predicting a worse outcome.  
Sections 4.1, 4.2, 4.4 and 5.1 of the SmPC have been revised accordingly."

**Action:** For adoption

The Committee discussed the issues identified in this application mainly relating to the wording of the indication.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP endorsed the DHPC and public health communication.

#### 5.1.6. [Lenvima - lenvatinib - Orphan - EMEA/H/C/003727/II/0011/G](#)

---

Eisai Europe Ltd.

Rapporteur: Bart Van der Schueren, Co-Rapporteur: Robert James Hemmings, PRAC  
Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of hepatocellular carcinoma (HCC) based on pivotal Study 304. Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are being updated and the package leaflet is updated accordingly. In addition, section 4.2 of the SmPC is being updated to add that the product can be administered as a

suspension in water or apple juice. In addition, the labelling is updated to include the unique identifier. An updated RMP version 10 was provided as part of the application.”

**Action:** For adoption

Request for Supplementary Information adopted on 22.02.2018, 09.11.2017.

The Committee discussed the issues identified in this application, mainly relating to the wording of the indication.

The Committee adopted a 3<sup>rd</sup> request for supplementary information with a specific timetable.

#### 5.1.7. Mozobil - plerixafor - Orphan - EMEA/H/C/001030/II/0034

---

Genzyme Europe BV

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sabine Straus

Scope: “Extension of Indication to include paediatric patients aged 1 to 18 years for Mozobil. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance.”

**Action:** For adoption

The Committee discussed the issues identified in this application. The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.8. Sprycel - dasatinib - EMEA/H/C/000709/II/0059

---

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Doris Stenver

Scope: “Extension of Indication to include a paediatric indication for Philadelphia chromosome positive acute lymphoblastic leukaemia for Sprycel; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, and 5.2 of the SmPC are updated.

The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes to the product information.

The RMP version 16.0 has also been submitted.”

**Action:** For adoption

The Committee discussed the issues identified in this application. Applicant is requested to provide further justification for the proposed dose. The Committee adopted a request for supplementary information with a specific timetable.

The CHMP adopted the similarity assessment report for Sprycel.

### 5.1.9. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0007/G

---

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include in combination with bevacizumab, paclitaxel and carboplatin the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC), based on the interim results of study GO29436 (IMpower 150). As a consequence sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated.

In addition update of section 4.8 of the SmPC in order to update the monotherapy safety data and reflect the largest pooled monotherapy population available (now including also data from IMvigor211 and PCD4989g studies).

The Package Leaflet and the RMP (version 4.0) are updated in accordance. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make small corrections and formatting changes throughout the SmPC."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

The Committee discussed the issues identified in this application. The discussion focused on the clinical data supporting the efficacy of the product, especially in relation to the proposed treatment combination and the proposed target population. The members agreed to request further clinical data and analysis to support the sought indication. The members also considered that further justification for the significant clinical benefit in comparison with all existing therapies was required in order to assess the request for an additional 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.10. Tecentriq - atezolizumab - ANX 003 and EMEA/H/C/004143/II/0010

---

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Update of section 4.1 and 5.1 of the SmPC in order to restrict for Tecentriq the indication 'for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible' by including 'whose tumours have a high expression of PDL-1', based on the review of interim analysis data by the independent data monitoring committee (IDMC) from study IMvigor 130 (WO30070) listed as a PAES in the Annex II; this is a Phase III, multicentre, randomized, placebo-controlled study of atezolizumab administered as monotherapy or in combination with platinum-based chemotherapy compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma enrolling patients in the first line setting who are both cisplatin eligible and cisplatin ineligible. The MAH is proposing to distribute a DHPC."

**Action:** For adoption



The Committee discussed the issues identified in this application mainly relating to the wording of the indication.

Finally the CHMP agreed to update sections 4.1, 4.2 and 5.1 of the SmPC for Tecentriq.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP endorsed the DHPC and public health communication.

#### 5.1.11. [Translarna - ataluren - Orphan - EMEA/H/C/002720/II/0037](#)

---

PTC Therapeutics International Limited

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Sabine Straus

Scope: "Extension of Indication to include a new population (children from 2 to less than 5 years of age) for Translarna; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and RMP (version 7.1) is updated in accordance."

**Action:** For adoption

Request for Supplementary Information adopted on 26.04.2018, 22.02.2018, 14.12.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.12. [Xarelto - rivaroxaban - EMEA/H/C/000944/II/0058](#)

---

Bayer AG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue

Scope: "Extension of Indication to include the prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischaemia and mortality in adult patients with coronary artery disease (CAD) or peripheral artery disease (PAD) for Xarelto 2.5 mg co-administered with acetylsalicylic acid; as a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.

In addition, section 4.8 of the SmPC is updated for all other dose strengths (10/15/20 mg) of Xarelto with relevant exposure information based on the provided clinical data.

The updated RMP version 11.1 has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 22.02.2018.

The Committee discussed the issues identified in this application. The members discussed the proposed extension of indication and considered that further justification was required for patients with peripheral arterial disease without coronary artery disease, patients 75 years of age and older as well as patients with lower body weight. In addition, amendments to the SmPC and RMP were requested.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

The CHMP agreed to consult a SAG and will adopt a list of questions to this group via written procedure.

#### 5.1.13. Xtandi - enzalutamide - EMEA/H/C/002639/II/0039/G

Astellas Pharma Europe B.V.

Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Eva A. Segovia

Scope: "C.I.4: Update of sections 4.4, 4.7, 4.8 and 5.2 of the SmPC in order to amend the warning on possible association with seizure, to amend the effects on driving or operating machines, to amend the identified adverse reactions and to amend the 'Race' subsection regarding pharmacokinetic properties based on the results from the completed studies PROSPER, a Phase 3 Randomized Controlled Study, designed to investigate the Safety and Efficacy of Enzalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer; and Asian PREVAIL, a Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy-naive Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy; and the updated integrated clinical safety database.

The Package Leaflet is updated in accordance.

C.I.6.a: Extension of Indication to include patients with non-metastatic castration-resistant prostate cancer (CRPC) for Xtandi;

as a consequence, sections 4.1 and 5.1 of the SmPC are updated, based on the supportive clinical study results of MDV3100-14 (PROSPER), a Phase 3 Randomized Controlled Study, designed to investigate the Safety and Efficacy of Enzalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer; MDV3100-09 (STRIVE), a Multicenter Phase 2 Study to investigate the Safety and Efficacy of Enzalutamide Versus Bicalutamide in Men With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer; and based on supportive non-clinical data from 7 new reports.

The Package Leaflet is updated in accordance.

An update RMP version 12.1 was submitted in order to include the changes related to the extension of indication."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to the long-term clinical benefit as well as the target population.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.14. [WS1274](#)  
[Mekinist - trametinib - EMEA/H/C/002643/WS1274/0023](#)  
[Tafinlar - dabrafenib - EMEA/H/C/002604/WS1274/0031](#)

---

Novartis Europharm Limited

Lead Rapporteur: Paula Boudewina van Hennik, Lead Co-Rapporteur: Filip Josephson, PRAC  
Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include the combination adjuvant treatment with trametinib and dabrafenib of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the Mekinist and Tafinlar SmPCs are updated. The Package Leaflet and the Risk Management plan (version 14.0 for Mekinist and version 9.0 for Tafinlar, according to GVP module V revision 2) are updated in accordance. In addition, the Worksharing applicant (WSA) took the opportunity to correct some typos throughout the Mekinist and Tafinlar product information, to include a cross reference to the Mekinist SmPC in section 4.6 of the Tafinlar SmPC regarding fertility, to update the list of local representatives for Bulgaria, Hungary, Estonia, Latvia and Lithuania in the Package Leaflet of both products."

**Action:** For adoption

Request for Supplementary Information adopted on 22.02.2018.

The Committee discussed the issues identified in this application.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

The CHMP agreed to consult a SAG.

Post meeting note: A revised 2<sup>nd</sup> request for supplementary information including the list of questions to the SAG oncology was adopted via written procedure after the plenary on 08.06.2018. Furthermore the final list of experts was adopted via written procedure on 15.06.2018.

5.1.15. [WS1278](#)  
[OPDIVO - nivolumab - EMEA/H/C/003985/WS1278/0042](#)  
[Yervoy - ipilimumab - EMEA/H/C/002213/WS1278/0053](#)

---

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Jorge Camarero Jiménez, Lead Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include the combination treatment with nivolumab and ipilimumab of adult patients with intermediate/poor-risk advanced renal cell carcinoma. As a consequence sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the Opdivo and Yervoy SmPCs are updated. The Package Leaflet and the Risk Management Plan (version 19.0 for Yervoy and version 13.0 for Opdivo) are updated in accordance. In addition, the Worksharing applicant (WSA) took the opportunity to correct some typos throughout the Yervoy and Opdivo product information."

**Action:** For adoption

Request for Supplementary Information adopted on 22.02.2018.

The Committee discussed the issues identified in this application, mainly relating the contribution of the monotherapy components to the observed effects of the combination therapy and uncertainties about the 1mg/kg dose.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

5.1.16. [WS1344](#)  
[Edistride - dapagliflozin - EMEA/H/C/004161/WS1344/0025](#)  
[Forxiga - dapagliflozin - EMEA/H/C/002322/WS1344/0044](#)

---

AstraZeneca AB

Lead Rapporteur: Kristina Dunder, Lead Co-Rapporteur: Martina Weise, PRAC Rapporteur: Qun-Ying Yue

Scope: "Extension of Indication to include new indication for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin, when insulin does not provide adequate glycaemic control, for Forxiga and Edistride; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The updated RMP version 16 has also been submitted.

In addition, the Worksharing applicant (WSA) took the opportunity to introduce minor editorial changes to SmPC and Package Leaflet."

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

The CHMP agreed to consult a SAG.

5.1.17. [WS1369](#)  
[Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781/WS1369/0001](#)  
[Trelegy Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363/WS1369/0001](#)

---

GlaxoSmithKline Trading Services Limited

Lead Rapporteur: Peter Kiely, Lead Co-Rapporteur: Harald Enzmann, PRAC Rapporteur: Qun-Ying Yue

Scope: "To modify the approved current COPD therapeutic indication to "maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)".

As a consequence, the indication section (4.1), Undesirable effects section (4.8) and Pharmacodynamic Properties section (5.1), Pharmacokinetic properties section (5.2), Preclinical Safety data section (5.3) of the EU SmPC, and the Possible side effects section (4) of the package leaflet are updated accordingly. This is based on the result of study CTT116855 and study 200812 and the population PK report 208059.

The updated RMP (version 02) has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application, concerning the wording of the indication and when to use the triple combination. In particular further information was requested on the benefit/risk in patients without high risk for exacerbations.

The Committee adopted a request for supplementary information with a specific timetable.

## 5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

### 5.2.1. Opdivo - nivolumab - EMEA/H/C/003985/II/0041

---

Bristol-Myers Squibb Pharma EEIG

Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: List of experts for the SAG-Oncology meeting

**Action:** For adoption

Request for Supplementary Information adopted on 26.04.2018, 25.01.2018.

The CHMP adopted the List of experts for the SAG-Oncology meeting .

## 5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

### 5.3.1. Sutent - sunitinib - EMEA/H/C/000687/II/0065

---

Pfizer Limited

Rapporteur: Daniela Melchiorri, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Carmela Macchiarulo

Scope: List of experts for the SAG-Oncology meeting

**Action:** For adoption

Opinion adopted on 22 February 2018.

The CHMP adopted a list of experts for the SAG-Oncology meeting.

## 6. Ancillary medicinal substances in medical devices

### 6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

### 6.2. Update of Ancillary medicinal substances in medical devices

No items

## 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

### 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

## 8. Pre-submission issues

### 8.1. Pre-submission issue

#### 8.1.1. Sodium salt of gamma-hydroxybutyric acid - H0004962

---

Support in the medium to long-term maintenance of alcohol abstinence in alcohol-dependent adult patients with a Very High Drinking Risk Level (consumption of more than 60 g alcohol/day for women and of more than 100 g alcohol/day for men) under careful medical supervision along with psychotherapy and social rehabilitation.

Treatment should be initiated only to patients whose duration of abstinence prior to treatment does not exceed 2 weeks.

Treatment of acute alcohol withdrawal syndrome in alcohol-dependent adult patients

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

#### 8.1.2. Angiotensin II - H0004930

---

For the treatment of hypotension in adults with distributive or vasodilatory shock who

remain hypotensive despite fluid and vasopressor therapy

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

## 8.2. Priority Medicines (PRIME)

Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information

### 8.2.1. List of applications received

---

**Action:** For information

The CHMP noted the list of applications received.

### 8.2.2. Recommendation for PRIME eligibility

---

**Action:** For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 8 recommendations for eligibility to PRIME: 4 were granted and 4 were denied. The individual outcomes are listed in PRIME Monthly Report on EMA website.

## 9. Post-authorisation issues

### 9.1. Post-authorisation issues

#### 9.1.1. Ceplene - histamine dihydrochloride - EMEA/H/C/000796/II/0034, Orphan

---

Noventia Pharma Srl

Rapporteur: Jayne Crowe

Scope: "Submission of study report X-03064-3306- to fulfil SOB 002 - A cohort study to follow-up Minimal Residual Disease (MRD) in patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) - Comparison of patients who receive Ceplene/Interleukin-2 as remission maintenance therapy with matched controls."

**Action:** For adoption

Request for Supplementary Information adopted on 22.03.2018.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

### 9.1.2. Daptomycin Hospira - daptomycin - EMEA/H/C/004310/II/0006/G

---

Hospira UK Limited

Rapporteur: Kolbeinn Gudmundsson

Scope: Request for an extension of clock stop to respond to the request for supplementary information.

**Action:** For adoption

Request for Supplementary Information adopted on 22.02.2018.

The CHMP agreed to the request for an extension of clock stop to respond to the request for supplementary information.

## 10. Referral procedures

### 10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

#### 10.1.1. Esmya - ulipristal acetate - EMEA/H/A-20/1460

---

Gedeon Richter Plc.

Rapporteurs for the Article 20 referral: PRAC Rapporteur: Ulla Wändel Liminga; PRAC Co-rapporteur: Menno van der Elst

Rapporteurs for Esmya: CHMP Rapporteur: Kristina Dunder, CHMP Co-rapporteur: Paula Boudewina van Hennik

PRAC Rapporteur: Ulla Wändel Liminga; PRAC Co-rapporteur: Menno van der Elst

Scope: Opinion

**Action:** For adoption

Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20 of Regulation (EC) No 726/2004 based on pharmacovigilance data.

The CHMP adopted an opinion based on the PRAC recommendation by majority (27 positive out of 28 votes), recommending that several measures be put in place to minimise the risk of rare but serious liver injury with Esmya. The measures include: contraindication in women with known liver problems; liver tests before, during and after stopping treatment; a card for patients to inform them about the need for liver monitoring and to contact their



doctor should they develop symptoms of liver injury. In addition, use of the medicine for more than one treatment course has been restricted to women who are not eligible for surgery.

The Norwegian Member was not in agreement with the CHMP recommendation.

The divergent position (Joseph Emmerich, Svein Tune Andersen) was appended to the opinion.

The CHMP noted the EMA public health communication.

### 10.1.2. Zinbryta - daclizumab – EMEA/H/A-20/1456

---

Biogen Idec Ltd

Rapporteurs for the Article 20 referral: PRAC Rapporteur: Eva Segovia; PRAC Co-rapporteur: Marcia Sofia Sanches de Castro Lopes Silva,

Rapporteurs for Zinbryta: CHMP Rapporteur: Bruno Sepodes, CHMP Co-rapporteur: Greg MarkeyPRAC Rapporteur: Eva Segovia; PRAC Co-rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Update on PRAC discussions

**Action:** For information

Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20 of Regulation (EC) No 726/2004 based on pharmacovigilance data

The CHMP noted the PRAC assessment report.

## 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

### 10.2.1. Norethisterone and Ethinylestradiol – EMEA/H/A-5(3)/1470

---

MAH various

Rapporteur: Paula Boudewina van Hennik, Co-rapporteur: Kristina Dunder,

Scope: Start of procedure, appointment of Rapporteurs, list of questions, timetable

Action: For adoption

Request from UK for a CHMP opinion on a recently published study using the zebrafish model for studying the developmental effect of norethisterone acetate and ethinylestradiol and any potential clinical implications on the human foetus

The CHMP appointed Paula Boudewina van Hennik (interest level 1) as Rapporteur and Kristina Dunder (interest level 1) as Co-Rapporteur.

The CHMP adopted a list of questions with a specific timetable.

Start of the procedure at CHMP: 31.05.2018

List of questions to SWP: 31.05.2018

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 03.10.2018

Comments: 08.10.2018

Safety WP discussion: 09.10.018

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 14.10.2018

CHMP list of outstanding issues /CHMP opinion: October 2018 CHMP

The CHMP agreed to consult the SWP and adopted a list of questions to this group.

### **10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004**

No items

### **10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**

No items

### **10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

#### **10.5.1. Scandonest and associated names – mepivacaine - EMEA/H/A-30/1455**

---

Septodont group of companies and associated companies

Rapporteur: Romaldas Maciulaitis, Co-rapporteur: Fatima Ventura

Scope: Opinion

**Action:** For adoption

Harmonisation exercise for Scandonest and associated names. Summary of Product Characteristics and Module 3 harmonisation was triggered by the MAH.

List of Outstanding issues adopted at 22.02.2018, List of Questions adopted at 12.10.2017

The CHMP adopted an opinion by consensus recommending that the concerned marketing authorisations should be varied together with the CHMP assessment report and translation timetable. The CHMP recommended that the SmPCs should be harmonised.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The CHMP noted the EMA public health communication.

## 10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

### 10.6.1. Bacterial lysates-containing based medicinal products for respiratory conditions - EMEA/H/A-31/1465

---

MAH various

Rapporteur: TBC, Co-rapporteur: TBC,

Scope: Start of procedure, appointment of Rapporteurs, list of questions

**Action:** For adoption

Review of the benefit-risk balance following notification by AIFA in Italy on 22 May 2018 of a referral under Article 31 of Directive 2001/83/EC.

The CHMP agreed to postpone the start of procedure in order to seek clarification on the procedure.

### 10.6.2. Metamizole containing medicinal products – metamizole sodium - EMEA/H/A-31/1469

---

MAH various

Rapporteur: Ewa Balkowiec, Co-rapporteur: Harald Enzmann

Scope: Start of procedure, appointment of Rapporteurs, list of questions, timetable

**Action:** For adoption

The Polish National Competent Authority triggered a referral under Article 31 of Directive 2001/83 based on interest of the Union, requesting an opinion to CHMP on whether the scientific data regarding the maximum daily dose and contraindications concerning pregnancy and breastfeeding are adequately presented in the product information of metamizole containing medicinal products.

The CHMP appointed Ewa Balkowiec (interest level 1) as Rapporteur and Harald Enzmann (interest level 1) as Co-Rapporteur.

The CHMP adopted a list of questions together with a specific timetable.

Start of the procedure (CHMP): May 2018 CHMP

List of questions: 31 May 2018

Submission of responses: 23 July 2018

Re-start of the procedure: 06 August 2018

Rapporteur/co-rapporteur AR(s) circulated to CHMP: 30 August 2018

Comments: 04 September 2018

Updated Rapporteur/co-rapporteur ARs circulated to CHMP: 07 September 2018

CHMP list of outstanding issues or CHMP opinion: September 2018 CHMP

## 10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

## 10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

## 10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

## 10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

## 10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

# 11. Pharmacovigilance issue

## 11.1. Early Notification System

May 2018 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action:** For information

The CHMP noted the ENS.

# 12. Inspections

## 12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

## 12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of

such inspections

### **12.3. Pharmacovigilance inspections**

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

### **12.4. GLP inspections**

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

## **13. Innovation Task Force**

### **13.1. Minutes of Innovation Task Force**

No items

### **13.2. Innovation Task Force briefing meetings**

Information related to briefing meetings taking place with applicants cannot be released at the present time as it is deemed to contain commercially confidential information

No items

### **13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004**

No items

### **13.4. Nanomedicines activities**

No items

## **14. Organisational, regulatory and methodological matters**

### **14.1. Mandate and organisation of the CHMP**

#### **14.1.1. PRAC and CHMP involvement in type II variations**

A proposal for an initiative is brought to the CHMP to create a working group of PRAC and CHMP members. The purpose of the group is to clarify the two committees' involvement in type II variations, in order to address issues encountered in the experience to date, most notably the lack of PRAC involvement in PRAC-requested variations (e.g. following signals, PSURs, other PRAC recommendations) or in the assessment of non-interventional PASS

results with implications for the PI.

Nomination of PRAC and CHMP representatives for the initiative.

**Action:** For discussion

The CHMP noted the initiative and identified volunteers.

#### 14.1.2. [Anti-PD-1/PD-L1 – Trend for initial worse efficacy performance](#)

---

CHMP: Daniela Melchiorri

**Action:** For discussion

The CHMP discussed the trend for initial worse efficacy performance. It was noted that while in most instances the overall B/R is clearly positive, there is a need to investigate risk factors/biomarkers that might allow to identify patients at highest risk for early deaths on PD-1/PD-L1 therapy so to provide information to clinicians in the SmPC on patient selection.

### 14.2. [Coordination with EMA Scientific Committees](#)

#### 14.2.1. [Pharmacovigilance Risk Assessment Committee \(PRAC\)](#)

---

Summary of recommendations and advice of PRAC meeting held on 14-17 May 2018

**Action:** For information

The CHMP noted the Summary of recommendations and advice.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2018

**Action:** For adoption

The CHMP noted the EURD list.

#### 14.2.2. [Committee for Advanced Therapies \(CAT\)](#)

---

CAT draft minutes of meeting held on 23-25 May 2018

**Action:** For information

The CHMP noted the draft minutes.

#### 14.2.3. [Paediatric Committee \(PDCO\)](#)

---

PIPs reaching D30 at May 2018 PDCO

**Action:** For information

The CHMP noted the information.

Report from the PDCO meeting held on 29 May – 1 June 2018

**Action:** For information

The CHMP noted the report.

Joint CHMP/PDCO session

Agenda for joint session

**Action:** For discussion

CHMP Rapporteurs participated in the PDCO discussion.

---

#### 14.2.4. Committee for Orphan Medicinal Products (COMP)

---

Report from the COMP meeting held on 22-24 May 2018

**Action:** For information

The CHMP noted the report.

---

#### 14.2.5. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)

---

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 28-30 May 2018

**Action:** For information

The CHMP noted the report.

CMDh questions to SAWP on multi-stakeholder scientific advice for OTC products (EMA/CMDh/296507/2018)

**Action:** For adoption

The CHMP noted the questions to the SAWP.

CMDh questions to BWP on leeches (EMA/CMDh/270304/2018)

**Action:** For adoption

The CHMP noted the CMDh questions to BWP on leeches.

---

### 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

---

#### 14.3.1. Scientific Advice Working Party (SAWP)

---

Report from the SAWP meeting held on 14-17 May 2018. Table of conclusions

**Action:** For information

Scientific advice letters: Disclosure of information related to scientific advice letters cannot

be released at present time as these contain commercially confidential information.

The CHMP noted the report.

#### 14.3.2. Name Review Group (NRG)

---

Table of Decisions of the NRG meeting held on 28-29 May 2018.

**Action:** For adoption

The CHMP noted the Table of Decisions of the NRG meeting.

#### 14.3.3. Biologics Working Party (BWP)

---

Chair: Sol Ruiz/Nanna Aaby Kruse,

Reports from BWP May 2018 meeting to CHMP for adoption:

- 13 reports on products in scientific advice and protocol assistance
- 15 reports on products in pre-authorisation procedures
- 1 report on products in plasma master file

**Action:** For adoption

The CHMP adopted the BWP reports.

#### 14.3.4. Coordination with EMA Working Parties/Working Groups/Drafting Groups on ICH E9 (R1) addendum on estimands

---

BSWP Chair: Anja Schiel, CHMP: Robert James Hemmnings

Reflection of the potential impact of ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials on the CHMP scientific guidelines – feedback from WPs and DGs

**Action:** For information

The CHMP noted the feedback from WPs and DGs.

#### 14.3.5. Modelling and Simulation Working Party (MSWP)

---

Chair (acting): Flora Musuamba Tshinanu

Appointment of members

**Action:** For adoption

The CHMP noted the proposal for composition. The final list of members will be adopted via written procedure after the Plenary.

Post-meeting note: the final list of members was adopted via written procedure on 15 June 2018.



Call for interest for Chair/Vice-Chair

**Action:** For information

The CHMP noted that call for interest for Chair/Vice-Chair and elections will be after appointment of members.

#### 14.3.6. Blood Products Working Party (BPWP)

---

Chair: Jacqueline Kerr

BPWP final response on signal of lupus like syndrome for immunoglobulins to PRAC (EMA/CHMP/810262/2018)

**Action:** For adoption

The CHMP adopted the BPWP final response.

#### 14.3.7. Pharmacogenomics Working Party (PGWP)

---

Chair: Krishna Prasad/Markus Paulmichl

Programme of EMA multi-stakeholder workshop on predictive biomarker-based assay development in the context of drug development and lifecycle (EMA/136048/2018): CHMP members are invited to participate in workshop

**Action:** For information

The CHMP noted the programme of workshop to be held on 18 June 2018, meeting room 3A. Volunteers from CHMP were invited to contribute in workshop.

#### 14.3.8. Pharmacokinetics Working Party (PKWP)

---

Chair: Jan Welink/Henrike Potthast

Product-specific bioequivalence guidelines:

- Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance ( Revision 1)  
Rapporteur: Christina Thygesen
- Dabigatran etexilate hard capsules 75 mg, 110 mg and 150 mg product-specific bioequivalence guidance (batch 6)  
Rapporteur: Christina Thygesen
- Dimethyl fumarate gastro-resistant capsules 120 mg and 240 mg product-specific bioequivalence guidance (batch 7)  
Rapporteur: Henrike Potthast
- Ibuprofen 200 - 800 mg oral use, immediate release formulations product-specific bioequivalence guidance (batch 7)  
Rapporteur: Susan Cole
- Paliperidone prolonged-release tablet 1.5 mg, 3 mg, 6 mg, 9 mg and 12 mg product-specific bioequivalence guidance revision 1 (Revision 1)

Rapporteur: Eva Berglund/Malin Filler

- Pegylated liposomal doxorubicin hydrochloride 2 mg/ml product-specific bioequivalence guidance (batch 8)

Rapporteur: Henrike Potthast

**Action:** For adoption

The CHMP adopted Product-specific bioequivalence guidelines.

Product-specific bioequivalence guidelines, batch 9:

- Aliskiren film-coated tablet 150 mg and 300 mg product-specific bioequivalence guidance  
Rapporteur: Janet Mifsud
- Apixaban film-coated tablets 2.5 and 5 mg product-specific bioequivalence guidance  
Rapporteur: Carolien Versantvoort
- Gefitinib film-coated tablet 250 mg product-specific bioequivalence guidance  
Rapporteur: Eva Berglund/ Malin Filler
- Lapatinib film-coated tablet 250 mg product-specific bioequivalence guidance  
Rapporteur: Eva Berglund/ Malin Filler
- Octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg or 30 mg product-specific bioequivalence guidance  
Rapporteur: Susan Cole

**Action:** For adoption for public consultation

The CHMP adopted Product-specific bioequivalence guidelines for public consultation.

PKWP response to CMDh request for clarification on paliperidone PR tablets PSBGL (EMA/CHMP/277265/2018)

Rapporteur: Eva Gil-Berglund/Malin Filler

**Action:** For adoption

The CHMP adopted the PKWP response.

#### **14.4. Cooperation within the EU regulatory network**

No items

#### **14.5. Cooperation with International Regulators**

No items

#### **14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee**

No items

## 14.7. CHMP work plan

No items

## 14.8. Planning and reporting

No items

## 14.9. Others

No items

## 15. Any other business

### 15.1. AOB topic

#### 15.1.1. Preparedness of the system and capacity increase

---

**Action:** For information

The CHMP noted the information.

#### 15.1.2. Article 58: Update from the March 2017 'Malta' CHMP meeting with African regulators

---

**Action:** For information

The CHMP noted the update from the March 2017 'Malta' CHMP meeting with African regulators regarding Article 58.

#### 15.1.3. Update on Ebola and Nipah Virus

---

**Action:** For information

The CHMP was informed about the Ebola virus disease status in the Democratic Republic of the Congo and was updated on the status of investigational therapeutics for Ebola. Furthermore, the Committee was informed about a Nipah virus outbreak in India. It was noted that, there is so far no case of Nipah in Europa.

## 16. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 28 – 31 May 2018 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Tomas Salmonson	Chair	Sweden	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Milena Stain	Alternate	Austria	No interests declared	
Bart Van der Schueren	Member	Belgium	No interests declared	
Mila Vlaskovska	Member	Bulgaria	No interests declared	
Assena Stoimenova	Alternate	Bulgaria	No interests declared	
Katarina Vučić	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Emilia Mavrokordatou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czech Republic	No interests declared	
Tomas Boran	Alternate	Czech Republic	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Mark Ainsworth	Alternate	Denmark	No restrictions applicable to this meeting	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Tuomo Lapveteläinen	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Joseph Emmerich	Alternate	France	No interests declared	
Harald Enzmann	Member (Vice-Chair)	Germany	No interests declared	
Martina Weise	Alternate	Germany	No restrictions applicable to this meeting	
Agnes Gyurasics	Member	Hungary	No interests declared	
Hrefna Gudmundsdottir	Alternate	Iceland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Daniela Melchiorri	Member	Italy	No restrictions applicable to this meeting	
Natalja Karpova	Alternate	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on:	5.1.9. Tecentriq - atezolizumab - EMEA/H/C/004143/I/0007/G 5.1.10. Tecentriq - atezolizumab - ANX 003 and EMEA/H/C/004143/I/0010
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Svein Rune Andersen	Member	Norway	No interests declared	
Bjorg Bolstad	Alternate	Norway	No restrictions applicable to this meeting	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No restrictions applicable to this meeting	
Simona Badoi	Member	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Rajko Kenda	Member	Slovenia	No restrictions applicable to this meeting	
Concepcion Prieto Yerro	Member	Spain	No interests declared	
Jorge Camarero Jiménez	Alternate	Spain	No participation in final deliberations and voting on:	5.1.9. Tecentriq - atezolizumab - EMEA/H/C/004143/I/0007/G 5.1.10. Tecentriq - atezolizumab - ANX 003 and EMEA/H/C/004143/I/0010
Kristina Dunder	Member	Sweden	No interests	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Filip Josephson	Alternate	Sweden	declared No interests declared	
Nithyanandan Nagercoil	Alternate	United Kingdom	No restrictions applicable to this meeting	
Robert James Hemmings	Co-opted member	United Kingdom	No interests declared	
Koenraad Norga	Co-opted member	Belgium	No participation in final deliberations and voting on:	5.1.17. WS1369 Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781/ WS1369/0001 Trelegy Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363/ WS1369/0001
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czech Republic	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Sabine Mayrhofer	Expert - in person*	Germany	No interests declared	
Sofia Oliveira Martins	Expert - in person*	Portugal	No interests declared	
Valerie Lescrainier	Expert - in person*	Belgium	No interests declared	
Andrew Pollard	Expert - via telephone*	United Kingdom	No restrictions applicable to this meeting	
Eskild Colding-Jorgensen	Expert - via telephone*	Denmark	No restrictions applicable to this meeting	
Runa Vavia Fenger	Expert - via telephone*	Denmark	No restrictions applicable to this meeting	
Clemens Mittmann	Expert - via telephone*	Germany	No interests declared	
Didier Meulendijks	Expert - via telephone*	Netherlands	No interests declared	
Berendina Maria van den Hoorn	Expert - via telephone*	Netherlands	No interests declared	
Antonius Ederveen	Expert - via telephone*	Netherlands	No interests declared	
Martina Schussler-Lenz	Expert - via telephone*	Germany	No interests declared	
Ilona G. Reischl	Expert - via telephone*	Austria	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Agnieszka Przybyszewska	Expert - via telephone*	Ireland	No interests declared	
Monique van Raamsdonk	Expert - via telephone*	Netherlands	No interests declared	
Rune Kjekken	Expert - via telephone*	Norway	No restrictions applicable to this meeting	
Helga Haugom Olsen	Expert - via telephone*	Norway	No interests declared	
Maria Elisabeth Kalland	Expert - via telephone*	Norway	No interests declared	
Ingebjørg Buajordet	Expert - via telephone*	Norway	No interests declared	
Anna Maria Urbaniak	Expert - via telephone*	Norway	No restrictions applicable to this meeting	
Rhea Fitzgerald	Expert - via telephone*	Ireland	No interests declared	
Macarena Rodriguez Mendizabal	Expert - via telephone*	Spain	No interests declared	
Carolien Versantvoort	Expert - via telephone*	Netherlands	No interests declared	
Agustin Portela Moreira	Expert - via telephone*	Spain	No interests declared	
Greg Markey	Member	United Kingdom	No interests declared	
Eeva Sofia Leinonen	Expert - via Adobe*	Finland	No interests declared	
Tiina Hakonen	Expert - via Adobe*	Finland	No restrictions applicable to this meeting	
Olga Kholmanskikh	Expert - via Adobe*	Belgium	No interests declared	
Flora Musuamba Tshinanu	Expert - via Adobe*	Belgium	No interests declared	
George Aislaitner	Expert - via Adobe*	Germany	No interests declared	
Christine Greiner	Expert - via Adobe*	Germany	No interests declared	
Janet Koenig	Expert - via Adobe*	Germany	No interests declared	

Representatives from the European Commission attended the meeting  
Meeting run with the help of EMA staff

\*Experts were only evaluated against the product(s) they have been invited to talk about.

## 17. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

### Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

### Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

### Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications



follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

### **Type II variations - Extension of indication procedures** (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

### **Ancillary medicinal substances in medical devices** (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

### **Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004** (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

### **Re-examination procedures** (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

### **Withdrawal of application** (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

### **Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use)** (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

### **Pre-submission issues** (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

### **Post-authorisation issues** (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

### **Referral procedures** (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures

can be found [here](#).

### **Pharmacovigilance issues** (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

### **Inspections Issues** (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

### **Innovation task force** (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

### **Scientific advice working party (SAWP)** (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

### **Satellite groups / other committees** (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

### **Invented name issues** (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)



30 July 2018  
EMA/520483/2018

## Annex to 28-31 May 2018 CHMP Minutes

### Pre submission and post authorisation issues

<b>A. PRE SUBMISSION ISSUES</b> .....	<b>4</b>
A.1. ELIGIBILITY REQUESTS.....	4
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications .....	4
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION .....	4
<b>B. POST-AUTHORISATION PROCEDURES OUTCOMES</b> .....	<b>4</b>
B.1. Annual re-assessment outcomes .....	4
B.1.1. Annual reassessment for products authorised under exceptional circumstances .....	4
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal .....	4
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	4
B.2.3. Renewals of Conditional Marketing Authorisations .....	7
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES.....	8
B.4. EPARs / WPARs .....	14
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES .....	14
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects .....	14
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .....	18
B.5.3. CHMP-PRAC assessed procedures .....	35
B.5.4. PRAC assessed procedures.....	46
B.5.5. CHMP-CAT assessed procedures .....	50
B.5.6. CHMP-PRAC-CAT assessed procedures .....	51
B.5.7. PRAC assessed ATMP procedures .....	51
B.5.8. Unclassified procedures and worksharing procedures of type I variations.....	51
B.5.9. Information on withdrawn type II variation / WS procedure .....	53
B.5.10. Information on type II variation / WS procedure with revised timetable.....	54
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION .....	54
B.6.1. Start of procedure for New Applications: timetables for information .....	54
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information .....	55
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information.....	56



B.6.4. Annual Re-assessments: timetables for adoption .....	59
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed .....	59
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	61
B.6.7. Type II Variations scope of the Variations: Extension of indication .....	61
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects .....	64
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .....	68
B.6.10. CHMP-PRAC assessed procedures.....	78
B.6.11. PRAC assessed procedures .....	81
B.6.12. CHMP-CAT assessed procedures .....	84
B.6.13. CHMP-PRAC-CAT assessed procedures.....	84
B.6.14. PRAC assessed ATMP procedures .....	84
B.6.15. Unclassified procedures and worksharing procedures of type I variations .....	84
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY.....	85
B.7.1. Yearly Line listing for Type I and II variations.....	85
B.7.2. Monthly Line listing for Type I variations.....	85
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) .....	85
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) .....	85
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) .....	85
B.7.6. Notifications of Type I Variations (MMD only) .....	85
<b>C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) .....</b>	<b>85</b>
<b>D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) .....</b>	<b>85</b>
<b>E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES .....</b>	<b>85</b>
E.1. PMF Certification Dossiers:.....	86
E.1.1. Annual Update.....	86
E.1.2. Variations: .....	86
E.1.3. Initial PMF Certification: .....	86
E.2. Time Tables – starting & ongoing procedures: For information .....	86
<b>F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver .....</b>	<b>86</b>
F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended.....	86
F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health.....	86
<b>G. ANNEX G.....</b>	<b>86</b>
G.1. Final Scientific Advice (Reports and Scientific Advice letters): .....	86
G.2. Ongoing procedures .....	86
G.3. PRIME.....	86
G.3.1. List of procedures concluding at 28-31 May 2018 CHMP plenary: .....	86
G.3.2. List of procedures starting in May 2018 for June 2018 CHMP adoption of outcomes .....	87

**H. ANNEX H - Product Shared Mailboxes – e-mail address .....87**

## A. PRE SUBMISSION ISSUES

### A.1. ELIGIBILITY REQUESTS

---

Report on Eligibility to Centralised Procedure for      Adopted  
May 2018: **For adoption**

---

### A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

---

Final Outcome of Rapporteurship allocation for      Adopted  
May 2018: **For adoption**

---

### A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

## B. POST-AUTHORISATION PROCEDURES OUTCOMES

### B.1. Annual re-assessment outcomes

#### B.1.1. Annual reassessment for products authorised under exceptional circumstances

---

<b>Ceplene - histamine dihydrochloride - EMA/H/C/000796/S/0035, Orphan</b> Noventia Pharma Srl, Rapporteur: Jayne Crowe, PRAC Rapporteur: Almath Spooner	Positive Opinion adopted by consensus together with the CHMP assessment report.  The Marketing Authorisation remains under exceptional circumstances.  The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
<b>Vyndaqel - tafamidis - EMA/H/C/002294/S/0044, Orphan</b> Pfizer Limited, Rapporteur: Joseph Emmerich, PRAC Rapporteur: Ghania Chamouni Request for Supplementary Information adopted on 22.03.2018.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.  The Marketing Authorisation remains under exceptional circumstances.  The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.

---

### B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

#### B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

#### B.2.2. Renewals of Marketing Authorisations for unlimited validity

---

**Abilify Maintena - aripiprazole -**      Request for supplementary information adopted

---

<p><b>EMA/H/C/002755/R/0025</b>  Otsuka Pharmaceutical Europe Ltd, Rapporteur:  Bruno Sepodes, Co-Rapporteur: Eleftheria Nikolaidi, PRAC Rapporteur: Qun-Ying Yue  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>with a specific timetable.</p>
<p><b>Ceplene - histamine dihydrochloride - EMA/H/C/000796/R/0036, Orphan</b>  Noventia Pharma Srl, Rapporteur: Jayne Crowe, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Almath Spooner</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Fortacin - lidocaine / prilocaine - EMA/H/C/002693/R/0023</b>  Recordati Ireland Ltd, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Dolores Montero Corominas  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>INTELENCE - etravirine - EMA/H/C/000900/R/0052</b>  Janssen-Cilag International NV, Rapporteur: Joseph Emmerich, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Caroline Laborde  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Invokana - canagliflozin - EMA/H/C/002649/R/0037</b>  Janssen-Cilag International NV, Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Valerie Strassmann</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Kadcyla - trastuzumab emtansine - EMA/H/C/002389/R/0039</b>  Roche Registration GmbH, Rapporteur: Sinan B. Sarac, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Doris Stenver  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

<p><b>NovoEight - turoctocog alfa - EMEA/H/C/002719/R/0025</b>  Novo Nordisk A/S, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Opsumit - macitentan - EMEA/H/C/002697/R/0027, Orphan</b>  Actelion Registration Limited, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Dolores Montero Corominas  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Procysbi - mercaptamine - EMEA/H/C/002465/R/0019, Orphan</b>  Chiesi Farmaceutici S.p.A, Rapporteur: Kristina Dunder, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Qun-Ying Yue  Request for Supplementary Information adopted on 22.03.2018.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Rasilez HCT - aliskiren / hydrochlorothiazide - EMEA/H/C/000964/R/0087</b>  Noden Pharma DAC, Rapporteur: Daniela Melchiorri, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Amelia Cupelli  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Relvar Ellipta - fluticasone furoate / vilanterol - EMEA/H/C/002673/R/0037</b>  Glaxo Group Ltd, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Dolores Montero Corominas</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Revinty Ellipta - fluticasone furoate / vilanterol - EMEA/H/C/002745/R/0033</b></p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and</p>



---

<p>Glaxo Group Ltd, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Dolores Montero Corominas</p>	<p>translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
---	---

---

<p><b>Tybost - cobicistat - EMEA/H/C/002572/R/0041</b> Gilead Sciences Ireland UC, Rapporteur: Robert James Hemmings, Co-Rapporteur: Joseph Emmerich, PRAC Rapporteur: Julie Williams Request for Supplementary Information adopted on 22.03.2018.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
--	--

---

### **B.2.3. Renewals of Conditional Marketing Authorisations**

---

<p><b>Bavencio - avelumab - EMEA/H/C/004338/R/0003, Orphan</b> Merck Serono Europe Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Anette Kirstine Stark  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
---	---

---

<p><b>Translarna - ataluren - EMEA/H/C/002720/R/0041, Orphan</b> PTC Therapeutics International Limited, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Sabine Straus Request for Supplementary Information adopted on 26.04.2018.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
---	--

---

<p><b>Zalmoxis - allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) - EMEA/H/C/002801/R/0010, Orphan, ATMP</b> MolMed S.p.A., Rapporteur: Johannes Hendrikus</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains</p>
--	--

---

---

Ovelgonne, CHMP Coordinator: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski Request for Supplementary Information adopted on 20.04.2018.	conditional.  The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
--	---

---

### B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

---

<b>Signal detection</b>	Noted.
-------------------------	--------

PRAC recommendations on signals adopted at the PRAC meeting held on 14-16 May 2018  
PRAC:

---

<b>Signal of drug interaction between apixaban or edoxaban and selective serotonin reuptake inhibitors (SSRI) and/or serotonin and noradrenaline reuptake inhibitors (SNRI) leading to increased risk of bleeding.</b>	Adopted.
--	----------

**Eliquis – apixaban – EMEA/H/C/002148**

Bristol-Myers Squibb/Pfizer EEIG, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Nithyanandan Nagercoil

**Lixiana – edoxaban – EMEA/H/C/002629**

**Roteas – edoxaban – EMEA/H/C/004339**  
Daiichi Sankyo Europe GmbH, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Martina Weise

**Ariclaim – duloxetine – EMEA/H/C/000552**

Eli Lilly Nederland B.V., Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Kristina Dunder

**Cymbalta – duloxetine –**

**EMEA/H/C/000572**

**Duloxetine Lilly – duloxetine –**

**EMEA/H/C/004000**

**Xeristar – duloxetine – EMEA/H/C/000573**

**Yentreve – duloxetine – EMEA/H/C/000545**

Eli Lilly Nederland B.V., Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Filip Josephson

**Duloxetine Mylan – duloxetine –**

**EMEA/H/C/003981**

Generics UK Limited, Rapporteur: John Joseph Borg

**Duloxetine Zentiva – duloxetine –**

**EMEA/H/C/003935**

Zentiva k.s., Rapporteur: Kristina Dunder

PRAC recommendation on a variation: **For**

---

<b>adoption</b>	Adopted.
<p><b>Signal of progressive multifocal leukoencephalopathy (PML)</b>  <b>Revlimid - lenalidomide – EMEA/H/C/000717</b>          Celgene Europe Limited, Rapporteur: Alexandre Moreau, Co-Rapporteur: Filip Josephson          PRAC recommendation on a variation: <b>For adoption</b></p>	
<p><b>Signal of pulmonary haemorrhage</b>  <b>Lenograstim; lipegfilgrastim, pegfilgrastim</b></p>	Adopted.
<p><b>Lonquex – lipegfilgrastim – EMEA/H/C/002556</b>          Sicor Biotech UAB., Rapporteur: Greg Markey, Co-Rapporteur: Johann Lodewijk Hillege</p> <p><b>Neulasta - pegfilgrastim – EMEA/H/C/000420</b>          Amgen Europe B.V., Rapporteur: Robert James Hemmings, Co-Rapporteur: Johann Lodewijk Hillege          PRAC recommendation on a variation: <b>For adoption</b></p>	
<p><b>Signal of aseptic meningitis</b>  <b>Keytruda – pembrolizumab – EMEA/H/C/003820</b></p>	Adopted.
<p>Merck Sharp &amp; Dohme B.V., Rapporteur: Daniela Melchiorri, Co-Rapporteur: Jan Mueller-Berghaus          PRAC recommendation on a variation: <b>For adoption</b></p>	
<p><b>Signal on evaluation of preliminary data on congenital neurological disorders from an observational study.</b></p>	Adopted.
<p><b>Tivicay – dolutegravir - EMEA/H/C/003820</b>          ViiV Healthcare B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Joseph Emmerich          DHPC and communication plan have been circulated for written adoption          PRAC recommendation on a variation: <b>For adoption</b></p>	
<p>PSUR procedures for which PRAC adopted a recommendation for variation of the terms of</p>	

---

the MA at its May 2018 meeting:

---

**EMA/H/C/PSUSA/0000235/201709**

(arsenic trioxide)

CAPS:

**Trisenox** (EMA/H/C/000388) (arsenic trioxide), Teva B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, "01.10.2014 to 30.09.2017"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.4 of the SmPC to introduce a warning on encephalopathy and of section 4.8 of the SmPC to add encephalopathy and Wernicke encephalopathy as new ADRs with a frequency 'not known'.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

---

**EMA/H/C/PSUSA/0000939/201710**

(deferasirox)

CAPS:

**EXJADE** (EMA/H/C/000670) (deferasirox), Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, "01 Nov 2016 – 31 Oct 2017"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following changes:

Update of section 4.4 of the SmPC to amend the current warnings on renal and hepatic functions to add that some cases were associated with loss of consciousness in a context of hyperammonaemic encephalopathy with specific focus on paediatric patients and to recommend early dosage of ammonia levels in patients developing unexplained changes in mental status. Consequential update to section 4.8 of the SmPC to add a new second footnote for the 'renal tubular function disorders' and 'hepatic failure' adverse drug reactions regarding cases with changes in consciousness in an hyperammonaemic encephalopathy context. Update of section 4.5 of the SmPC to include a new drug-drug interaction between busulfan and deferasirox. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

---

**EMA/H/C/PSUSA/0002051/201710**

(micafungin)

CAPS:

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation

---

---

**Mycamine** (EMA/H/C/000734) (micafungin),  
Astellas Pharma Europe B.V., Rapporteur: Harald  
Enzmann, PRAC Rapporteur: Martin Huber, "09  
Oct 2016- 08 Oct 2017"

and the PRAC assessment report as appended,  
recommends by consensus the variation to the  
terms of the marketing authorisation(s) for the  
above mentioned medicinal product(s),  
concerning the following change(s):

Based on the PRAC review of data on safety and  
efficacy, the PRAC considers that the risk-benefit  
balance of medicinal products containing  
micafungin remains unchanged but recommends  
that the terms of the marketing authorisation(s)  
should be varied as follows:

Update of section 4.8 of the SmPC to add the  
adverse reaction "anaphylactic and  
anaphylactoid shock" with a frequency "not  
known" in order to align with the existing  
warning in section 4.4 of the SmPC. The  
Package leaflet is updated accordingly.

---

**EMA/H/C/PSUSA/0002919/201710**  
(thalidomide)

CAPS:

**Thalidomide Celgene** (EMA/H/C/000823)  
(thalidomide), Celgene Europe Limited,  
Rapporteur: Alexandre Moreau, PRAC  
Rapporteur: Ghania Chamouni, "10 October  
2016 to 09 October 2017"

The CHMP, having considered in accordance with  
Article 28 of Regulation (EC) No 726/2004 the  
PSUR on the basis of the PRAC recommendation  
and the PRAC assessment report as appended,  
recommends by consensus, the variation to the  
terms of the marketing authorisation(s) for the  
above mentioned medicinal product(s),  
concerning the following change(s):

Update of section 4.8 of the SmPC to add the  
adverse reaction leukocytoclastic vasculitis with  
a frequency 'not known'. The Package leaflet is  
updated accordingly.

The Icelandic and the Norwegian CHMP  
members agree with the above-mentioned  
recommendation of the CHMP.

---

**EMA/H/C/PSUSA/0002999/201709**  
(toremifene)

CAPS:

**Fareston** (EMA/H/C/000091) (toremifene),  
Orion Corporation, Rapporteur: Alexandre  
Moreau, PRAC Rapporteur: Ghania Chamouni,  
"01/10/2014 - 30/09/2017"

The CHMP, having considered in accordance with  
Article 28 of Regulation (EC) No 726/2004 the  
PSUR on the basis of the PRAC recommendation  
and the PRAC assessment report as appended,  
recommends by consensus, the variation to the  
terms of the marketing authorisation(s) for the  
above mentioned medicinal product(s),  
concerning the following change(s):

Update of section 4.8 of the SmPC to add  
"hepatic steatosis" with a frequency "unknown".

The Icelandic and the Norwegian CHMP  
members agree with the above-mentioned  
recommendation of the CHMP.

---

**EMA/H/C/PSUSA/00010318/201710**

The CHMP, having considered in accordance with

---

---

(nintedanib (oncology indications))

CAPS:

**Vargatef** (EMA/H/C/002569) (nintedanib),  
Boehringer Ingelheim International GmbH,  
Rapporteur: Sinan B. Sarac, PRAC Rapporteur:  
Agni Kapou, "22 Nov 2016 to 15 Oct 2017"

Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following changes:

Update of section 4.4 of the SmPC to add a new warning on renal impairment/failure and update of section 4.8 of the SmPC to add 'renal failure' as a new adverse drug reaction with a frequency 'uncommon'. Update of section 4.4 of the SmPC to update the current warning on gastrointestinal perforations to include that fatal post-marketing cases have been reported. Update of section 4.8 of the SmPC to add 'myocardial infarction' as a new adverse drug reaction with a frequency 'uncommon'. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

---

**EMA/H/C/PSUSA/00010319/201710**

(nintedanib (respiratory indication))

CAPS:

**OFEV** (EMA/H/C/003821) (nintedanib),  
Boehringer Ingelheim International GmbH,  
Rapporteur: Jayne Crowe, PRAC Rapporteur:  
Nikica Mirošević Skvrce, "16 Apr 2017 to 15 Oct 2017"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following changes:

Update of section 4.4 of the SmPC to add a warning that cases of renal impairment/failure, some with fatal outcome have been reported with nintedanib and that patients should be monitored and dose adjustment should be considered in case of renal impairment/failure. Update of section 4.8 of the SmPC to add the adverse reactions 'rash' with a frequency 'common', 'pruritus' with a frequency 'uncommon' and 'renal failure' with a frequency 'unknown'. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

---

**EMA/H/C/PSUSA/00010387/201710**

(edoxaban)

CAPS:

**Lixiana** (EMA/H/C/002629) (edoxaban),  
Daiichi Sankyo Europe GmbH, Rapporteur:

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the

<p>Concepcion Prieto Yerro</p> <p><b>Roteas</b> (EMA/H/C/004339) (edoxaban), Daiichi Sankyo Europe GmbH, Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Julie Williams, "22-APR-2017 – 21-OCT-2017"</p>	<p>terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add 'thrombocytopenia' with a frequency 'uncommon'. The Package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010449/201711</b> (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide)</p> <p>CAPS:</p> <p><b>Genvoya</b> (EMA/H/C/004042) (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide), Gilead Sciences International Limited, Rapporteur: Robert James Hemmings, PRAC Rapporteur: Amelia Cupelli, "05 May 2017 to 04 November 2017"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following changes:</p> <p>Update of section 4.3 of the SmPC to add the contraindication of co-administration with lurasidone and update of section 4.5 to add a corresponding warning on the contraindicated concomitant use. The Package Leaflet is updated accordingly.</p>
<p><b>EMA/H/C/PSUSA/00010459/201710</b> (talimogene laherparepvec)</p> <p>CAPS:</p> <p><b>Imlygic</b> (EMA/H/C/002771) (talimogene laherparepvec), Amgen Europe B.V., Rapporteur: Olli Tenhunen, PRAC Rapporteur: Brigitte Keller-Stanislawski, "27 April 2017 to 26 October 2017"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.4 of the SmPC to include additional wording regarding the possibility of qPCR-testing for talimogene laherparepvec following accidental exposure to Imlygic. The Package Leaflet has been updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010612/201710</b> (sodium oxybate (oral use))</p> <p>CAPS:</p> <p><b>Xyrem</b> (EMA/H/C/000593) (sodium oxybate), UCB Pharma Limited, Rapporteur: Bruno Sepodes</p> <p>NAPS:</p> <p><b>ALCOVER</b> - LABORATORIO FARMACEUTICO C.T.</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred</p>

S.R.L. PRAC Rapporteur: Ana Sofia Diniz Martins, "13-Oct-2016 to 12-Oct-2017"	active substance(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction "nocturia" with a frequency "not known". The Package leaflet is updated accordingly.
--	--

#### B.4. EPARs / WPARs

<b>Biktarvy - bictegrovir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449</b> Gilead Sciences International Limited, treatment of adults infected with human immunodeficiency virus-1 (HIV-1), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the EPL in case necessary.
<b>Carmustine Obvius - carmustine - EMEA/H/C/004326</b> Obvius Investment B.V, treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphomas, Generic, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the EPL in case necessary.
<b>Dzuevo - sufentanil - EMEA/H/C/004335</b> FGK Representative Service GmbH, management of acute moderate to severe pain, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the EPL in case necessary.

#### B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

##### B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

<b>Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMEA/H/C/001206/II/0058/G</b> GlaxoSmithkline Biologicals SA, Informed Consent of Pandemrix (EXP), Rapporteur: Greg Markey Opinion adopted on 25.05.2018.	Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>ATryn - antithrombin alfa - EMEA/H/C/000587/II/0033/G</b> Laboratoire Francais du Fractionnement et des Biotechnologies, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.



---

on 03.05.2018, 15.02.2018.

---

**Benepali - etanercept -  
EMA/H/C/004007/II/0035**

Samsung Bioepis UK Limited, Rapporteur:  
Andrea Laslop  
Request for Supplementary Information adopted  
on 17.05.2018.

Request for supplementary information adopted  
with a specific timetable.

---

**BYETTA - exenatide -  
EMA/H/C/000698/II/0061/G**

AstraZeneca AB, Rapporteur: Kristina Dunder  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on  
17.05.2018. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

**Cervarix - human papillomavirus vaccine  
[types 16, 18] (recombinant, adjuvanted,  
adsorbed) - EMA/H/C/000721/II/0094**

GlaxoSmithkline Biologicals SA, Rapporteur:  
Bart Van der Schueren  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on  
17.05.2018. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

**Cosentyx - secukinumab -  
EMA/H/C/003729/II/0034**

Novartis Europharm Limited, Rapporteur:  
Tuomo Lapveteläinen  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on  
17.05.2018. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

**Cyramza - ramucirumab -  
EMA/H/C/002829/II/0022**

Eli Lilly Nederland B.V., Rapporteur: Paula  
Boudewina van Hennik  
Opinion adopted on 03.05.2018.

Positive Opinion adopted by consensus on  
03.05.2018. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

**Dupixent - dupilumab -  
EMA/H/C/004390/II/0003/G**

sanofi-aventis groupe, Rapporteur: Jan Mueller-  
Berghaus  
Opinion adopted on 25.05.2018.  
Request for Supplementary Information adopted  
on 12.04.2018.

Positive Opinion adopted by consensus on  
25.05.2018. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

**Entyvio - vedolizumab -  
EMA/H/C/002782/II/0029**

Takeda Pharma A/S, Rapporteur: Greg Markey  
Request for Supplementary Information adopted  
on 17.05.2018.

Request for supplementary information adopted  
with a specific timetable.

---

**Eptifibatide Accord - eptifibatide -  
EMA/H/C/004104/II/0003**

Accord Healthcare Limited, Generic, Generic of  
Integrilin, Rapporteur: Jayne Crowe  
Opinion adopted on 25.05.2018.  
Request for Supplementary Information adopted  
on 19.04.2018.

Positive Opinion adopted by consensus on  
25.05.2018. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

<p><b>Eylea - aflibercept -</b>  <b>EMA/H/C/002392/II/0046</b>  Bayer AG, Rapporteur: Alexandre Moreau  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Flixabi - infliximab -</b>  <b>EMA/H/C/004020/II/0025</b>  Samsung Bioepis UK Limited, Rapporteur: Jan Mueller-Berghaus  Opinion adopted on 17.05.2018.</p>	<p>Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>Fluenz Tetra - influenza vaccine (live attenuated, nasal) -</b>  <b>EMA/H/C/002617/II/0078/G</b>  AstraZeneca AB, Rapporteur: Bart Van der Schueren  Opinion adopted on 17.05.2018.</p>	<p>Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>Gliolan - aminolevulinic acid -</b>  <b>EMA/H/C/000744/II/0016/G</b>  medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Bruno Sepodes  Request for Supplementary Information adopted on 17.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Imatinib Teva - imatinib -</b>  <b>EMA/H/C/002585/II/0033</b>  Teva B.V., Generic, Generic of Glivec, Rapporteur: Jorge Camarero Jiménez  Request for Supplementary Information adopted on 03.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Imraldi - adalimumab -</b>  <b>EMA/H/C/004279/II/0005/G</b>  Samsung Bioepis UK Limited (SBUK), Rapporteur: Outi Mäki-Ikola  Opinion adopted on 25.05.2018.  Request for Supplementary Information adopted on 15.03.2018.</p>	<p>Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>Insuman - insulin human -</b>  <b>EMA/H/C/000201/II/0124</b>  Sanofi-Aventis Deutschland GmbH, Rapporteur: Bart Van der Schueren  Opinion adopted on 31.05.2018.</p>	<p>Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>NovoSeven - eptacog alfa (activated) -</b>  <b>EMA/H/C/000074/II/0101/G</b>  Novo Nordisk A/S, Rapporteur: Paula Boudewina van Hennik  Opinion adopted on 17.05.2018.</p>	<p>Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>

---

Request for Supplementary Information adopted on 15.02.2018.

---

**Ontruzant - trastuzumab -  
EMA/H/C/004323/II/0007**

Samsung Bioepis UK Limited (SBUK),  
Rapporteur: Koenraad Norga  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**OPDIVO - nivolumab -  
EMA/H/C/003985/II/0051/G**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:  
Jorge Camarero Jiménez  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Prepandrix - A/Indonesia/05/2005  
(H5N1) like strain used (PR8-IBCDC-RG2) -  
EMA/H/C/000822/II/0075/G**

GlaxoSmithKline Biologicals SA, Rapporteur:  
Greg Markey  
Opinion adopted on 25.05.2018.

Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Simponi - golimumab -  
EMA/H/C/000992/II/0082/G**

Janssen Biologics B.V., Rapporteur: Kristina  
Dunder  
Request for Supplementary Information adopted on 31.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Strensiq - asfotase alfa -  
EMA/H/C/003794/II/0027/G, Orphan**

Alexion Europe SAS, Rapporteur: Greg Markey  
Opinion adopted on 03.05.2018.  
Request for Supplementary Information adopted on 22.03.2018.

Positive Opinion adopted by consensus on 03.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Vaxelis - diphtheria, tetanus, pertussis  
(acellular, component), hepatitis B (rDNA),  
poliomyelitis (inact.) and Haemophilus  
type B conjugate vaccine (adsorbed) -  
EMA/H/C/003982/II/0030**

MCM Vaccine B.V., Rapporteur: Bart Van der  
Schueren  
Opinion adopted on 31.05.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Vimizim - elosulfase alfa -  
EMA/H/C/002779/II/0022/G, Orphan**

BioMarin Europe Ltd, Rapporteur: Johann  
Lodewijk Hillege  
Opinion adopted on 25.05.2018.  
Request for Supplementary Information adopted on 22.02.2018.

Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Xolair - omalizumab -**

Request for supplementary information adopted

---

---

**EMA/H/C/000606/II/0084** with a specific timetable.  
Novartis Europharm Limited, Rapporteur:  
Kristina Dunder  
Request for Supplementary Information adopted  
on 03.05.2018.

---

**WS1347**  
**Blitzima-**  
**EMA/H/C/004723/WS1347/0008**  
**Ritemvia-**  
**EMA/H/C/004725/WS1347/0008**  
**Rituzena-**  
**EMA/H/C/004724/WS1347/0009**  
**Truxima-**  
**EMA/H/C/004112/WS1347/0009**  
Celltrion Healthcare Hungary Kft., Lead  
Rapporteur: Sol Ruiz  
Opinion adopted on 31.05.2018.  
Request for Supplementary Information adopted  
on 22.03.2018.

---

#### **B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

---

**Afinitor - everolimus -**  
**EMA/H/C/001038/II/0058**  
Novartis Europharm Limited, Rapporteur: Harald  
Enzmann, "Submission of the final report from  
study CRAD001Y2201, listed as a category 1  
study in the RMP. This is a three arm  
randomised study investigating the combination  
of everolimus with exemestane versus  
everolimus alone versus capecitabine in patients  
with oestrogen receptor positive metastatic  
breast cancer after recurrence or progression on  
letrozole or anastrozole. Consequently, Annex II  
of the Product Information was updated to  
remove this study."  
  
Request for Supplementary Information adopted  
on 31.05.2018.

---

**Atripla - efavirenz / emtricitabine /**  
**tenofovir disoproxil -**  
**EMA/H/C/000797/II/0129**  
Bristol-Myers Squibb and Gilead Sciences Ltd.,  
Rapporteur: Martina Weise, "Update of sections  
4.4 and 4.5 of the Atripla SmPC in order to add  
drug-drug interaction data based on the final  
results from study GS-US-342-1167 listed as  
category 3 study in the RMP;  
  
This is a Phase I Study to Evaluate the

---

---

Pharmacokinetic Drug-Drug Interactions between Sofosbuvir/GS-5815 Fixed Dose Combination (FDC) Tablets and Antiretrovirals Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF; Atripla), Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF; Complera), Dolutegravir (DTG; Tivicay) or Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (EVG/COBI/FTC/TAF) in Healthy Subjects,

Section 2 of the Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10 and minor linguistic amendments to the following languages: BG, CS, ET, HU, LT, LV, RO, SK."

Opinion adopted on 17.05.2018.

---

**Brilique - ticagrelor -  
EMA/H/C/001241/II/0038**

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.5 of the SmPC in order to include interaction information between morphine and ticagrelor based on the conclusion of the legally binding measure LEG 022; the Package Leaflet is updated accordingly."  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Caprelsa - vandetanib -  
EMA/H/C/002315/II/0029**

Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of section 5.3 of the SmPC to reflect the results from pre-clinical study titled "ZD6474: A 104 Week Carcinogenicity Study by Oral Gavage in Rats", study number 521826."  
Opinion adopted on 31.05.2018.  
Request for Supplementary Information adopted on 22.02.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Ceplene - histamine dihydrochloride -  
EMA/H/C/000796/II/0034, Orphan**

Noventia Pharma Srl, Rapporteur: Jayne Crowe, "Submission of study report X-03064-3306- to fulfil SOB 002 - A cohort study to follow-up Minimal Residual Disease (MRD) in patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) - Comparison of patients who receive Ceplene/Interleukin-2 as remission

See 9.1

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

maintenance therapy with matched controls.”

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 22.03.2018.

---

**Darzalex - daratumumab -  
EMA/H/C/004077/II/0013, Orphan**

Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, “Update of sections 4.4 and 4.8 of the SmPC in order to add the adverse reaction serious infusion-related reactions, including anaphylactic reactions with frequency unknown based on the cumulative review of clinical trial and post-marketing data. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to add a traceability statement to bring the product information in line with the guideline on good pharmacovigilance practices and to add specific text relating to the excipient sodium to align the product information with the updated published EMA EU excipient guideline.”

Opinion adopted on 03.05.2018.

Request for Supplementary Information adopted on 15.03.2018.

Positive Opinion adopted by consensus on 03.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Deltyba - delamanid -  
EMA/H/C/002552/II/0021, Orphan**

Otsuka Novel Products GmbH, Rapporteur: Greg Markey, “Update of sections 4.4, 4.8, 4.9 and 5.1 of the SmPC to reflect the results of the final study report of 242-09-213 (A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis), submitted to fulfil SOB 001. Annex II is updated to reflect that SOB 001 has been fulfilled. The Package Leaflet is updated to amend the details of the local representatives.”

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 25.01.2018, 14.09.2017.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Dynastat - parecoxib -  
EMA/H/C/000381/II/0072**

Pfizer Limited, Duplicate, Duplicate of Xapit (SRD), Rapporteur: Jayne Crowe, “Update of sections 4.2, 4.4 and 5.1 of the SmPC in order

Request for supplementary information adopted with a specific timetable.

---

to update the information on the use of parecoxib beyond 3 days based on a recent publication on the 'Safety of parecoxib when used for more than 3 days for the management of postoperative pain'; this is an observatory study of the Pfizer clinical trial database to identify randomized, double-blind, placebo controlled trials in which patients could have, potentially, received parecoxib for longer than 3 days for the management of postoperative pain. The Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the Package Leaflet in line with the SmPC with the inclusion of diazepam and omeprazole in section 2 of the Package Leaflet."

Request for Supplementary Information adopted on 17.05.2018.

---

**Eliquis - apixaban -**

**EMA/H/C/002148/II/0051**

Bristol-Myers Squibb / Pfizer EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to reflect all adverse drug reactions for all indications with the correct calculated frequency based on clinical trials data. The package leaflet is updated accordingly."

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 15.02.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) -**

**EMA/H/C/003852/II/0024/G**

MSD Vaccins, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update the information following results from long-term follow-up (LTFU) studies. Specifically:

- a long-term effectiveness sub-section is added, based on the first interim reports from the 9vHPV studies V503-021-01 and V503-002-20 (two category 3 studies included in the pharmacovigilance plan of the 9vHPV vaccine - MEA-004 and MEA 005, respectively).

- update of the immunogenicity sub-section based on the data from the two 9vHPV studies listed above as well as final results from studies

Request for supplementary information adopted with a specific timetable.

---

V503-001-04 and V503-010-01.

- update of the qHPV clinical data based on the efficacy/effectiveness results and/or immunogenicity results of the qHPV studies V501-015-21 (4th interim report), V501-019-21 (final study report), V501-020-21 (final study report) and the extension of study V501-167."

Request for Supplementary Information adopted on 31.05.2018.

---

**Humira - adalimumab -**

**EMA/H/C/000481/II/0179**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add Lichenoid skin reactions with a rare frequency following a signal detection request (EPITT ref. No. 19128) for cumulative review (SDA106). The Package Leaflet is updated accordingly"

Request for Supplementary Information adopted on 31.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**HyQvia - human normal immunoglobulin -**

**EMA/H/C/002491/II/0040/G**

Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC to include aseptic meningitis as adverse reaction. The PL is updated accordingly. Update of section 4.2 of the SmPC to include the option of handpush administration of the rHuPH20 component (in addition to administration with a pump). This change is a correction in order to harmonize with the PIL."

---

**IBRANCE - palbociclib -**

**EMA/H/C/003853/II/0011**

Pfizer Limited, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC to update the clinical efficacy data from pivotal Phase 3 Study A5481008 (PALOMA-2), a study of IBRANCE in combination with letrozole, to include the results from recent analyses of the study with a data cutoff date of 31 May 2017. In addition, the MAH took the opportunity to update section 4.2 to include that when coadministered with an aromatase inhibitor, the later should be administered according to the dose schedule reported in the Summary of Product Characteristics."

Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.



---

on 17.05.2018.

---

**Iclusig - ponatinib -**

**EMA/H/C/002695/II/0045/G, Orphan**

Incyte Biosciences Distribution B.V.,

Rapporteur: Greg Markey, "Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to reflect updated safety and efficacy information based on 64-month follow-up data from the completed study AP24534-10-201 (PACE) " A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia", as well as data from the final study AP24534-07-101 "A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients with Refractory or Advanced Chronic Myelogenous Leukemia and other Hematologic Malignancies". The Package Leaflet is updated accordingly."

Opinion adopted on 31.05.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Imbruvica - ibrutinib -**

**EMA/H/C/003791/II/0042, Orphan**

Janssen-Cilag International NV, Rapporteur:

Filip Josephson, "Update of section 5.3 of the SmPC in order to update preclinical safety data information based on final results from a non-clinical carcinogenicity study in mouse (MEA011.1). In addition, the Marketing authorisation holder (MAH) took the opportunity to align the Package leaflet to information already included in the SmPC and to update the list of local representatives for Lithuania, Czech Republic, Netherlands, Slovenia and Portugal in the Package Leaflet."

Opinion adopted on 31.05.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Inflectra - infliximab -**

**EMA/H/C/002778/II/0061**

Hospira UK Limited, Duplicate, Duplicate of

Remsima, Rapporteur: Greg Markey, "To submit the final report from study CT-P13 3.4, listed as a category 3 study in the RMP. A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients with Active Crohn's Disease."

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Jinarc - tolvaptan -**

Positive Opinion adopted by consensus on

<p><b>EMA/H/C/002788/II/0016</b>  Otsuka Pharmaceutical Europe Ltd, Rapporteur: Greg Markey, "Update of sections 4.3 and 4.4 of the SmPC in order to add a contraindication and a warning on hypersensitivity to benzazepine derivatives, thus aligning the product information to the patient population studied in clinical trials and the RMP for Jinarc. The Package Leaflet is updated accordingly."  Opinion adopted on 31.05.2018.</p>	<p>31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>Keytruda - pembrolizumab - EMA/H/C/003820/II/0044</b>  Merck Sharp &amp; Dohme B.V., Rapporteur: Daniela Melchiorri, "Update of section 5.1 of the SmPC in order to reflect the final overall survival efficacy data from study Keynote-024; a randomized, open-label phase III trial of pembrolizumab versus platinum based chemotherapy in 1L subjects with PD-L1 strong metastatic non-small cell lung cancer (NSCLC)."  Request for Supplementary Information adopted on 31.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>NovoEight - turoctocog alfa - EMA/H/C/002719/II/0023</b>  Novo Nordisk A/S, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to reflect data on untreated patients resulting from final results of the Guardian 2 (NN7008-3568) study and the Guardian 4 (NN7008-3809) study for Novoeight. The Package Leaflet was updated accordingly."  Opinion adopted on 31.05.2018.  Request for Supplementary Information adopted on 22.03.2018.</p>	<p>Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>Ozempic - semaglutide - EMA/H/C/004174/II/0001</b>  Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC in order to reflect final results from the SUSTAIN 7 trial (NN9535-4216), a 40-week open-label trial comparing the safety and efficacy of 0.5 mg of Ozempic to 0.75 mg of dulaglutide and 1 mg of Ozempic to 1.5 mg of dulaglutide in patients on metformin with type-2 diabetes."  Request for Supplementary Information adopted on 25.05.2018.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Pradaxa - dabigatran etexilate - EMA/H/C/000829/II/0111</b>  Boehringer Ingelheim International GmbH,</p>	<p>Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP</p>

---

Rapporteur: Mark Ainsworth, PRAC Rapporteur: Anette Kirstine Stark, "Update of section 5.1 of the SmPC to reflect the phase II outcome results from the Global Registry on Long-Term Oral Antithrombotic Treatment In Patients with Atrial Fibrillation (GLORIA-AF) including the main objective "to collect real-world data on important outcome events of antithrombotic treatments for the prevention of stroke" for patients taking pradaxa. recommendation.

The RMP (version 35.0) has also been updated to reflect the study results."  
Opinion adopted on 31.05.2018.  
Request for Supplementary Information adopted on 26.04.2018.

---

**Remsima - infliximab -  
EMA/H/C/002576/II/0052**

Celltrion Healthcare Hungary Kft., Rapporteur: Greg Markey, "To submit the final report from study CT-P13 3.4, listed as a category 3 study in the RMP. A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients with Active Crohn's Disease."  
Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Revestive - teduglutide -  
EMA/H/C/002345/II/0043, Orphan**

Shire Pharmaceuticals Ireland Limited, Rapporteur: Mark Ainsworth, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on the final CSR of study TED-C14-006 ("a 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years With Short Bowel Syndrome who are Dependent on Parenteral Support"; a category 3 study in the RMP). The Package Leaflet is updated accordingly."  
Request for Supplementary Information adopted on 31.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Revolade - eltrombopag / eltrombopag  
olamine - EMA/H/C/001110/II/0046**

Novartis Europharm Limited, Rapporteur: Concepcion Prieto Yerro, "Update of the PI to align with the company's Core Safety Data

Request for supplementary information adopted with a specific timetable.

---

Sheet:

Update of information related to liver function tests, thrombotic and thromboembolic complications, MDS in the section 4.4;  
Update of DDI and food interaction information in the sections 4.5 and 5.2;  
Update of the section 4.8 by: inclusion and removal of ADRs, changes in some ADRs frequencies following pooling of safety data;  
Reorganisation of the section 5.1 in relation to severe aplastic anaemia;  
Update of the section 5.3 with information related to Juvenile animal studies.  
The MAH took the opportunity to make some editorial changes throughout the PI. The Package leaflet is updated accordingly."  
Request for Supplementary Information adopted on 03.05.2018.

---

**Samsca - tolvaptan -**

**EMA/H/C/000980/II/0031**

Otsuka Pharmaceutical Europe Ltd, Rapporteur: Greg Markey, "Update of sections 4.3 and 4.4 of the SmPC in order to add a contraindication and a warning on hypersensitivity to benzazepine derivatives, thus aligning the product information to the patient population studied in clinical trials and the RMP for Jinarc.

The Package Leaflet is updated accordingly."

Opinion adopted on 31.05.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Simponi - golimumab -**

**EMA/H/C/000992/II/0079**

Janssen Biologics B.V., Rapporteur: Kristina Dunder, "Update of sections 4.2 and 5.1 of the SmPC in order to update the information on maintenance regimen for patients weighing <80 kg based on analyses of PK, efficacy and safety from the pivotal C0524T18 study. The Package Leaflet is updated accordingly."

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 22.02.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Stelara - ustekinumab -**

**EMA/H/C/000958/II/0063**

Janssen-Cilag International NV, Rapporteur: Greg Markey "Update of section 4.8 of the SmPC in order to revise the immunogenicity rate in patients with psoriasis from "less than 8%" to "up to 12.4 %" following based on new

Request for supplementary information adopted with a specific timetable.

---

data

generated from a Phase 3b study in psoriasis patients, CNTO1275PSO3009 (PSTELLAR) - A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis (PSTELLAR).

In addition, the MAH took the opportunity to update section 4.4 of the SmPC and package leaflet with additional warning of the excipient sodium to align with the recent updates to the Annex of the EC guideline on excipients in labelling."

Request for Supplementary Information adopted on 31.05.2018, 22.03.2018.

---

**Taltz - ixekizumab -**

**EMA/H/C/003943/II/0018**

Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC, providing a short summary of the results of study RHBO (IXORA-Q): a multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab versus placebo in patients with moderate-to-severe genital psoriasis."

Opinion adopted on 25.05.2018.

Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**TECFIDERA - dimethyl fumarate -**

**EMA/H/C/002601/II/0051/G**

Biogen Idec Ltd, Rapporteur: Martina Weise, "Submission of the final report from study 109HV114. This is a randomised, open-label, single-dose, crossover study in healthy volunteers to assess the pharmacokinetics of 4 new formulations compared to Tecfidera 240mg capsules.

Submission of the final report from study 109MS201 listed as a category 3 study in the RMP. This is an open-label, multicentre study in patients with Relapsing-Remitting Multiple Sclerosis to evaluate the safety and tolerability of 240 mg Tecfidera three times daily administered as add-on therapy to beta interferons (IFN $\beta$ ) or Glatiramer Acetate (GA).

Submission of the synopsis report from study 109MS308. This is a randomised, multicentre, double-blind, placebo-controlled study of the efficacy and safety of Tecfidera in delaying disability progression in patients with secondary

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

progressive multiple sclerosis.

Submission of the final report (abbreviated) from study 109MS416. This is a randomised, multicentre, treatment-blinded, parallel group Phase IIIb study aimed to evaluate the effect of 6-week up-titration of Tecfidera treatment on the severity of gastrointestinal adverse effects in patients with multiple sclerosis.”

Opinion adopted on 17.05.2018.

---

**Tivicay - dolutegravir -  
EMA/H/C/002753/11/0034**

ViiV Healthcare B.V., Rapporteur: Filip Josephson, “Update of section 4.8 of the SmPC to add the new ADRs ‘acute hepatic failure’ and ‘weight increased’ based on post-marketing and clinical trial data. The Package Leaflet has been updated accordingly.”

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Triumeq - dolutegravir / abacavir /  
lamivudine - EMA/H/C/002754/11/0053**

ViiV Healthcare UK Limited, Rapporteur: Filip Josephson, “Update of section 4.8 of the SmPC to add the new ADRs ‘acute hepatic failure’ and ‘weight increased’ based on post-marketing and clinical trial data. The Package Leaflet has been updated accordingly.”

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Truvada - emtricitabine / tenofovir  
disoproxil - EMA/H/C/000594/11/0147**

Gilead Sciences Ireland UC, Rapporteur: Greg Markey, “Update of sections 4.8 and 5.1 of the Truvada SmPC based on the final results from study Study ATN-113 (CO-US-164-0455): listed as a category 3 study in the RMPI; this is a Project PeEPare - An open label demonstration project and phase II safety study of pre-exposure prophylaxis use among 15 to 17 year old men who have sex with men (YMSM) in the United States.”

Request for Supplementary Information adopted on 25.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Zebinix - eslicarbazepine acetate -  
EMA/H/C/000988/11/0064**

Bial - Portela & C<sup>a</sup>, S.A., Rapporteur: Martina Weise, “Update of section 4.8 of the SmPC to

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

add urticaria, angioedema and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) as adverse drug reactions with unknown frequency, based on recent safety signal evaluation information. The Package Leaflet is updated accordingly. In addition, revision of section 4.4 of the SmPC to align the information on the adverse event angioedema with the information already present in the Package Leaflet."

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 15.03.2018.

---

**Zykadia - ceritinib -**

**EMA/H/C/003819/II/0016**

Novartis Europharm Limited, Rapporteur: Jorge Camarero Jiménez, "Update of sections 4.2, 4.4, 4.8 and 5.2 of the SmPC in order to include amendments to the posology in hepatically impaired patients and update the safety information, respectively. The updates are based on the results from the hepatic function Study CLDK378A2110 which evaluated the PK, safety and tolerability of a single oral dose of ceritinib in subjects with varying degrees of impaired hepatic function and results from physiology-based pharmacokinetic (PBPK) modeling at steady-state.

Submission of the Report for Study A2110 fulfils MEA 001 for Zykadia. Data from Study DMPK R1700954-01 were also submitted in support of the application.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 22.03.2018, 14.12.2017, 09.11.2017, 14.09.2017.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1273/G**

**Effentora-**

**EMA/H/C/000833/WS1273/0047/G**

Teva B.V., Lead Rapporteur: Martina Weise, "Update of sections 4.2 and 4.4 of the SmPC in order to add a warning on Hyperalgesia following an internal cumulative review. The Package Leaflet is updated accordingly.

Update of sections 4.4 and 4.45 of the SmPC in

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

order to add a warning on the interaction of fentanyl with benzodiazepines or other CNS depressants including alcohol following an internal cumulative review. The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to introduce editorial and format changes in the SmPC and PL.”

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 22.03.2018, 01.02.2018.

---

**WS1295**  
**Advagraf-**  
**EMA/H/C/000712/WS1295/0048**  
**Modigraf-**  
**EMA/H/C/000954/WS1295/0026**

Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, “Update of section 4.8 of the SmPC in order to add new information on pain in extremity reported as part of calcineurin-inhibitor induced pain syndrome (CIPS). In addition, the Worksharing applicant (WSA) took the opportunity to introduce minor updates throughout the Product Information. The Package Leaflet was updated accordingly.”

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 15.03.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1316**  
**Glyxambi-**  
**EMA/H/C/003833/WS1316/0011**  
**Jardiance-**  
**EMA/H/C/002677/WS1316/0037**  
**Synjardy-**  
**EMA/H/C/003770/WS1316/0032**

Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, “Update of section 5.1 of the SmPC for Jardiance, Synjardy and Glyxambi in order to add clinically relevant information on heart failure and microvascular endpoints based on the results from trial 1245.25 (EMPA-REG OUTCOME study).

The Package Leaflet is updated accordingly.

In addition, the Worksharing applicant (WSA) took the opportunity to update section 4.4 of the SmPC to align the statement regarding diabetic ketoacidosis for all SGLT-2 Inhibitors.”

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.



---

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 22.02.2018.

---

**WS1322**

**Genvoya-**

**EMA/H/C/004042/WS1322/0042**

**Stribild-EMA/H/C/002574/WS1322/0090**

**Tybost-EMA/H/C/002572/WS1322/0042**

Gilead Sciences International Limited, Lead Rapporteur: Robert James Hemmings, "Update of Section 4.5 of the SmPC for Genvoya, Tybost and Stribild based on data on Drug-drug Interaction between cobicistat containing products and Direct Oral Anticoagulants (DOACs).

Request for supplementary information adopted with a specific timetable.

The Patient Leaflet (PIL) has been updated for all three products as a consequence.

The Worksharing MAH has taken this opportunity to introduce some minor administrative amendments throughout the product information for all three products respectively, as needed (i.e., correction of abbreviations, correction of formatting errors and correction of spelling mistakes). Minor administrative update is also made to Annex III for all three products.

The MAH has also taken this opportunity to implement some minor linguistic amendments (MLAs) to the translations of the respective product information annexes:

- Genvoya: CS, DA, DE, FI, HR, HU, IS, NO, PT and RO languages
- Tybost: DA, ES and HU languages
- Stribild: DA, DE, ES, FI, FR, IS, LV, MT, NO and RO languages"

Request for Supplementary Information adopted on 17.05.2018, 22.02.2018.

---

**WS1346**

**Aprovel-**

**EMA/H/C/000141/WS1346/0170**

**CoAprovel-**

**EMA/H/C/000222/WS1346/0185**

**Irbesartan Hydrochlorothiazide Zentiva-**

**EMA/H/C/000783/WS1346/0099**

**Irbesartan Zentiva-**

**EMA/H/C/000785/WS1346/0078**

**Karvea-EMA/H/C/000142/WS1346/0174**

**Karvezide-**

---

---

**EMEA/H/C/000221/WS1346/0187**

Sanofi Clir SNC, Lead Rapporteur: Concepcion Prieto Yerro, "Update of sections 4.4 and 4.8 of the SmPC in order to add a warning and update the safety information for irbesartan and for irbesartan/ hydrochlorothiazide linked to irbesartan INN by adding "Psoriasis : the use of irbesartan in patients with psoriasis or a history of psoriasis should be carefully weighed as it may exacerbate psoriasis" and include new undesirable effects "anaphylactic reaction including anaphylactic shock", "psoriasis", "photosensitivity"; and update of the corresponding section of PL.

In addition, the Worksharing applicant (WSA) took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10."

---

**WS1351****Eviplera-****EMEA/H/C/002312/WS1351/0090****Stribild-EMEA/H/C/002574/WS1351/0091****Truvada-****EMEA/H/C/000594/WS1351/0146****Viread-EMEA/H/C/000419/WS1351/0185**

Gilead Sciences International Limited, Lead Rapporteur: Joseph Emmerich, "Update of section 4.4 of the SmPC for Viread, Truvada and Stribild and Section 4.5 of the SmPC for Viread, Truvada, Eviplera and Stribild in order to add the results from study Study GS-US-367-1657, listed as a category 3 study in the RMP; this is a Phase 1 Multiple Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Potential between Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination and HIV Antiretroviral in Healthy Subjects.

The corresponding section 2 of the Package Leaflet for Viread, Truvada and Stribild has been updated.

In addition, the Worksharing applicant (WSA) took the opportunity to make administrative updates to Section 4.1 and 4.5 of the Stribild SmPC and to implement some linguistic amendments (MLAs) to the translations of the product information annexes."

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**WS1356/G****Humalog-****EMA/H/C/000088/WS1356/0163/G****Liprolog-****EMA/H/C/000393/WS1356/0125/G**

Eli Lilly Nederland B.V., Lead Rapporteur:  
Robert James Hemmings, "B.II.e.5.b: To delete the BASAL presentations: EU/1/96/007/010, 029, 037 and 038 for Humalog Basal and EU/1/01/195/022, 023, 026 and 027 for Liprolog Basal.

C.I.4: Update of sections 4.2 and 6.6 of the SmPC of Humalog/Liprolog in pre-filled pens and cartridges to address the PRAC recommendation regarding the potential increased risk of medication error associated with withdrawing insulin from pre-filled pens and cartridges, leading to dysglycaemia.

In addition, the Worksharing applicant (WSA) took the opportunity to combine all SmPCs resulting in four SmPCs: 100 units/ml presentations, Mix 25 100 units/ml presentations, Mix50 100 units/ml presentations and 200 units/ml presentations. The MAH also brought the product information in line with the latest QRD template version 10, 02/2016, and included the recommendation to only use Lilly insulin cartridges with Lilly reusable pens. Minor editorial changes have been included.

The Package Leaflet and Labelling are updated accordingly."

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 12.04.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1359****Invega-EMA/H/C/000746/WS1359/0059****Trevicta-****EMA/H/C/004066/WS1359/0012****Xeplion-EMA/H/C/002105/WS1359/0038**

Janssen-Cilag International NV, Lead Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to include somnambulism and sleep-related eating disorder under a rare and not known frequency, respectively, after post marketing reports analysis. The Package Leaflet is updated accordingly. In addition, for INVEGA/XEPLION/TREVICTA minor editorial changes have been introduced and the details of the local representatives in Portugal, Belgium

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

Iceland, Slovenia, Netherlands and Luxembourg are updated in the Package Leaflet. An update is also proposed to the INVEGA Package Leaflet in section 2 to add a standard statement concerning sodium content according to the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. Updated wording to align to the Excipients Guideline is also proposed for Risperdal Oral, together with removing the brand name (West Medimop) for the vial adaptors for Risperdal Consta."

Opinion adopted on 31.05.2018.

---

**WS1362**

**Enbrel-EMEA/H/C/000262/WS1362/0217**  
**LIFMIOR-**  
**EMEA/H/C/004167/WS1362/0014**

Pfizer Limited, Lead Rapporteur: Robert James Hemmings, "Submission of the final report from the study 20050111 listed as category 3 study in the RMP, in order to fulfil Enbrel P46 0134.2. This is a multicentre, open-label extension study to evaluate the long-term safety and efficacy of etanercept in paediatric subjects with moderate to severe plaque psoriasis for up to 264 weeks (or until the quarterly visit after the subject's 18th birthday, whichever comes last) who participated in controlled study 20030211."

Opinion adopted on 25.05.2018.

Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1363**

**Kispplx-EMEA/H/C/004224/WS1363/0010**  
**Lenvima-**  
**EMEA/H/C/003727/WS1363/0013**

Eisai Europe Ltd., Lead Rapporteur: Bart Van der Schueren, "Update of sections 4.4 and 4.8 of the SmPC to add wound healing and aortic dissection. The PIL is updated accordingly."

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**WS1371**

**Rasilez-EMEA/H/C/000780/WS1371/0119**  
**Rasilez HCT-**  
**EMEA/H/C/000964/WS1371/0086**

Noden Pharma DAC, Lead Rapporteur: Daniela Melchiorri, "Update of section 4.8 and 5.1 of the Rasilez SmPC and section 4.8 of the Rasilez/HCTZ SmPC in order to reflect the results from paediatric study CSPP100A2365E2 (a multicenter, 52 to 104 week extension study

Request for supplementary information adopted with a specific timetable.

---

to evaluate the long term growth and development of pediatric hypertensive patients 6–17 years of age treated previously with aliskiren) provided as per the requirement of article 46.”

Request for Supplementary Information adopted on 31.05.2018.

---

### **B.5.3. CHMP-PRAC assessed procedures**

---

#### **Adenuric - febuxostat -**

**EMA/H/C/000777/II/0047**

Menarini International Operations Luxembourg S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser, “Update of sections 4.4 and 4.5 of the SmPC in order to reflect the results of preclinical study MRPO-2015-PKM-005 “Pharmacokinetic of azathioprine in the rat after one-week daily oral treatment at three different dosages and with the concomitant oral administration of febuxostat or allopurinol” and clinical study REP-POPPK-MRP-2015-PKM-005 “Population Pharmacokinetic analysis from study titled Pharmacokinetic of azathioprine in the rat after one-week daily oral treatment at three different dosages and with the concomitant oral administration of febuxostat or allopurinol”, investigating the drug-drug interaction with azathioprine when co-administered with febuxostat.

The RMP version 6.0 has also been submitted.

In addition, the MAH took the opportunity to correct the typing errors and to bring the PI in line with the latest QRD template version 10.”

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 25.01.2018, 14.09.2017.

---

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### **Amyvid - florbetapir (18F) -**

**EMA/H/C/002422/II/0029**

Eli Lilly Nederland B.V., Rapporteur: Harald Enzmann, PRAC Rapporteur: Valerie Strassmann, “Submission of the final report from study I6E-MC-AVBF listed as a category 3 study in the RMP. This is a non-interventional category 3 PASS: European Drug Usage Survey for Amyvid to assess the usage pattern of Amyvid in the EU.

Section 4.4 of SmPC has been reformatted as

---

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

result of this study.

The RMP version 3.1 has also been submitted.”

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 08.02.2018.

---

**Cosentyx - secukinumab -  
EMA/H/C/003729/II/0033/G**

Novartis Europharm Limited, Rapporteur:  
Tuomo Lapveteläinen, PRAC Rapporteur: Eva A. Segovia, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to include information on dose up-titration for Psoriatic Arthritis (PsA) and update of the radiographic sub-section for Psoriatic Arthritis (PsA) based on results from the 24-week data from study CAIN457F2342, the pooled data from PsA Phase 3 studies, the pooled data from patients who up-titrated their secukinumab dose in studies CAIN457F2306E1, CAIN457F2312 and CAIN457F2318, and long-term study observations which demonstrate higher rates of discontinuation for patients on secukinumab 150 mg compared to patients on secukinumab 300 mg. the Package leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to bring the Package leaflet in line with the latest approved SmPC as per procedure (EMA/H/C/003729/IB/0028). The RMP (v.3.0) has also been updated including suicidal ideation and behavior as an important potential risk in the RMP and including minor administrative/editorial changes (LEG 005.2).”  
Request for Supplementary Information adopted on 31.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Dacogen - decitabine -  
EMA/H/C/002221/II/0033, Orphan**

Janssen-Cilag International N.V., Rapporteur:  
Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, “Update of section sections 4.2, 4.8, 5.1 and 5.2 of the SmPC to reflect the results from paediatric study DACOGENAML2004 titled ‘Phase 1-2 Safety and Efficacy Study of DACOGEN in sequential administration with Cytarabine in children with relapsed or refractory acute myeloid leukemia’, provided as per the requirement of article 46. The RMP version 3.1 (in line with the revision 2 of the RMP template) has also been submitted.

Request for supplementary information adopted with a specific timetable.

---

In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.4 of the SmPC to align the safety warning related to sodium excipient with the Annex to the revised European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. The Package Leaflet is updated in accordance. Moreover, the contact details of the local representative in Slovenia have been updated in the Package Leaflet."

Request for Supplementary Information adopted on 31.05.2018.

---

**Difclir - fidaxomicin -**

**EMA/H/C/002087/II/0032/G**

Astellas Pharma Europe B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Qun-Ying Yue, "C.I.11.b)

Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to update the safety information following final results from the drug utilisation study ANEMONE listed as an additional pharmacovigilance activity in the RMP. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

C.I.3

Update of sections 4.4 and 5.2 of the SmPC in order to update the safety information based on results from the PROFILE study, an open label study designed to evaluate the pharmacokinetics of fidaxomicin in IBD subjects with CD. The Package Leaflet is updated accordingly.

The RMP version 9.0 has also been submitted."

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 30.11.2017.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Eylea - aflibercept -**

**EMA/H/C/002392/II/0045**

Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, "Update of sections 4.2 and 5.1 of the SmPC in order to add information for the Health Care Professional related to earlier treatment extension and related increments intervals based on final results from phase 4 study ALTAIR. This is an interventional study evaluating the efficacy and

Request for supplementary information adopted with a specific timetable.

---

safety of repeated doses of intravitreal (IVT) aflibercept with variable treatment intervals in Japanese subjects with neovascular AMD. The Package Leaflet is updated accordingly. The RMP version 24.1 has also been submitted.”

Request for Supplementary Information adopted on 17.05.2018.

---

**Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0023, Orphan**  
Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Patrick Batty, “Update of section 4.8 and 5.1 of the SmPC in order to update the overall survival data based on final results from study BO21004/CLL11 listed as a category 3 study in the RMP; this is the pivotal study that evaluated the efficacy and safety of obinutuzumab as therapy for patients with previously untreated CLL with comorbidities; The RMP version 4.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity format the listing of “other side effects” and correct the term heart attack to heart failure in section 4 of the Package Leaflet.”

Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Gilenya - fingolimod - EMEA/H/C/002202/II/0047**  
Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, “Submission of the CSR for Study D2399, a long-term safety and tolerability study of fingolimod 0.5 mg/day in approximately 5000 patients with relapsing multiple sclerosis.”

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 08.03.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Harvoni - ledipasvir / sofosbuvir - EMEA/H/C/003850/II/0064**  
Gilead Sciences International Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of section 4.2, 4.4,4.8, 5.1 and 5.2 of the SmPC in order to update the safety and efficacy information based on interim results from study GS-US-334-0154 listed as a category 3 study in the RMP; this is a study to evaluate the safety, efficacy and pharmacokinetics of treatment with Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Genotype 1 or 4 HCV-Infected

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.



---

Subjects with Renal Insufficiency; the Package Leaflet is updated accordingly. The RMP version 3.2 has also been submitted.”  
Opinion adopted on 31.05.2018.  
Request for Supplementary Information adopted on 22.02.2018.

---

**Invokana - canagliflozin -  
EMA/H/C/002649/II/0034**

Janssen-Cilag International NV, Rapporteur: Martina Weise, PRAC Rapporteur: Valerie Strassmann, “Update of sections 4.1, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information on cardiovascular events following final results from CANVAS Program (DIA3008 and DIA4003); the Package Leaflet is updated accordingly.  
Study DIA3008 is phase 3 Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus  
Study DIA4004 is phase 4 Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus  
The RMP version 7.2 has also been submitted.”  
Request for Supplementary Information adopted on 31.05.2018, 25.01.2018.

Request for supplementary information adopted with a specific timetable.

---

**Ocrevus - ocrelizumab -  
EMA/H/C/004043/II/0002**

Roche Registration GmbH, Rapporteur: Mark Ainsworth, PRAC Rapporteur: Julie Williams, “Update of sections 4.4 and 4.5 of the SmPC in order to include information on vaccination based on interim results from study BN29739 listed as a category 3 study in the RMP; this is a phase IIIb, multicentre, randomised, parallel-group, open-label study to evaluate the effects of ocrelizumab on immune response in patients with relapsing forms of multiple sclerosis. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted.”  
Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**OFEV - nintedanib -  
EMA/H/C/003821/II/0018/G, Orphan**

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP

---

Boehringer Ingelheim International GmbH,  
Rapporteur: Jayne Crowe, PRAC Rapporteur:  
Nikica Mirošević Skvrce, "Update of section 4.4  
in order to amend the current warning on co-  
administration with pirfenidone and update of  
section 5.1 to include the results of study  
1199.222, a phase IV, 12 week, open label,  
randomised, parallel group study to evaluate  
the safety, tolerability and pharmacokinetics of  
oral nintedanib in combination with oral  
pirfenidone in comparison with nintedanib alone  
in patients with idiopathic pulmonary disease  
(IPF). The Package Leaflet is updated  
accordingly.

Update of section 5.2 of the SmPC in order to  
include the results of study 1199.229, a phase  
IV, open label, multi-dose, 2 groups study to  
investigate the drug-drug interaction between  
nintedanib and pirfenidone in patients with IPF,  
a category 3 study in the RMP. The RMP version  
5.1 has also been submitted. In addition, the  
Marketing authorisation holder (MAH) took the  
opportunity to implement some corrections to  
the French and Swedish translations."

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted  
on 08.03.2018, 11.01.2018.

Members were in agreement with the CHMP  
recommendation.

---

**Oncaspar - pegaspargase -  
EMA/H/C/003789/II/0016/G**

Baxalta Innovations GmbH, Rapporteur:  
Alexandre Moreau, PRAC Rapporteur: Patrick  
Batty, "Update of sections 4.2, 4.3, 4.4, 4.5,  
4.6, 4.7, 4.8, 4.9, 5.1 5.2 and 5.3 of the SmPC  
with the final results from studies DFCI 11-001  
and AALL07P4 listed as category 3 studies in the  
RMP;

Study DFCI 11-001 is a Phase 2, open-label,  
randomized, multicenter study to determine the  
safety and feasibility of administering an  
investigational asparaginase product  
(asparaginase formulation) compared with  
Oncaspar in subjects aged 1 to <22 years with  
newly diagnosed ALL and lymphoblastic  
lymphoma.

Study AALL07P4 is a multicenter, open label,  
randomized, active-controlled, parallel design  
clinical pilot study conducted to evaluate the PK,  
pharmacodynamics, safety, immunogenicity and  
efficacy of an investigational asparaginase

Request for supplementary information adopted  
with a specific timetable.

---

product in comparison with Oncaspar in patients aged 1 to <31 years newly diagnosed with high risk B-precursor ALL.

The Package Leaflet is proposed to be updated accordingly.

The RMP version 3.0 has also been submitted." Request for Supplementary Information adopted on 17.05.2018.

---

**Ozempic - semaglutide -  
EMA/H/C/004174/II/0002/G**

Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Qun-Ying Yue  
Opinion adopted on 31.05.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Remicade - infliximab -  
EMA/H/C/000240/II/0209**

Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of the current warning on colon cancer and dysplasia of Section 4.4 of the SmPC based on final report of the OPUS Registry (Prospective, Observational, Non-Interventional, Post-marketing Safety Surveillance Program in Subjects with UC; P04808) as per MEA 121. In addition, the MAH is taking the opportunity to add a warning on screening tests for tuberculosis to align it with current medical practice, add a reminder on the patient alert card in package leaflet and include some editorial changes in line with the QRD template." Request for Supplementary Information adopted on 17.05.2018, 11.01.2018.

Request for supplementary information adopted with a specific timetable.

---

**Revlimid - lenalidomide -  
EMA/H/C/000717/II/0098, Orphan**

Celgene Europe Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, "Update of section 4.4 of the SmPC and of the Annex II key elements of the risk minimisation programme with information on prescription duration and to revise due dates of the PASS CC-5013-MDS-10 and 12; furthermore, the RMP version 35.1 has been revised in line with the updated Guideline on Good Pharmacovigilance Practices (GVP) Module V to propose the reclassification and/or renaming of known safety concerns associated with the use of lenalidomide. Consequently, Annex IID has been updated accordingly also to remove

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

activities deemed not to belong to the risk minimisation measures. In addition, the labelling information related to the pregnancy prevention has been updated in line with other products in the class. Minor editorial changes have also been introduced throughout the PI.”  
Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 12.04.2018.

---

**TAGRISO - osimertinib -  
EMA/H/C/004124/II/0021**

AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Sabine Straus, “Update of SmPC sections 4.5, 4.6 and 5.2 to reflect the results of Study D5160C00036, undertaken to assess the effect of single and multiple oral doses of osimertinib on the pharmacokinetics of a P-glycoprotein probe drug (Fexofenadine) in patients with advanced EGFRm NSCLC that have progressed on a prior EGFR-TKI regimen. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make a minor correction in Annex II and to implement minor editorial and/or QRD-template related changes in the SmPC and Package Leaflet. A revised RMP version 9 was provided as part of the application.”

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**TAGRISO - osimertinib -  
EMA/H/C/004124/II/0024**

AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Sabine Straus, “Update of sections 4.2 and 5.2 of the SmPC based on the results from Study D5160C00008, undertaken to determine the pharmacokinetics, safety and tolerability of AZD9291 following a single oral dose to patients with advanced solid tumours and normal hepatic function or mild or moderate hepatic impairment. An updated RMP version 9 was provided as part of the application.”

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**Truberzi - eluxadoline -  
EMA/H/C/004098/II/0005/G**

Allergan Pharmaceuticals International Ltd,  
Rapporteur: Harald Enzmann, PRAC Rapporteur:

Request for supplementary information adopted with a specific timetable.

---

Adam Przybylkowski, "C.I.13: Submission of the final report from study ELX-PH-08 listed as a category 3 study. This is an in vitro evaluation study aimed to investigate the effects on treating primary cultures of cryopreserved human hepatocytes with eluxadoline on the expression of cytochrome P450 (CYP) enzymes

C.I.13: Submission of the final report from study 3030-102-002 listed as a category 3 study. This is a randomised, open label study aimed to evaluate the effect of eluxadoline as a potential time dependent inhibitor of CYP3A4 with the substrate midazolam.

C.I.11.a: To update the RMP for Truberzi to version v2.0 to update the important identified risk from "SO spasm" to "SO spasm (Sphincter of Oddi dysfunction, SOD)" and to include pancreatitis as an important identified risks. This change has been agreed by the CHMP/PRAC in the outcome of EMEA/H/C/PSUSA/00010528/201703." Request for Supplementary Information adopted on 17.05.2018, 08.03.2018.

---

**Vokanamet - canagliflozin / metformin - EMEA/H/C/002656/II/0034**

Janssen-Cilag International NV, Rapporteur: Martina Weise, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.1, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information on cardiovascular events following final results from CANVAS Program (DIA3008 and DIA4003); the Package Leaflet is updated accordingly.

Study DIA3008 is phase 3 Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus

Study DIA4004 is phase 4 Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus

The RMP version 7.2 has also been submitted.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD

Request for supplementary information adopted with a specific timetable.

---

template version 10.”

Request for Supplementary Information adopted on 31.05.2018, 25.01.2018.

---

**Zelboraf - vemurafenib -**

**EMA/H/C/002409/II/0048/G**

Roche Registration GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, “Update of the SmPC section 5.2 with the information on mean bioavailability of vemurafenib at steady state together with information on renal elimination based on the phase I study GO28395.

Submission of the CSR from the study GO27826: A Phase III, Randomised, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence. Minor editorial changes have been included in the PI. The RMP version 11.0 has also been updated.”

Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1312**

**Prezista-**

**EMA/H/C/000707/WS1312/0093**

**Rezolsta-**

**EMA/H/C/002819/WS1312/0023**

**Symtuza-**

**EMA/H/C/004391/WS1312/0005**

Janssen-Cilag International NV, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst, “Update of sections 4.2, 4.4, 4.6 and 5.2 of the SmPCs for Prezista, Rezolsta and Symtuza to reflect the data of the category 3 study TMC114HIV3015 in HIV-1 infected pregnant women. The PL of Prezista, Rezosta and Symtuza are also updated accordingly.

Updated RMPs (version 25.6 for Prezista, 4.6 for Rezolsta and 4.0 for Symtuza) are agreed accordingly.

In addition, the MAH took the opportunity to implement the template version 2 for the Prezista and Rezolsta RMPs, removal of the fulfilled category 4 DAD study from the Prezista and Rezolsta RMPs, removal of observational study on growth in children and ‘growth abnormalities in the paediatric population’ as important potential risk in the Prezista RMP and addition of the missing information ‘Safety in

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

patients with cardiac conduction disorders' in the Rezolsta RMP (alignment with Tybost RMP). Correction of data for TMC114HIV3015 (DRV/r/v arm) in section 5.1 of the SmPC were also implemented."

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 22.03.2018.

---

**WS1333**

**Blitzima-**

**EMA/H/C/004723/WS1333/0007**

**Ritemvia-**

**EMA/H/C/004725/WS1333/0007**

**Rituzena-**

**EMA/H/C/004724/WS1333/0008**

**Truxima-**

**EMA/H/C/004112/WS1333/0008**

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, Lead PRAC Rapporteur: Doris Stenver, "Submission of the clinical study report (CSR) of Study CT-P10 3.2 (A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis). The RMP (version 9.0) is updated in accordance."

Opinion adopted on 31.05.2018.

Request for Supplementary Information adopted on 08.03.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1349/G**

**Gardasil-**

**EMA/H/C/000703/WS1349/0076/G**

**Silgard-**

**EMA/H/C/000732/WS1349/0064/G**

MSD Vaccins, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Qun-Ying Yue, "Update of section 5.1 of the SmPC in order to update the information following final results from two Long-term follow-up (LTFU) studies:

- Protocol V501-020-21, a category 3 study part of the pharmacovigilance activities foreseen in the Risk Management Plan (RMP) of the qHPV vaccine. It is an extension of study V501-020 (the pivotal efficacy study of qHPV vaccine in young men 16 to 26 years of age) to assess effectiveness and immunogenicity of the qHPV vaccine for up to 10 years of follow-up.

Submission of this final report fulfils Gardasil

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

MEA 070.3 and Silgard MEA 069.3.

- Extension of Protocol V501-16. The base study was an MSD-sponsored randomized clinical trial that assessed the immunogenicity of a 2 dose Schedule of the qHPV in adolescents 9 to 13 years of age compared to a 3-dose schedule in young women 16 to 26 years of age. The study provides additional immunogenicity follow-up through 5 years post-vaccination. Submission of this study fulfils Gardasil REC 083 and Silgard REC 080.

RMP version 12 has also been submitted, updated to to reflect completion of the above-mentioned category 3 study.

In addition, the Worksharing applicant (WSA) took the opportunity to bring the PI in line with the latest QRD template version 10 and to amend the details of one local representative in the package leaflet."

Opinion adopted on 17.05.2018.

---

#### **B.5.4. PRAC assessed procedures**

---

PRAC Led  
**Bronchitol - mannitol -  
EMA/H/C/001252/II/0031, Orphan**  
Pharmaxis Pharmaceuticals Limited,  
Rapporteur: Nithyanandan Nagercoil, PRAC  
Rapporteur: Julie Williams, PRAC-CHMP liaison:  
Robert James Hemmings, "Submission of the  
final report of a survey of healthcare  
professionals to measure to the effectiveness of  
the communication of risk minimisation  
messages in the educational materials at 6  
months post-launch and 6 months post-  
redistribution of the revised healthcare  
professional leaflet. The RMP version 7.0 has  
also been approved."  
Opinion adopted on 17.05.2018.  
Request for Supplementary Information adopted  
on 12.04.2018.

Positive Opinion adopted by consensus on  
17.05.2018. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

PRAC Led  
**Inflectra - infliximab -  
EMA/H/C/002778/II/0060**  
Hospira UK Limited, Duplicate, Duplicate of  
Remsima, Rapporteur: Greg Markey, PRAC  
Rapporteur: Patrick Batty, PRAC-CHMP liaison:  
Greg Markey, "To update the RMP for Inflectra

Request for supplementary information adopted  
with a specific timetable.

---



---

to version 8.0 to introduce the new RMP template, update some milestones of the Pharmacovigilance plan and delete some safety concerns from the educational material to Health Care Professionals.”  
Request for Supplementary Information adopted on 17.05.2018.

---

PRAC Led  
**Remsima - infliximab -  
EMA/H/C/002576/II/0051**  
Celltrion Healthcare Hungary Kft., Rapporteur: Greg Markey, PRAC Rapporteur: Patrick Batty, PRAC-CHMP liaison: Greg Markey, “To update the RMP for Remsima to version 8.0 to introduce the new RMP template, update some milestones of the Pharmacovigilance plan and delete some safety concerns from the educational material to HCP.”  
Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led  
**Renvela - sevelamer carbonate -  
EMA/H/C/000993/II/0043**  
Genzyme Europe BV, PRAC Rapporteur: Laurence de Fays, PRAC-CHMP liaison: Bart Van der Schueren, “Submission of the final report from study SEVELC08371. This was a historical cohort study of adult patients with severe chronic kidney disease assessing the risk of bladder cancer by sevelamer exposure.”  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

PRAC Led  
**Suboxone - buprenorphine / naloxone -  
EMA/H/C/000697/II/0037**  
Indivior Europe Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, “C.I.13: Submission of the final report for study PEUS005” SUBOXONE mortality study in the UK with The Health Improvement Network Database (THIN)”. This is a PASS to estimate the all-cause mortality among patients exposed to SUBOXONE in comparison to buprenorphine and methadone.  
  
RMP version 13.0 has been submitted.”  
Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

PRAC Led  
**Sycrest - asenapine -**

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP

---

**EMEA/H/C/001177/II/0031/G**

N.V. Organon, Rapporteur: Greg Markey, PRAC Rapporteur: Julie Williams, PRAC-CHMP liaison: Greg Markey, "Submission of the final reports from studies P08307 (EP04026.001), P08308 (EP04026.003), P08309 (EP04026.002) and P08310 (EP04026.004) listed as a category 3 studies in the RMP. They are observational studies with the aim to assess safety and utilisation of asenapine in different contexts. No changes in the PI are proposed. The RMP (version 5.1) is updated accordingly." Opinion adopted on 17.05.2018.

Members were in agreement with the CHMP recommendation.

---

PRAC Led

**TAGRISSO - osimertinib -****EMEA/H/C/004124/II/0022**

AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Sabine Straus, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 9 in order to remove the category 3 PASS Study D5165C00001 (CAURAL) from the Pharmacovigilance Plan." Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**TAGRISSO - osimertinib -****EMEA/H/C/004124/II/0023**

AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Sabine Straus, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 9 in order to remove the category 3 PASS Study D5160C00022 (ASTRIS) from the Pharmacovigilance plan." Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**WS1270****Enbrel-EMEA/H/C/000262/WS1270/0216****LIFMIOR-****EMEA/H/C/004167/WS1270/0013**

Pfizer Limited, Lead Rapporteur: Robert James Hemmings, Lead PRAC Rapporteur: Patrick Batty, PRAC-CHMP liaison: Robert James Hemmings, "Submission of the final report from study B1801396, a non-interventional PASS listed as a category 3 study in the RMP. This is a

Request for supplementary information adopted with a specific timetable.

---

non-interventional, population-based, multi-country, observational cohort register study to evaluate the risk of adverse pregnancy outcomes in patients with rheumatoid arthritis and related inflammatory diseases, who were treated with etanercept compared to patients with the same diseases of interest who were treated with non-biologic systemic drugs, but without etanercept or other biologics during pregnancy, using merged data from Sweden, Denmark and Finland.”

Request for Supplementary Information adopted on 17.05.2018.

---

PRAC Led

**WS1326**

**Truvada-**

**EMA/H/C/000594/WS1326/0145**

**Viread-EMA/H/C/000419/WS1326/0184**

Gilead Sciences International Limited, Lead Rapporteur: Joseph Emmerich, Lead PRAC Rapporteur: Caroline Laborde, PRAC-CHMP liaison: Joseph Emmerich, “Submission of the final report from study GS-EU-104-0433, listed as a category 3 study in the RMP. This is an observational, drug utilisation study of Viread in children and adolescents with HIV-1 infection, in fulfilment of a post-authorisation measure (PAM) for Viread (MEA 46) and Truvada (MEA 276).”

Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 08.03.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

PRAC Led

**WS1364**

**Lyrica-EMA/H/C/000546/WS1364/0092**

**Pregabalin Pfizer-**

**EMA/H/C/003880/WS1364/0021**

Pfizer Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Sabine Straus, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of an updated RMP version 12.0 in order to include the changes proposed by EMA/H/C/PSUSA/00002511/201701, updating the safety specifications and risk minimisation measures. The pharmacovigilance plan has also been updated. The draft protocol for non-interventional non-imposed PASS (A0081359) titled “A population-based cohort study of Pregabalin to characterize pregnancy

Request for supplementary information adopted with a specific timetable.

---

outcomes" has been submitted.

The MAH has taken the opportunity to include minor updates and to align the RMP to template revision 2."

Request for Supplementary Information adopted on 17.05.2018.

---

#### **B.5.5. CHMP-CAT assessed procedures**

---

##### **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0020, ATMP**

Amgen Europe B.V., Rapporteur: Olli Tenhunen, "Update of section 4.8 of the SmPC in order to add the new ADR 'hypersensitivity' with a frequency allocation of 'unknown'. The Package Leaflet is updated accordingly. Further, the MAH is implementing a minor editorial change in section 3 of the SmPC in order to clarify that the current description of the liquid applies to both strengths, and minor changes in section 4.4 of the SmPC and the Package Leaflet regarding sorbitol and sodium subsequent to the revised Annex to the EC guideline on excipients in the labelling (EMA/CHMP/302620/2017). In addition, the MAH took the opportunity to update the contact details of the local representative in Slovenia in the Package Leaflet."

Opinion adopted on 31.05.2018, 25.05.2018.

Positive Opinion adopted by consensus on 31.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

##### **Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0002/G, ATMP**

CO.DON AG, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder, "Update of sections 4.2, 4.7, 4.8 and 5.1, of the SmPC in order to revise the wording and to update the safety and efficacy information based on the interim results from studies 16 HS 13 (24-month follow-up data) and 16 HS 14 (48-month follow-up data); the Package leaflet is updated accordingly.

Study 16 HS 13 is listed as a specific obligation post-authorisation efficacy study (PAES) in Annex II. It is a phase III, randomised, open label study aimed to evaluate the long-term efficacy and safety of Spherox vs. microfracture in patients with cartilage defects of the knee with a defect size between 1 and 4 cm<sup>2</sup>.

Request for supplementary information adopted with a specific timetable.

---

Study 16 HS 14 is listed as a category 3 study in the RMP. It is a phase II, randomised, open label study, aimed to evaluate the efficacy and safety of the treatment of large defects (4-10 cm<sup>2</sup>) with 3 different doses of Spherox (ACT3D-CS) in subjects with cartilage defects of the knee.”

Request for Supplementary Information adopted on 25.05.2018, 20.04.2018.

---

#### **B.5.6. CHMP-PRAC-CAT assessed procedures**

#### **B.5.7. PRAC assessed ATMP procedures**

#### **B.5.8. Unclassified procedures and worksharing procedures of type I variations**

---

##### **WS1320/G**

**Tivicay-**

**EMA/H/C/002753/WS1320/0035/G**

**Triumeq-**

**EMA/H/C/002754/WS1320/0054/G**

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson

Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

##### **WS1324/G**

**Afinitor-**

**EMA/H/C/001038/WS1324/0056/G**

**Votubia-**

**EMA/H/C/002311/WS1324/0050/G**

Novartis Europharm Limited, Lead Rapporteur: Harald Enzmann

Request for Supplementary Information adopted on 03.05.2018.

Request for supplementary information adopted with a specific timetable.

---

##### **WS1352/G**

**Corlantor-**

**EMA/H/C/000598/WS1352/0049/G**

**Ivabradine Anpharm-**

**EMA/H/C/004187/WS1352/0008/G**

**Procoralan-**

**EMA/H/C/000597/WS1352/0048/G**

Les Laboratoires Servier, Lead Rapporteur: Johann Lodewijk Hillege

Opinion adopted on 03.05.2018.

Positive Opinion adopted by consensus on 03.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

##### **WS1353/G**

**Hexacima-**

**EMA/H/C/002702/WS1353/0079/G**

**Hexaxim-**

**EMA/H/W/002495/WS1353/0084/G**

Request for supplementary information adopted with a specific timetable.

---

---

**Hexyon-****EMA/H/C/002796/WS1353/0083/G**

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 17.05.2018.

---

**WS1360****Zutectra-****EMA/H/C/001089/WS1360/0035**

Biotest Pharma GmbH, Lead Rapporteur: Jan Mueller-Berghaus, "To harmonise section 4.8 of the SmPC following the PRAC Rapporteur's recommendation provided during the PSUSA PRAC Assessment Report

(EMA/H/C/PSUSA/00001631/201611). In addition, the MAH took the opportunity to update Annex II and Annex IIIA according to latest QRD template v 10.0. Finally, the contact details of the MAH in section 7 and of the SmPC and in the PL and the contact details for the HR local representative in the PL were updated." Opinion adopted on 17.05.2018.

Request for Supplementary Information adopted on 15.03.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1368/G****Aflunov-****EMA/H/C/002094/WS1368/0043/G****Foclivia-****EMA/H/C/001208/WS1368/0037/G**

Seqirus S.r.l, Lead Rapporteur: Daniela Melchiorri

Request for Supplementary Information adopted on 17.05.2018.

Request for supplementary information adopted with a specific timetable.

---

**WS1378****Blitzima-****EMA/H/C/004723/WS1378/0011****Ritemvia-****EMA/H/C/004725/WS1378/0011****Rituzena-****EMA/H/C/004724/WS1378/0012****Truxima-****EMA/H/C/004112/WS1378/0012**

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, "B.II.f.1.b.5 - Extension of the shelf life of the finished product of Truxima, Blitzima, Rituzena and Ritemvia for 100 mg presentation from 24 months to 30 months and 500 mg presentation from 36 months to 48 months."

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

Opinion adopted on 17.05.2018.

**WS1379**

**Blitzima-**

**EMA/H/C/004723/WS1379/0012**

**Ritemvia-**

**EMA/H/C/004725/WS1379/0012**

**Rituzena-**

**EMA/H/C/004724/WS1379/0013**

**Truxima-**

**EMA/H/C/004112/WS1379/0013**

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, "B.I.d.1.a.4 - Extension of shelf-life for active substance rituximab from currently approved 36-months to 48-months based on real life data."

Opinion adopted on 17.05.2018.

Positive Opinion adopted by consensus on 17.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1386**

**Competact-**

**EMA/H/C/000655/WS1386/0070**

**Glubrava-**

**EMA/H/C/000893/WS1386/0057**

Takeda Pharma A/S, Lead Rapporteur: Peter Kiely

Opinion adopted on 25.05.2018.

Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS1388/G**

**Actos-**

**EMA/H/C/000285/WS1388/0079/G**

**Competact-**

**EMA/H/C/000655/WS1388/0069/G**

**Glubrava-**

**EMA/H/C/000893/WS1388/0056/G**

**Glustin-**

**EMA/H/C/000286/WS1388/0078/G**

**Tandemact-**

**EMA/H/C/000680/WS1388/0057/G**

Takeda Pharma A/S, Lead Rapporteur: Peter Kiely,

Opinion adopted on 25.05.2018.

Positive Opinion adopted by consensus on 25.05.2018. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

#### **B.5.9. Information on withdrawn type II variation / WS procedure**

---

**Zinplava - bezlotoxumab -**

**EMA/H/C/004136/II/0010**

Merck Sharp & Dohme Limited, Rapporteur: Jan Mueller-Berghaus,

Withdrawal request submitted on 09.05.2018.

The MAH withdrew the procedure on 09.05.2018.

## B.5.10. Information on type II variation / WS procedure with revised timetable

## B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

### B.6.1. Start of procedure for New Applications: timetables for information

---

**ambrisentan - EMEA/H/C/004985**

, treatment of pulmonary arterial hypertension (PAH), Generic, Generic of Volibris

---

**ambrisentan - EMEA/H/C/004955**

, treatment of pulmonary arterial hypertension (PAH), Generic, Generic of Volibris

---

**cabazitaxel - EMEA/H/C/004951**

, treatment of prostate cancer

---

**avatrombopag - EMEA/H/C/004722**

, treatment of thrombocytopenia

---

**etanercept - EMEA/H/C/004711**

, Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Axial spondyloarthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Plaque psoriasis, Paediatric plaque psoriasis

---

**febuxostat - EMEA/H/C/004773**

, treatment of hyperuricaemia, Generic, Generic of Adenuric

---

**levodopa - EMEA/H/C/004786**

, treatment of symptoms of OFF periods in Parkinson's disease

---

**posaconazole - EMEA/H/C/005005**

, treatment of fungal infections, Generic, Generic of Noxafil

---

**delafloxacin - EMEA/H/C/004860**

, treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in adults, treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults

---

**edaravone - EMEA/H/C/004938**

, treatment of amyotrophic lateral sclerosis (ALS)

---

**risankizumab - EMEA/H/C/004759**

, treatment of psoriasis in adults

---

**silodosin - EMEA/H/C/004964**

, treatment of prostatic hyperplasia (BPH), Generic, Generic of Urorec

---



---

**crisaborole - EMEA/H/C/004863**

, treatment of mild to moderate atopic dermatitis

---

**ioflupane (123i) - EMEA/H/C/004745**

, indicated for detecting loss of functional dopaminergic neuron terminals in the striatum, Generic, Generic of DaTSCAN

---

**talazoparib - EMEA/H/C/004674**

, for the treatment of adult patients with germline breast cancer susceptibility gene (BRCA) mutated human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer.

---

**treprostinil - EMEA/H/C/004847, Orphan**

SciPharm Sarl, Treatment of chronic thromboembolic pulmonary hypertension

---

**ulipristal acetate - EMEA/H/C/005017**

, treatment of uterine fibroids, Informed Consent of Esmya

---

**B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information**

---

**Simponi - golimumab -****EMEA/H/C/000992/X/0083/G**

Janssen Biologics B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to add a new strength of 100 mg/ml solution for injection for paediatric use.

C.I.6.a - Extension of indication to include paediatric patients from the age of 2 years and older for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) with Simponi 100 mg/ml solution for injection. As a consequence, sections 4.1, 4.2, 5.1 and section 4.1 of the 50mg strength have been updated accordingly.

C.I.11.z - To update the RMP to version 18.0 to delete the following safety concerns: vasculitis, psoriasis (new onset or worsening of pre-existing), and sarcoidosis/sarcoid like reaction. This change has been agreed by the CHMP in the outcome of variation Type II/068.

C.I.11.z - To update the RMP to version 18.0 to change the due date of the category 3 study MK-8259-050. This change has been agreed by the CHMP in the outcome of MEA033.

In addition, the marketing authorisation holder

---

---

took the opportunity to:

- update the Product Information in line with the latest QRD template (version 10);
- implement the recommendations stated in the revised Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' with regards to the excipient Sorbitol (E420);
- add a statement in Section 4.4 of the SmPC to record the name and the batch number of the administered product, in line with Good Pharmacovigilance Practice (GVP) Module PII: Biological medicinal products."

---

**Trisenox - arsenic trioxide -**

**EMA/H/C/000388/X/0068**

Teva B.V., Rapporteur: Alexandre Moreau, PRAC  
Rapporteur: Ghania Chamouni, "Extension application to add a new strength of 2 mg/ml (concentrate for solution for solution for infusion) in vials.  
The RMP (version 2.0) is updated accordingly."

---

**Zykadia - ceritinib -**

**EMA/H/C/003819/X/0025**

Novartis Europharm Limited, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to introduce a new pharmaceutical form (film-coated tablets)."

---

**B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information**

---

**ropeginterferon alfa-2b -**

**EMA/H/C/004128, Orphan**

AOP Orphan Pharmaceuticals AG, treatment of polycythemia vera  
List of Questions adopted on 22.06.2017.

---

**buprenorphine - EMA/H/C/004651**

, treatment of opioid dependence within a framework of medical, social and psychological treatment  
List of Questions adopted on 25.01.2018.

---

**doravirine - EMA/H/C/004747**

, treatment of adults infected with HIV-1 without past or present evidence of viral resistance to treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine

---

---

List of Questions adopted on 22.03.2018.

---

**doravirine / lamivudine / tenofovir  
disoproxil - EMEA/H/C/004746**

, treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir

List of Questions adopted on 22.03.2018.

---

**doxorubicin hydrochloride -  
EMEA/H/C/004110**

, treatment of breast and ovarian cancer

List of Questions adopted on 14.09.2017.

---

**galcanezumab - EMEA/H/C/004648**

, prophylaxis of migraine

List of Questions adopted on 22.03.2018.

---

**pacritinib - EMEA/H/C/004793, Orphan**

CTI Life Sciences Limited, treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have thrombocytopenia (platelet counts  $\leq 100,000$  / $\mu$ L).

List of Questions adopted on 09.11.2017.

---

**fexinidazole - EMEA/H/W/002320, Article  
58**

, treatment of human African trypanosomiasis (HAT)

List of Questions adopted on 24.04.2018.

---

**fingolimod -**

**EMEA/H/C/002202/X/0044/G**

, "Extension application to introduce a new strength of hard capsules (0.25 mg) to the currently approved presentations of Gilenya, grouped with a type II variation (extension of indication) to add a new indication for the treatment of paediatric patients of 10 years of age and above with relapsing multiple sclerosis (RMS). As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 5.3, 6 and 8 of the SmPC are updated . The Package Leaflet and Labelling are updated in accordance. In addition, Annex II is updated to be brought in line with the latest QRD template version 10."

List of Questions adopted on 22.03.2018.

Request for 1 year of market protection for a

---

---

new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**enoxaparin sodium -  
EMEA/H/C/004264/X/0026**

, "Extension application to add two new strengths of 30,000 IU (300 mg)/3 mL and 50,000 IU (500 mg)/5 mL for enoxaparin sodium solution for injection in vial, for subcutaneous, extracorporeal and intravenous administration."

List of Questions adopted on 22.03.2018.

---

**damoctocog alfa pegol -  
EMEA/H/C/004054, Orphan**

Bayer AG, Treatment and prophylaxis of haemophilia A

List of Questions adopted on 25.01.2018.

---

**patisiran - EMEA/H/C/004699, Orphan**

Alnylam UK Limited, treatment of hereditary transthyretin-mediated amyloidosis.

List of Questions adopted on 24.04.2018.

---

**pegfilgrastim - EMEA/H/C/004700**

, treatment of neutropenia

List of Questions adopted on 25.01.2018.

---

**mogamulizumab - EMEA/H/C/004232,  
Orphan**

Kyowa Kirin Limited, treatment of cutaneous T-cell lymphoma

List of Questions adopted on 22.02.2018.

---

**influenza vaccine surface antigen  
inactivated prepared in cell cultures -  
EMEA/H/C/004814, Article 28**

, prophylaxis of influenza in adults and children from 4 years of age

List of Questions adopted on 22.03.2018.

---

**sevelamer carbonate -  
EMEA/H/C/000993/X/0039**

, "Extension application to add a new strength of 0.8 g powder for oral suspension."

List of Questions adopted on 22.02.2018.

---

**sevelamer carbonate -  
EMEA/H/C/003971/X/0011**

, "Add a new strength of 0.8 g powder for oral suspension."

List of Questions adopted on 22.02.2018.

---

**pegfilgrastim - EMEA/H/C/004802**

, treatment of neutropenia

---

#### **B.6.4. Annual Re-assessments: timetables for adoption**

---

##### **Chenodeoxycholic acid Lediand -**

##### **chenodeoxycholic acid -**

##### **EMA/H/C/004061/S/0006, Orphan**

Lediand GmbH, Rapporteur: Robert James  
Hemmings, PRAC Rapporteur: Adam  
Przybylkowski

---

##### **Elaprase - idursulfase -**

##### **EMA/H/C/000700/S/0075**

Shire Human Genetic Therapies AB, Rapporteur:  
Greg Markey, PRAC Rapporteur: Patrick Batty

---

##### **Qarziba - dinutuximab beta -**

##### **EMA/H/C/003918/S/0006, Orphan**

EUSA Pharma (UK) Limited, Rapporteur: Robert  
James Hemmings, PRAC Rapporteur: Brigitte  
Keller-Stanislawski

---

#### **B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed**

---

##### **Adcetris - brentuximab vedotin -**

##### **EMA/H/C/002455/R/0058, Orphan**

Takeda Pharma A/S, Rapporteur: Paula  
Boudewina van Hennik, PRAC Rapporteur:  
Sabine Straus

---

##### **Brintellix - vortioxetine -**

##### **EMA/H/C/002717/R/0019**

H. Lundbeck A/S, Rapporteur: Bart Van der  
Schueren, Co-Rapporteur: Martina Weise, PRAC  
Rapporteur: Laurence de Fays

---

##### **Diacomit - stiripentol -**

##### **EMA/H/C/000664/R/0021**

BIOCODEX, Rapporteur: Greg Markey, Co-  
Rapporteur: Daniela Melchiorri, PRAC  
Rapporteur: Julie Williams

---

##### **Grastofil - filgrastim -**

##### **EMA/H/C/002150/R/0020**

Apotex Europe BV, Rapporteur: Robert James  
Hemmings, Co-Rapporteur: Sol Ruiz, PRAC  
Rapporteur: Patrick Batty

---

##### **Izba - travoprost -**

##### **EMA/H/C/002738/R/0011**

Novartis Europharm Limited, Rapporteur:  
Concepcion Prieto Yerro, Co-Rapporteur: Greg

---

---

Markey, PRAC Rapporteur: Almath Spooner

---

**Lartruvo - olaratumab -**

**EMA/H/C/004216/R/0010, Orphan**

Eli Lilly Nederland B.V., Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Sabine Straus

---

**Levetiracetam Hospira - levetiracetam -**

**EMA/H/C/002783/R/0018**

Hospira UK Limited, Generic, Generic of Keppra, Rapporteur: Juris Pokrotnieks, PRAC Rapporteur: Laurence de Fays

---

**Neuraceq - florbetaben (18F) -**

**EMA/H/C/002553/R/0025**

Life Radiopharma Berlin GmbH, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Patrick Batty

---

**NINLARO - ixazomib -**

**EMA/H/C/003844/R/0012, Orphan**

Takeda Pharma A/S, Rapporteur: Greg Markey, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Ulla Wändel Liminga

---

**Sovaldi - sofosbuvir -**

**EMA/H/C/002798/R/0050**

Gilead Sciences International Limited, Rapporteur: Filip Josephson, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Julie Williams

---

**TECFIDERA - dimethyl fumarate -**

**EMA/H/C/002601/R/0053**

Biogen Idec Ltd, Rapporteur: Martina Weise, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Martin Huber

---

**Tivicay - dolutegravir -**

**EMA/H/C/002753/R/0040**

ViiV Healthcare B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Joseph Emmerich, PRAC Rapporteur: Julie Williams

---

**Venclyxto - venetoclax -**

**EMA/H/C/004106/R/0013, Orphan**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, PRAC Rapporteur: Patrick Batty

---

**Xigduo - dapagliflozin / metformin -**

**EMA/H/C/002672/R/0044**

AstraZeneca AB, Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC

---

#### **B.6.6. VARIATIONS – START OF THE PROCEDURE**

**Timetables for adoption** provided that the validation has been completed.

#### **B.6.7. Type II Variations scope of the Variations: Extension of indication**

---

##### **Coagadex - human coagulation factor X - EMA/H/C/003855/II/0007, Orphan**

Bio Products Laboratory Limited, Rapporteur:  
Andrea Laslop, PRAC Rapporteur: Julie Williams,  
"Update of section sections 4.2, 4.8, 5.1 and 5.2  
of the SmPC in order to include safety and  
efficacy data in children aged less than 12 years  
of age based on final results from the study  
Ten02, a phase III open-label multicentre study  
to confirm the safety, pharmacokinetics and  
efficacy of BPL's high purity factor X in the  
prophylaxis of bleeding in factor X deficient  
children under the age of 12 years, provided in  
accordance with the agreed paediatric  
investigational plan. The Package Leaflet is  
updated accordingly. The RMP version 7.0 has  
also been submitted."

---

##### **Hemlibra - emicizumab - EMA/H/C/004406/II/0002**

Roche Registration GmbH, Rapporteur:  
Nithyanandan Nagercoil, Co-Rapporteur:  
Alexandre Moreau, PRAC Rapporteur: Amelia  
Cupelli, "Extension of Indication to include  
routine prophylaxis of bleeding episodes in  
patients with hemophilia A without factor VIII  
inhibitors, for Hemlibra. As a consequence,  
sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC  
are updated with efficacy and safety information  
of the pivotal trials:

- Study BH30071 (HAVEN 3) - an ongoing, multicenter, open-label, randomized Phase III clinical study evaluating the efficacy, safety and PK of emicizumab prophylaxis at doses of 1.5 mg/kg/week (QW) and 3 mg/kg/every 2 weeks (Q2W) versus no prophylaxis in adults and adolescent patients (age of 12 or above) with haemophilia A without inhibitors against factor VIII (FVIII).

- Study BO39182 (HAVEN 4) - an ongoing multicenter, open-label, non-randomized Phase III study evaluating the efficacy, safety and PK of emicizumab given as the dose of 6

---

---

mg/kg/every 4 weeks (Q4W) in adults and adolescent patients (age of 12 or above) with hemophilia A with or without FVIII inhibitors.

- Study BH29992 (HAVEN 2) - a multicenter, open-label, non-randomized Phase III study evaluating the efficacy, safety and PK of emicizumab at the QW dose in pediatric patients (<12 years old or 12-17 years old and <40kg) with hemophilia A with FVIII inhibitors.

The Package Leaflet and the Risk Management Plan ( v.2.0) is updated in accordance.

In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor corrections and clarity to sections 4.4, 4.5 and 4.6 of the SmPC."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**Keytruda - pembrolizumab -  
EMA/H/C/003820/II/0047**

Merck Sharp & Dohme B.V., Rapporteur:  
Daniela Melchiorri, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sabine Straus,  
"Extension of Indication to include (as monotherapy) adjuvant treatment of melanoma in adults with lymph node involvement who have undergone complete resection, based on study KEYNOTE-054; a randomized, double-blind, phase 3 study conducted in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC), undertaken to evaluate adjuvant therapy with pembrolizumab compared to placebo in patients with resected high-risk melanoma (Stage IIIA [> 1 mm lymph node metastasis], IIIB and IIIC). As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly. An updated RMP version 17.1 was provided as part of the application."

---

**Keytruda - pembrolizumab -  
EMA/H/C/003820/II/0052**

See agenda 5.1

Merck Sharp & Dohme B.V., Rapporteur:  
Daniela Melchiorri, "Restriction of the currently authorised indication in cisplatin-ineligible urothelial carcinoma patients to exclude patients whose tumors express PD-L1 CPS<10, as well as to exclude only the patients who have 1 or

---



---

more risk factors predicting a worse outcome. Sections 4.1, 4.2, 4.4 and 5.1 of the SmPC have been revised accordingly.”

Opinion adopted on 31.05.2018.

---

**NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0104**

Novo Nordisk A/S, Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Nithyanandan Nagercoil, “Extension of Indication to extend patient population of NovoSeven for use in patients with Glanzmann’s thrombasthenia without antibodies to platelets, or where platelets are not readily available, based on a prospective observational registry and literature references. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes in section 4.8 of the SmPC and in Package Leaflet.”

---

**Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0049**

Novartis Europharm Limited, Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, “Extension of Indication to include first line treatment of adult and paediatric patients aged 2 years and older with severe aplastic anaemia for Revolade; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 50 has also been updated.”

---

**Tecentriq - atezolizumab - EMEA/H/C/004143/II/0010**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Update of section 4.1 and 5.1 of the SmPC in order to restrict for Tecentriq the indication ‘for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible’ by including ‘whose tumours have a high expression of PDL-1’, based on the review of interim analysis data by the independent data monitoring committee (IDMC) from study IMvigor 130 (WO30070) listed as a PAES in the Annex II; this is a Phase III, multicentre, randomized, placebo-controlled study of atezolizumab administered as monotherapy or in combination with platinum-based

See 5.1

Opinion adopted on 31.05.2018.

---

---

chemotherapy compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma enrolling patients in the first line setting who are both cisplatin eligible and cisplatin ineligible. The MAH is proposing to distribute a DHPC.”

Opinion adopted on 31.05.2018.

---

**WS1372**

**OPDIVO-**

**EMA/H/C/003985/WS1372/0053**

**Yervoy-EMA/H/C/002213/WS1372/0057**

Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Jorge Camarero Jiménez, Lead Co-Rapporteur: Paula Boudewina van Hennik, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski, “Extension of Indication to include first-line treatment of adult patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC) for OPDIVO and Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add information from the pivotal study CA209227 (an open-label, randomised phase 3 trial of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in subjects with chemotherapy-naïve stage IV or recurrent NSCLC). The Package Leaflet and RMP (version 14.0 for Opdivo and version 21.0 for Yervoy) are updated in accordance. In addition, the MAH has taken the opportunity to introduce minor editorial and formatting revisions in the PI.”

---

**B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects**

---

**Adcetris - brentuximab vedotin -**

**EMA/H/C/002455/II/0056/G, Orphan**

Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik

---

**Circadin - melatonin -**

**EMA/H/C/000695/II/0053/G**

RAD Neurim Pharmaceuticals EEC Ltd., Rapporteur: Bruno Sepodes

---

**Cuprior - trientine -**

**EMA/H/C/004005/II/0001/G**

GMP-Orphan SA, Rapporteur: Jayne Crowe

---

**Cyramza - ramucirumab -**

**EMA/H/C/002829/II/0024/G**

---

---

Eli Lilly Nederland B.V., Rapporteur: Paula  
Boudewina van Hennik

---

**Cyramza - ramucirumab -**  
**EMA/H/C/002829/II/0025**

Eli Lilly Nederland B.V., Rapporteur: Paula  
Boudewina van Hennik

---

**Dacogen - decitabine -**  
**EMA/H/C/002221/II/0034/G, Orphan**

Janssen-Cilag International N.V., Rapporteur:  
Alexandre Moreau

---

**Dupixent - dupilumab -**  
**EMA/H/C/004390/II/0006/G**

sanofi-aventis groupe, Rapporteur: Jan Mueller-  
Berghaus

---

**Episalvan - birch bark extract -**  
**EMA/H/C/003938/II/0010**

Amryt AG, Rapporteur: Kristina Dunder

---

**Evicel - human fibrinogen / human**  
**thrombin - EMA/H/C/000898/II/0059**

Omrix Biopharmaceuticals N. V., Rapporteur:  
Jan Mueller-Berghaus

---

**EXJADE - deferasirox -**  
**EMA/H/C/000670/II/0061**

Novartis Europharm Limited, Rapporteur:  
Alexandre Moreau

---

**Fluenz Tetra - influenza vaccine (live**  
**attenuated, nasal) -**

**EMA/H/C/002617/II/0082**

AstraZeneca AB, Rapporteur: Bart Van der  
Schueren

---

**Fuzeon - enfuvirtide -**

**EMA/H/C/000514/II/0051/G**

Roche Registration GmbH, Rapporteur: Kristina  
Dunder

---

**Gardasil - human papillomavirus vaccine**  
**[types 6, 11, 16, 18] (recombinant,**  
**adsorbed) - EMA/H/C/000703/II/0077**

MSD Vaccins, Rapporteur: Kristina Dunder

---

**Gardasil - human papillomavirus vaccine**  
**[types 6, 11, 16, 18] (recombinant,**  
**adsorbed) - EMA/H/C/000703/II/0078**

MSD Vaccins, Rapporteur: Kristina Dunder

---

**Gardasil 9 - human papillomavirus vaccine**  
**[types 6, 11, 16, 18, 31, 33, 45, 52, 58]**  
**(recombinant, adsorbed) -**

---

---

**EMA/H/C/003852/II/0025**

MSD Vaccins, Rapporteur: Kristina Dunder

---

**Gazyvaro - obinutuzumab -**

**EMA/H/C/002799/II/0028, Orphan**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac

---

**Gliolan - aminolevulinic acid -**

**EMA/H/C/000744/II/0015**

medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Bruno Sepodes

---

**Keytruda - pembrolizumab -**

**EMA/H/C/003820/II/0051/G**

Merck Sharp & Dohme B.V., Rapporteur: Daniela Melchiorri

---

**Kineret - anakinra -**

**EMA/H/C/000363/II/0060**

Swedish Orphan Biovitrum AB (publ), Rapporteur: Mark Ainsworth

---

**Litak - cladribine -**

**EMA/H/C/000504/II/0015**

Lipomed GmbH, Rapporteur: Robert James Hemmings

---

**NovoEight - turoctocog alfa -**

**EMA/H/C/002719/II/0026/G**

Novo Nordisk A/S, Rapporteur: Jan Mueller-Berghaus

---

**Olanzapine Apotex - olanzapine -**

**EMA/H/C/001178/II/0034**

Apotex Europe BV, Generic, Generic of Zyprexa, Rapporteur: John Joseph Borg

---

**Rekovelte - follitropin delta -**

**EMA/H/C/003994/II/0008/G**

Ferring Pharmaceuticals A/S, Rapporteur: Joseph Emmerich

---

**Repatha - evolocumab -**

**EMA/H/C/003766/II/0026/G**

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege

---

**Respreeza - human alpha1-proteinase**

**inhibitor - EMA/H/C/002739/II/0023/G**

CSL Behring GmbH, Rapporteur: Kristina Dunder

---

**Rotarix - human rotavirus, live attenuated**

**- EMA/H/C/000639/II/0106/G**

---

---

GlaxoSmithKline Biologicals S.A., Rapporteur:  
Bart Van der Schueren

---

**Shingrix - herpes zoster vaccine  
(recombinant, adjuvanted) -  
EMA/H/C/004336/II/0001**

GlaxoSmithKline Biologicals SA, Rapporteur:  
Bart Van der Schueren

---

**Strensiq - asfotase alfa -  
EMA/H/C/003794/II/0030/G, Orphan**  
Alexion Europe SAS, Rapporteur: Greg Markey

---

**Synflorix - pneumococcal polysaccharide  
conjugate vaccine (adsorbed) -  
EMA/H/C/000973/II/0126**

GlaxoSmithKline Biologicals SA, Rapporteur:  
Kristina Dunder

---

**Synflorix - pneumococcal polysaccharide  
conjugate vaccine (adsorbed) -  
EMA/H/C/000973/II/0127/G**

GlaxoSmithKline Biologicals SA, Rapporteur:  
Kristina Dunder

---

**Trulicity - dulaglutide -  
EMA/H/C/002825/II/0030**

Eli Lilly Nederland B.V., Rapporteur: Greg  
Markey

---

**Trumenba - meningococcal group B vaccine  
(recombinant, adsorbed) -  
EMA/H/C/004051/II/0008**

Pfizer Limited, Rapporteur: Johann Lodewijk  
Hillege

---

**Xiapex - collagenase clostridium  
histolyticum - EMA/H/C/002048/II/0099**

Swedish Orphan Biovitrum AB (publ),  
Rapporteur: Martina Weise

---

**Yervoy - ipilimumab -  
EMA/H/C/002213/II/0058/G**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:  
Paula Boudewina van Hennik

---

**WS1393/G**

**Hexacima-**

**EMA/H/C/002702/WS1393/0080/G**

**Hexaxim-**

**EMA/H/W/002495/WS1393/0085/G**

**Hexyon-**

**EMA/H/C/002796/WS1393/0084/G**

Sanofi Pasteur Europe, Duplicate, Duplicate of  
Hexacima, Lead Rapporteur: Jan Mueller-

---

---

Berghaus

---

**WS1404**

**Nuwiq-EMEA/H/C/002813/WS1404/0022**

**Vihuma-**

**EMEA/H/C/004459/WS1404/0004**

Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus

---

**B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

---

**Abraxane - paclitaxel -**

**EMEA/H/C/000778/II/0089**

Celgene Europe Limited, Rapporteur: Paula Boudewina van Hennik, "Update of section 4.6 and 5.3 of the SmPC in order to introduce pre-clinical safety information regarding the excretion of paclitaxel metabolites into the milk of lactating rats as well as an effect on male and female fertility of rats based on a review of the available literature."

---

**BESPONSA - inotuzumab ozogamicin -**

**EMEA/H/C/004119/II/0006, Orphan**

Pfizer Limited, Rapporteur: Robert James Hemmings, "Update of sections 4.8 and 5.1 of the SmPC based on the supplemental Clinical Study Report for the pivotal phase 3 Study B1931022 (Study 1022) that was prepared following last patient last visit. The Package Leaflet is updated accordingly. The MAH took the opportunity to make minor editorial changes for added clarity in sections 4.2, 4.4, 4.8, 5.1, 5.3 and 6.6 of the SmPC and Package Leaflet."

---

**Cayston - aztreonam -**

**EMEA/H/C/000996/II/0073, Orphan**

Gilead Sciences Ireland UC, Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from study GX US 205-0128, listed as a category 3 study in the RMP. This is a prospective, observational, 5 year registry study carried out to monitor the susceptibility to aztreonam of *Pseudomonas aeruginosa* isolates from patients with Cystic Fibrosis in the US. The population eligible for the registry included paediatric subjects, and the final study population included approximately 26% of subjects of less than 18 years of age.

No changes to the SmPC are proposed based on the results from this non-interventional, registry

---

---

study.”

---

**Dacogen - decitabine -**

**EMA/H/C/002221/11/0035, Orphan**

Janssen-Cilag International N.V., Rapporteur: Alexandre Moreau, “Update of section 4.4, and 4.8 of the SmPC in order to add the adverse events “Hepatic Function abnormal” and “Hyperbilirubinaemia” with the frequency common and to include clinical recommendations in patients developing signs or symptoms of hepatic impairment based on a cumulative review of post-marketing data; the Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the contact details of the local representative in Portugal in the Package Leaflet. Furthermore, the term “(for pH adjustment)” has been removed from the Annex IIIA in accordance with the revision 2 of the European Commission guideline on Excipients in the labelling and package leaflet of medicinal products for human use.”

---

**DaTSCAN - ioflupane (123i) -**

**EMA/H/C/000266/11/0055**

GE Healthcare Ltd, Rapporteur: Robert James Hemmings, “Update of section 4.8 of the SmPC in order to add Erythema, pruritus, rash, urticaria, hyperhidrosis, Dyspnea, Vomiting and Blood pressure decreased as undesirable effects all with a not known frequency. The Package leaflet has been updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 11 of the SmPC in line with ICRP Publication 128, Radiation Dose to Patients from “Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances, 2015”. The Marketing authorisation holder (MAH) took also the opportunity to bring the PI in line with the latest QRD template version 10.0.”

---

**Dukoral - cholera vaccine (inactivated, oral) - EMA/H/C/000476/11/0058**

Valneva Sweden AB, Rapporteur: Kristina Dunder, “Update of the Product Information to reduce the risk of medication errors. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the

---

---

latest QRD template version 10, to update Annex II with regards to PSUR requirements, to correct the description of the container of the vaccine suspension and to introduce minor linguistic and layout improvements to the Annexes.”

---

**Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/II/0046**

Gilead Sciences International Limited,  
Rapporteur: Robert James Hemmings, “Update of sections 4.8 and 5.1 of the SmPC for Genvoya in order to amend the safety and pharmacodynamic information based on the final results from study Study GS-US-292-1515, listed as a category 3 study in the RMP; this is A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents.

The MAH also took the opportunity to make administrative updates to Section 4.5 and 5.1 of the SmPC.”

---

**Giotrif - afatinib - EMEA/H/C/002280/II/0028**

Boehringer Ingelheim International GmbH,  
Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to update the efficacy section with data in EGFR TKI-naïve NSCLC patients whose tumours harbour uncommon EGFR mutations based on a meta-analysis across three trials (1200.22, 1200.32 and 1200.34). In addition, the Marketing authorisation holder (MAH) took the opportunity to implement minor linguistic amendments to the translations of the product information annexes: BG, CZ, DE, DK, FI, IS, IT, NO, PT, SE and SK.”

---

**Keytruda - pembrolizumab - EMEA/H/C/003820/II/0048**

Merck Sharp & Dohme B.V., Rapporteur: Daniela Melchiorri, “Update of sections 4.2, 5.1 and 5.3 of the SmPC in order to align the posology of Keytruda for the melanoma -and 2nd line NSCLC indications to a 200 mg Q3W fixed dose regimen already approved for more recent indications (1st line NSCLC, classical Hodgkin lymphoma and urothelial carcinoma) based on the available overall PK and exposure

---



---

data. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representative in Belgium in the Package Leaflet."

---

**Lemtrada - alemtuzumab -  
EMA/H/C/003718/II/0023**

Genzyme Therapeutics Ltd, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Mark Ainsworth, "Update of section 4.8 of the SmPC in order to update the table of frequencies of adverse reactions in accordance with the SmPC guideline following request from PRAC in procedure EMA/H/C/PSUSA/00010055/201703. This procedure also included an update in section 4.4 to add warning on acute acalculous cholecystitis following a cumulative review of the cases. The Package Leaflet is updated accordingly."

---

**Lokelma - sodium zirconium cyclosilicate -  
EMA/H/C/004029/II/0003/G**

AstraZeneca AB, Rapporteur: Romaldas Mačiulaitis, "1) type II (C.I.4): Update of sections 4.8 and 5.1 of the SmPC in order to update the information based on final results from study ZS-005 (category 3 PASS study in the RMP). This is an open-label, multicentre, multi-dose, prospective maintenance study to investigate the long-term safety and efficacy of Lokelma (sodium zirconium cyclosilicate) in subjects with hyperkalaemia.

2) type II (C.I.4): Update of section 4.5 of the SmPC in order to add information regarding the use with drugs that have the potential for drug-drug interaction based on an increase in gastric PH.

The Package Leaflet has been updated accordingly."

---

**Orgalutran - ganirelix -  
EMA/H/C/000274/II/0041**

Merck Sharp & Dohme Limited, Rapporteur: Outi Mäki-Ikola, "Update of section 4.3 of the SmPC to expand the existing contraindication regarding hypersensitivity to include also wording regarding dry natural rubber/latex and sections 4.4 and 6.5 of the SmPC to clarify that this product is in contact with dry natural rubber/latex. The labelling and Package Leaflet have been updated accordingly. In addition, the MAH took the opportunity to update the contact

---

---

details of the local representative in Belgium in the Package Leaflet.”

---

**Pandemic influenza vaccine H5N1**

**AstraZeneca - pandemic influenza vaccine (H5N1) (live attenuated, nasal) -**

**EMA/H/C/003963/II/0015**

AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, “Update of section 4.6 of the SmPC with regards to pregnancy information based on the review and summary of pregnancy data from published literature and MAH pharmacovigilance database.

The MAH took the opportunity to include editorial changes in section 4.8 and 5.1 of the SmPC.”

---

**Perjeta - pertuzumab -**

**EMA/H/C/002547/II/0039**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Update of section 4.8 of the SmPC and relevant section of the PL to include tumour lysis syndrome (TLS) as a rare adverse reaction.”

---

**Praluent - alirocumab -**

**EMA/H/C/003882/II/0040**

sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, “Submission of the final clinical study report of study R727-CL-1018 (study title: A Phase 2 Pilot Study with a Randomized Double-Blind Treatment Phase to Evaluate the Pharmacodynamics and Safety of Alirocumab in Patients with Autosomal Dominant Hypercholesterolemia and Gain-of-Function Mutations in 1 or Both Alleles of the PCSK9 Gene or Loss-of-Function Mutations in 1 or More Alleles of the Apolipoprotein B Gene), as per MEA012.”

---

**Saxenda - liraglutide -**

**EMA/H/C/003780/II/0018**

Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.2, 4.8 and 5.2 of the SmPC in order to update the safety information based on the conclusions of the assessment of Clinical trial reports NN8022-3967 and NN8022-4181, previously submitted in accordance with Article 46 of Regulation (EC) No1901/2006, as amended, and assessed by the CHMP (P46 016).”

---

---

**Soliris - eculizumab -****EMA/H/C/000791/II/0103, Orphan**

Alexion Europe SAS, Rapporteur: Jorge Camarero Jiménez, "To update SmPC section 4.4 describing reports of serious infections with *Neisseria* species (other than *Neisseria meningitidis*), including disseminated gonococcal infections, SmPC section 4.5 describing the theoretical potential for drug-drug interaction between eculizumab and intravenous human immunoglobulin (IVIg), SmpC section 4.6 clarifying that there is currently insufficient data to adequately characterize the safety of eculizumab in pregnant women with refractory gMG and SmPC section 4.8, clarifying sepsis as the most common presentation of *Neisseria meningococcal* infections. The annex II and the package leaflet are updated accordingly. The MAH took the opportunity to align the Product information with the QRD template."

---

**Somavert - pegvisomant -****EMA/H/C/000409/II/0084**

Pfizer Limited, Rapporteur: Joseph Emmerich, "Update of sections 4.2 and 4.4 of the SmPC to introduce posology recommendations to recommend an assessment of baseline levels of liver tests (LTs) [serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP)] prior initiation of treatment with Somavert following analysis of the interim result for study "A6291010 (ACROSTUDY) - A multicenter, post marketing surveillance study of pegvisomant therapy in patients with acromegaly – extension" as requested in procedure EMA/H/C/000409/MEA 061.1. The PL has been updated accordingly."

---

**Stocrin - efavirenz -****EMA/H/C/000250/II/0114**

Merck Sharp & Dohme B.V., Duplicate, Duplicate of Sustiva, Rapporteur: Bruno Sepodes, "Update of sections 4.3 and 4.5 of the SmPC in order to add contraindication with elbasvir/grazoprevir and to update information on interactions between efavirenz and elbasvir/grazoprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, and etonogestrel implant; based on the post-

---

---

approval and literature data. The Package Leaflet is updated accordingly.”

---

**Strensiq - asfotase alfa -  
EMEA/H/C/003794/II/0029, Orphan**

Alexion Europe SAS, Rapporteur: Greg Markey, “Update of annex II after submission of the final report from study AA-HPP-208 listed as a category 1 study in the RMP (ANX001.2). This is a multicentre, randomized, open-label, Phase 2a study of Strensiq in patients with hypophosphatasia.”

---

**Sustiva - efavirenz -  
EMEA/H/C/000249/II/0145/G**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Bruno Sepodes, “Update of sections 4.3 and 4.5 of the SmPC in order to add contraindication with elbasvir/grazoprevir due to the potential for significant decreases in plasma concentrations of elbasvir and grazoprevir, based on the post-approval and literature data, the Package Leaflet is updated accordingly.

Update of sections 4.4 and 4.5 to include warnings in relation to the co-administration of efavirenz and sofosbuvir/velpatasvir; efavirenz and velpatasvir/sofosbuvir/voxilaprevir and efavirenz and glecaprevir/pibrentasvir; based on the post-approval and literature data, the Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.”

---

**Tamiflu - oseltamivir -  
EMEA/H/C/000402/II/0133**

Roche Registration GmbH, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, “Update of the RMP (v.16) to discontinue the guided questionnaires (GQ) for neurological and psychiatric adverse events (NPAE), hepatobiliary disorders and hypothermia.”

---

**Tivicay - dolutegravir -  
EMEA/H/C/002753/II/0041/G**

ViiV Healthcare B.V., Rapporteur: Filip Josephson, “Update of sections 4.8 and 5.1 of the SmPC with Week 24 data (secondary analysis) from the pivotal Phase III studies, 204861 [GEMINI-1] and 205543 [GEMINI-2] in ART-naïve adult subjects. The Package Leaflet

---

---

has been updated accordingly.”

---

**Vargatef - nintedanib -**

**EMA/H/C/002569/II/0021**

Boehringer Ingelheim International GmbH,  
Rapporteur: Sinan B. Sarac, “Update of section 4.8 of the SmPC in order to add ‘pruritus’ as a new adverse drug reaction with a frequency ‘common’ following a routine review of post-marketing data. The Package Leaflet is updated accordingly.”

---

**Venclyxto - venetoclax -**

**EMA/H/C/004106/II/0011, Orphan**

AbbVie Deutschland GmbH & Co. KG,  
Rapporteur: Filip Josephson, “Submission of the interim report from study M14-032 a phase II open-label study investigating efficacy and safety of venetoclax in patients with CLL with relapse or refractory to B-cell receptor signalling pathway inhibitor therapy, listed as a category 2 study in the RMP.

Consequently, the remaining SOB is fulfilled and Annex II E is updated accordingly.”

---

**Viekirax - ombitasvir / paritaprevir / ritonavir - EMA/H/C/003839/II/0047**

AbbVie Limited, Rapporteur: Filip Josephson, “Submission of the final report from study (M14-567) listed as a category 3 study in the RMP. This is a randomized, open-label study to evaluate the safety and efficacy of the co-administration of ombitasvir/ABT-450/Ritonavir (ombitasvir/ABT-450/r) with sofosbuvir (SOF) with or without ribavirin (RBV) in subjects with genotype 2 chronic hepatitis C virus (HCV) infection or genotype 3 HCV infection with or without Cirrhosis.”

---

**Visudyne - verteporfin -**

**EMA/H/C/000305/II/0097**

Novartis Europharm Limited, Rapporteur: Alexandre Moreau, “Update of SPC section 4.8 to include cases of anaphylactic reactions have been observed in patients receiving Visudyne as well as to include “Anaphylactic Reaction” with frequency ‘not known’. The Package Leaflet have been updated accordingly”

---

**Votubia - everolimus -**

**EMA/H/C/002311/II/0051, Orphan**

Novartis Europharm Limited, Rapporteur: Harald

---

---

Enzmann, "Update of sections 4.8 (all pharmaceutical pharms) and 5.1 (dispersible tablets only) of the SmPC in order to update the safety and efficacy information based on final results from study CRAD001M2304, listed as a category 3 study in the RMP; this is a three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures. The Package Leaflet is updated accordingly."

---

**Xyrem - sodium oxybate -**

**EMA/H/C/000593/II/0075**

UCB Pharma Limited, Rapporteur: Bruno Sepodes, "Update of section 4.9 of the SmPC in order to include safety information on hypernatremia based on a cumulative review of post-marketing data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in sections 4.2 and 4.4 of the SmPC and in the Package Leaflet, as well as to align the annexes with the latest QRD template v.10. Moreover, the Package Leaflet was updated to include information on hypoaesthesia."

---

**WS1380**

**Ebymect-**

**EMA/H/C/004162/WS1380/0033**

**Edistride-**

**EMA/H/C/004161/WS1380/0027**

**Forxiga-**

**EMA/H/C/002322/WS1380/0046**

**Xigduo-EMA/H/C/002672/WS1380/0045**

AstraZeneca AB, Lead Rapporteur: Kristina Dunder, "Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to reflect the final study results from study D1690C00024 (DERIVE); A Multicentre, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III Study to Evaluate the Glycaemic Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) Who Have Inadequate Glycaemic Control.

In addition, the Worksharing applicant took the opportunity to implement minor editorial changes in Edistride, Ebymect and Xigduo SmPCs, as well as Ebymect Labelling. The

---

---

Package Leaflets for Xigduo and Ebymect are updated accordingly.”

---

**WS1392**

**ProQuad-**

**EMA/H/C/000622/WS1392/0125**

MSD Vaccins, Lead Rapporteur: Jan Mueller-Berghaus, “Update of section 4.8 of the SmPC in order to add the adverse reaction (ADR) meningitis with a frequency “not known” and to add a clarifying foot note for immunocompromised or immunocompetent individuals applicable to the ADR meningitis, herpes zoster and encephalitis. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to make some editorial changes in the product information and to update the list of local representatives in the package leaflet.”

---

**WS1400**

**Exviera-EMA/H/C/003837/WS1400/0039**

**Viekirax-**

**EMA/H/C/003839/WS1400/0046**

AbbVie Limited, Lead Rapporteur: Filip Josephson, “Submission of the final report from study M14-224: An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, listed as a category 3 study in the RMP.”

---

**WS1401**

**Genvoya-**

**EMA/H/C/004042/WS1401/0047**

**Stribild-EMA/H/C/002574/WS1401/0094**

**Tybost-EMA/H/C/002572/WS1401/0044**

Gilead Sciences International Limited, Lead Rapporteur: Robert James Hemmings, “Update of section 4.6 the SmPC for Tybost, Stribild and Genvoya based on pharmacokinetics data in pregnancy from IMPAACT study P1026s (ClinicalTrials.gov ID NCT00042289); this is an ongoing, nonrandomized, open-label, parallel-group, multi-centre phase 4 prospective study of antiretroviral (ARV) pharmacokinetics (PK) and safety in HIV-1 infected pregnant

---

---

women that includes an arm for EVG/COBI.

The Package Leaflet is updated accordingly.

In addition, the Worksharing applicant (WSA) took the opportunity to bring the PI in line with the latest QRD template version 10.”

---

#### **B.6.10. CHMP-PRAC assessed procedures**

---

##### **Bydureon - exenatide -**

##### **EMA/H/C/002020/11/0050**

AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, “Update of sections 4.1, 4.2, 4.4 and 5.1 of the SmPC based on the final CSR of study EXSCEL (EXenatide Study of Cardiovascular Event Lowering; ‘A randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus’) in fulfilment of PAM (LEG 009). The Package Leaflet is updated accordingly. In addition, RMP version 31 has been submitted as part of this application.”

---

##### **Erivedge - vismodegib -**

##### **EMA/H/C/002602/11/0039/G**

Roche Registration GmbH, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, “C.I.4 Update of SmPC section 4.4 in order to update the special warnings and precautions for use on the effects of post-natal development and 4.8. in order to include a new adverse event (precocious puberty) observed in children in post marketing.

C.I.11.z To submit the final study report for observational study ML28296 (post approval commitment MEA 18) and reflect the newly available information in the RMP version 13.0. In addition, the Marketing authorisation holder (MAH) took the opportunity to include some editorial changes in the product information.”

---

##### **Herzuma - trastuzumab -**

##### **EMA/H/C/002575/11/0006**

Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

---

##### **Olumiant - baricitinib -**

##### **EMA/H/C/004085/11/0006**

Eli Lilly Nederland B.V., Rapporteur: Johann

---



---

Lodewijk Hillege, PRAC Rapporteur: Patrick Batty, "Update of section 4.8 of the SmPC in order to include pneumonia as adverse drug reaction with frequency 'common' following PRAC outcome on signal of pneumonia. The Package Leaflet is updated accordingly. The RMP version 6.0 has also been submitted as part of this application."

---

**Remicade - infliximab -  
EMA/H/C/000240/II/0214**

Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of the RMP (v 17.0) and Annex II-D of the Product Information to remove the Educational material for health care professionals. In addition, the MAH is taking the opportunity to update the package leaflet with some missing warnings and ADRs already reflected in the SmPC, as requested by CHMP, and to introduce some minor QRD related changes."

---

**Soliris - eculizumab -  
EMA/H/C/000791/II/0102, Orphan**

Alexion Europe SAS, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Eva A. Segovia, "Submission of the Clinical Study Report of the study C11-003 listed as Cat 3 study in the RMP. This is an observational, multi-center, multinational long term follow up study of atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab in a prior clinical study. The Risk Management Plan is updated to version 18 with: The new EU format, the proposal to remove the missing information "Long term safety in aHUS patients", the proposal to align the frequency of the submission of the reports on the HCP survey, the controlled distribution and the aHUS registry to the PSUR submission every 2 years."

---

**Tarceva - erlotinib -  
EMA/H/C/000618/II/0058**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Doris Stenver, "Update of sections 4.2, and 5.1 of the SmPC based on phase III clinical study MO22162 (CURRENTS) comparing a higher dose of Tarceva (300 mg) over the recommended daily dose (150 mg) in current smokers with locally advanced or metastatic non-small cell lung

---

---

cancer (NSCLC) in the second-line setting after failure of chemotherapy. The Package Leaflet is updated accordingly. The RMP version 7.0 has been submitted, as part of this application. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes in sections 4.4, 4.5, 4.6, 4.7, 4.8 and 5.2 of the SmPC.”

---

**Tremfya - guselkumab -**

**EMA/H/C/004271/II/0002/G**

Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski“Update of sections 1, 2, 3, 5.1, 6.4, 6.5, 6.6, of the SmPC based on the results from study CNTO1959PSO3006; this is study is an open-label, randomized, study to assess the design features of an investigational prefilled syringe-facilitated injection device (PFS-FID) and the ability of subjects With rheumatoid arthritis or psoriasis to self-administer Placebo With the PFS-FID.

---

**Varuby - rolapitant -**

**EMA/H/C/004196/II/0007/G**

Tesaro UK Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adam Przybylkowski, “- Update of SmPC section 4.5 regarding interaction with OCT1 substrates following the submission of the non-clinical study: in vitro evaluation of the substrate and inhibitor potential of rolapitant for efflux and update of transporters (17TESAP2R1).

- Update of SmPC section 4.5 regarding interaction with UGT substrates following the submission of the 2 non-clinical studies: evaluation of potential UGT inhibition by rolapitant in cryopreserved human hepatocytes (170594) and evaluation of potential rolapitant metabolism by recombinantly expressed human UGT enzymes (TSRP/REP/07CRD75486/2017)

- Update of SmPC section 4.5 following the submission of the open-label, single-dose study to assess the effects of rolapitant (oral) on the pharmacokinetics of caffeine (CYP1A2) in healthy subjects (1000-01-001)

The RMP version 1.2 has also been submitted.”

---

**WS1396**

**Kispilix-EMA/H/C/004224/WS1396/0011**

**Lenvima-**

**EMA/H/C/003727/WS1396/0015**

---

---

Eisai Europe Ltd., Lead Rapporteur: Bart Van der Schueren, Lead PRAC Rapporteur: Ulla Wandel Liminga, "Update of section 4.5 of the SmPC to include that there is no significant drug-drug interaction risk with midazolam, based on the results of study E7080-A001-109 (A Phase 1 Study to determine DDI of lenvatinib and midazolam, a cytochrome P450 3A4 (CYP3A4) substrate, in subjects with advanced solid tumors). The RMP is updated (version 10.4)"

---

**WS1406**

**Abseamed-**

**EMEA/H/C/000727/WS1406/0070**

**Binocrit-**

**EMEA/H/C/000725/WS1406/0070**

**Epoetin alfa Hexal-**

**EMEA/H/C/000726/WS1406/0069**

Sandoz GmbH, Lead Rapporteur: Alexandre Moreau, Lead PRAC Rapporteur: Ghania Chamouni, "Extension of indication to include the treatment of symptomatic anaemia (haemoglobin concentration of  $\leq 10$  g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin ( $< 200$  mU/ml) for Binocrit, Epoetin alfa Hexal and Abseamed; as a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated with safety and efficacy information. The Package Leaflet and the risk management plan (version 17.0) are updated in accordance. In addition, the worksharing applicant (WSA) took the opportunity to align information with the reference medicinal product and with the EC guideline on Excipients, to improve the quality and readability of the translations in the product information and to update the Annex A in line with EMA guideline."

---

**B.6.11. PRAC assessed procedures**

---

PRAC Led

**Bosulif - bosutinib -**

**EMEA/H/C/002373/II/0030**

Pfizer Limited, Rapporteur: Harald Enzmann, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Harald Enzmann, "Submission of an updated RMP version 4.3 in line with changes requested by the CHMP following variation II/25/G in fulfilment of PAM (REC 014). In

---

---

addition, the MAH took the opportunity to extend due date of SOB (Specific Obligation). Annex II has been updated accordingly.”

---

PRAC Led

**Neulasta - pegfilgrastim -**

**EMA/H/C/000420/11/0099**

Amgen Europe B.V., Rapporteur: Robert James Hemmings, PRAC Rapporteur: Patrick Batty, PRAC-CHMP liaison: Robert James Hemmings, “Submission of an updated RMP version 5.1 in order to add study 20160176, a retrospective cohort study of female breast cancer patients aged 66 years and over selected from the US SEER-Medicare database to estimate the risk of acute myeloid leukemia/myelodysplastic syndrome for breast cancer patients, as a new Pharmacovigilance activity (category 3). In addition the MAH submitted the draft protocol for study 20160176.”

---

PRAC Led

**Nimenrix - meningococcal group A, C, W135 and Y conjugate vaccine -**

**EMA/H/C/002226/11/0078**

Pfizer Limited, PRAC Rapporteur: Julie Williams, PRAC-CHMP liaison: Greg Markey, “To update the RMP (version 8.0). The update includes changes approved in procedure II-49 and II-73. The RMP is also being revised to align with current EU RMP template, as per GVP Module V Rev. 2 including proposals for the removal of some Important Potential Risks: Guillain-Barré syndrome, Purpura, Vasculitis, Acute disseminated encephalomyelitis, Brachial neuritis, Anaphylaxis, Change in meningococcal epidemiology/serogroup replacement, Lack of efficacy, Administration via the intravascular, intradermal or subcutaneous route, and Administration to patients with thrombocytopenia or any coagulation disorder with a risk of haemorrhage. The MAH also proposes removal of the missing information: Use in patients with chronic diseases and Use during pregnancy and lactation.”

---

PRAC Led

**Volibris - ambrisentan -**

**EMA/H/C/000839/11/0055, Orphan**

Glaxo Group Ltd, Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Dolores Montero Corominas, PRAC-CHMP liaison: Concepcion

---

---

Prieto Yerro, "C.I.11: Submission of an updated RMP (version 7.6) in order to remove the provision of the educational materials for healthcare professionals given the availability of the SmPC and the experience of using ambrisentan as requested by the PRAC in the PSUR procedure PSUSA/00000129/201706. The Annex II of the product information is updated accordingly. In addition, the MAH also took the opportunity to update the Annex II as requested by the Portuguese Agency following the approval of the last update to the educational materials (risks of decreases in haemoglobin or haematocrit, renal impairment, peripheral oedema and fluid retention, and hypersensitivity reaction) and to correct typographical errors in the Annex II of the product information."

---

PRAC Led

**Zavesca - miglustat -**

**EMA/H/C/000435/II/0062/G, Orphan**

Actelion Registration Limited, Rapporteur:

Kristina Dunder, PRAC Rapporteur: Qun-Ying

Yue, PRAC-CHMP liaison: Kristina Dunder,

"C.I.13: Submission of the final report of the 9th

NPC registry report including an RMP update

within the context of variation

EMA/H/C/000435/II/0056

C.I.11: Submission of an updated RMP version

14 in order to remove the important identified

risks: reduced platelet counts and weight loss

based on the current ongoing PSUR procedure

for miglustat

(EMA/H/C/PSUSA/00002062/201710)"

---

PRAC Led

**WS1370**

**Zoledronic acid Mylan-**

**EMA/H/C/002482/WS1370/0015**

Mylan S.A.S, Generic, Generic of Zometa, Lead

PRAC Rapporteur: Doris Stenver, PRAC-CHMP

liaison: Sinan B. Sarac, "The RMP has been

updated to the latest template. In addition the

MAH has included "and other anatomical sites"

in addition to "Osteonecrosis of the jaw" as an

important identified risk, to be in line with CHMP

assessment report for zoledronic acid, procedure

number EMA/H/C/PSUSA/00003149/201608,

dated 21 April 2017."

---

**B.6.12. CHMP-CAT assessed procedures**

**B.6.13. CHMP-PRAC-CAT assessed procedures**

**B.6.14. PRAC assessed ATMP procedures**

**B.6.15. Unclassified procedures and worksharing procedures of type I variations**

---

**WS1365/G**

**Ambirix-**

**EMA/H/C/000426/WS1365/0091/G**

**Fendrix-**

**EMA/H/C/000550/WS1365/0063/G**

**Infanrix hexa-**

**EMA/H/C/000296/WS1365/0240/G**

**Twinrix Adult-**

**EMA/H/C/000112/WS1365/0125/G**

**Twinrix Paediatric-**

**EMA/H/C/000129/WS1365/0126/G**

GlaxoSmithKline Biologicals, Lead Rapporteur:

Bart Van der Schueren

---

**WS1377/G**

**Infanrix hexa-**

**EMA/H/C/000296/WS1377/0241/G**

GlaxoSmithKline Biologicals SA, Lead

Rapporteur: Bart Van der Schueren

---

**WS1387**

**Infanrix hexa-**

**EMA/H/C/000296/WS1387/0242**

GlaxoSmithKline Biologicals SA, Lead

Rapporteur: Bart Van der Schueren

---

**WS1395**

**Fluenz Tetra-**

**EMA/H/C/002617/WS1395/0081**

**Pandemic influenza vaccine H5N1**

**AstraZeneca-**

**EMA/H/C/003963/WS1395/0014**

AstraZeneca AB, Lead Rapporteur: Bart Van der

Schueren,

---

**WS1405**

**Fiasp-EMA/H/C/004046/WS1405/0006**

**NovoMix-**

**EMA/H/C/000308/WS1405/0094**

**NovoRapid-**

**EMA/H/C/000258/WS1405/0122**

---

---

**Ryzodeg-**

**EMA/H/C/002499/WS1405/0027**

Novo Nordisk A/S, Lead Rapporteur: Kristina

Dunder

---

**WS1408**

**Enbrel-EMA/H/C/000262/WS1408/0221**

**LIFMIOR-**

**EMA/H/C/004167/WS1408/0016**

Pfizer Limited, Lead Rapporteur: Robert James

Hemmings

---

**B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY**

**B.7.1. Yearly Line listing for Type I and II variations**

**B.7.2. Monthly Line listing for Type I variations**

**B.7.3. Opinion on Marketing Authorisation transfer (MMD only)**

**B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)**

**B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)**

**B.7.6. Notifications of Type I Variations (MMD only)**

**C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)**

**D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)**

**E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES**

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

## **E.1. PMF Certification Dossiers:**

### **E.1.1. Annual Update**

### **E.1.2. Variations:**

### **E.1.3. Initial PMF Certification:**

## **E.2. Time Tables – starting & ongoing procedures: For information**

---

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

---

## **F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver**

### **F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended**

### **F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health**

## **G. ANNEX G**

### **G.1. Final Scientific Advice (Reports and Scientific Advice letters):**

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

### **Qualification of Biomarkers:**

### **HTA:**

### **G.2. Ongoing procedures**

---

---

### **G.3. PRIME**

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

### **G.3.1. List of procedures concluding at 28-31 May 2018 CHMP plenary:**

---

<i>Vaccines</i>	
1. <b>MV-CHIK vaccine</b> ; (SME); Prevention of Chikungunya fever	The CHMP granted eligibility to PRIME and adopted the critical summary report.
<i>Uro-nephrology</i>	
2. Treatment of Immunoglobulin A nephropathy	The CHMP denied eligibility to PRIME and

---



		adopted the critical summary report.
<i>Oncology</i>		
3.	Treatment of Relapsed / Refractory Diffuse Large B-Cell Lymphoma	The CHMP denied eligibility to PRIME and adopted the critical summary report.
4.	<b>Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (KTE-C19)</b> ; ; ATMP; Treatment of adult patients with relapsed or refractory mantle cell lymphoma	The CHMP granted eligibility to PRIME and adopted the critical summary report.
5.	Treatment of adult patients with B-cell precursor relapsed or refractory acute lymphoblastic leukemia	The CHMP denied eligibility to PRIME and adopted the critical summary report.
<i>Immunology-Rheumatology-Transplantation</i>		
6.	<b>Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (NLA101)</b> ; (SME); ATMP; Treatment in Haematopoietic Stem Cell Transplantation (HSCT)	The CHMP granted eligibility to PRIME and adopted the critical summary report.
<i>Dermatology</i>		
7.	Treatment of psoriasis	The CHMP denied eligibility to PRIME and adopted the critical summary report.
<i>Other</i>		
8.	<b>Adeno-associated viral vector serotype 8 containing the human MTM1 gene (AT132)</b> ; (SME); ATMP; Treatment of X-linked Myotubular Myopathy	The CHMP granted eligibility to PRIME and adopted the critical summary report.

### G.3.2. List of procedures starting in May 2018 for June 2018 CHMP adoption of outcomes

### H. ANNEX H - Product Shared Mailboxes – e-mail address